0001144204-18-026144.txt : 20180508 0001144204-18-026144.hdr.sgml : 20180508 20180508162207 ACCESSION NUMBER: 0001144204-18-026144 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180508 DATE AS OF CHANGE: 20180508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZYNEX INC CENTRAL INDEX KEY: 0000846475 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 870403828 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 033-26787-D FILM NUMBER: 18814922 BUSINESS ADDRESS: STREET 1: 9990 PARK MEADOWS DRIVE CITY: LONE TREE STATE: CO ZIP: 80124 BUSINESS PHONE: (303) 703-4906 MAIL ADDRESS: STREET 1: 9990 PARK MEADOWS DRIVE CITY: LONE TREE STATE: CO ZIP: 80124 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20050812 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20040120 FORMER COMPANY: FORMER CONFORMED NAME: FOX RIVER HOLDINGS INC DATE OF NAME CHANGE: 20031126 10-Q 1 tv491631_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2018

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 33-26787-D

Zynex, Inc.

(Exact name of registrant as specified in its charter)

NEVADA		90-0275169
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

9555 Maroon Cir. Englewood, CO		80112
(Address of principal executive offices)		(Zip Code)

(303) 703-4906

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Shares Outstanding as of May 4, 2018
Common Stock, par value $0.001		33,116,334

ZYNEX, INC. AND SUBSIDIARIES

INDEX TO FORM 10-Q

		Page
PART I—FINANCIAL INFORMATION		3

Item 1.	Financial Statements	3

	Condensed Consolidated Balance Sheets as of March 31, 2018 (unaudited) and December 31, 2017	3

	Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2018 and 2017	4

	Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and 2017	5

	Unaudited Notes to Condensed Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17

Item 4.	Controls and Procedures	17

PART II—OTHER INFORMATION		17

Item 1.	Legal Proceedings	17

Item 1A.	Risk Factors	17

Item 2.	Unregistered Sales of Equity Securities And Use of Proceeds	18

Item 3.	Defaults Upon Senior Securities	18

Item 4.	Mine Safety Disclosures	18

Item 5.	Other Information	18

Item 6.	Exhibits	18

SIGNATURES		19

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ZYNEX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES)

(unaudited)

	March 31,			December 31,
	2018			2017
ASSETS
Current assets:
Cash	$	4,366		$	5,565
Accounts receivable, net		2,668			2,185
Inventory, net		710			423
Prepaid expenses and other assets		615			198
Total current assets		8,359			8,371

Property and equipment, net		575			188
Deposits		375			370
Total assets	$	9,309		$	8,929

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of unsecured subordinated promissory notes	$	7		$	231
Current portion of capital leases		93			123
Accounts payable and accrued expenses		2,112			2,243
Accrued payroll and related taxes		661			538
Deferred insurance reimbursement		880			880
Total current liabilities		3,753			4,015
Long-term liabilities:
Deferred rent		329			-
Warranty liability		12			12
Total liabilities		4,094			4,027


Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares
issued and outstanding as of March 31, 2018 and December 31, 2017		-			-
Common stock, $0.001 par value; 100,000,000 shares authorized;
33,101,834 issued and 32,606,743 outstanding as of March 31, 2018 and
32,864,877 issued and 32,778,040 outstanding as of December 31, 2017		33			33
Additional paid-in capital		7,761			7,612
Treasury stock 495,091 and 86,837 shares, at March 31, 2018
and December 31, 2017, respectively, at cost		(2,000	)		(243	)
Accumulated deficit		(490	)		(2,411	)
Total Zynex, Inc. stockholders' equity		5,304			4,991
Non-controlling interest		(89	)		(89	)
Total stockholders' equity		5,215			4,902
Total liabilities and stockholders' equity	$	9,309		$	8,929

The accompanying notes are an integral part of these condensed consolidated financial statements

ZYNEX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

(unaudited)

	For the Three Months Ended March 31,
	2018			2017
NET REVENUE
Devices	$	1,588		$	1,384
Supplies		5,288			2,052
Total Net revenue		6,876			3,436

COSTS OF REVENUE AND OPERATING EXPENSES
Costs of revenue - device & supply		1,236			923
Selling, general and administrative expense		3,685			2,030
Total costs of revenue and operating expenses		4,921			2,953

Income from operations		1,955			483


Interest expense		(115	)		(121	)

Income from operations before income taxes		1,840			362
Income tax expense (benefit)		(81	)		9
Net Income		1,921			353
Plus: net loss - noncontrolling interest		-			-
Net income - attributable to Zynex, Inc.	$	1,921		$	353

Net income per share attributable to Zynex, Inc.:
Basic	$	0.06		$	0.01

Diluted	$	0.06		$	0.01


Weighted average basic shares outstanding		32,601			31,418
Weighted average diluted shares outstanding		34,414			32,036

* There is no difference between net income and comprehensive income

The accompanying notes are an integral part of these condensed consolidated financial statements

ZYNEX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(AMOUNTS IN THOUSANDS)

(unaudited)

	For the Three Months Ended March 31,
	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided by operating activities	$	993		$	23

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(160	)		(57	)
Net cash used in investing activities		(160	)		(57	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Net (repayments) borrowings on line of credit		-			(600	)
Principal payments on subordinated		(331	)
Proceeds from unsecured subordinated promissory notes		-			1,035
Payment of commission and placement agent fees and related expenses		-			(155	)
Payments on capital lease obligations		(30	)		(31	)
Purchase of treasury stock		(1,757	)		-
Proceeds from the issuance of stock		86			-
Net cash (used in) provided by financing activities		(2,032	)		249

Net (decrease) increase in cash and cash equivalents		(1,199	)		215
Cash and cash equivalents at beginning of period		5,565			247
Cash and cash equivalents at end of period	$	4,366		$	462

Supplemental disclosure of cash and non-cash transactions:
Interest paid	$	8		$	121
Property and Equipment purchased and included in accrued liabilities but not settled	$	253		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

ZYNEX, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(1) BASIS OF PRESENTATION

Organization

Zynex, Inc. (a Nevada corporation) has its headquarters in Englewood, Colorado. We operate one primary business segment, medical devices which include Electrotherapy and Pain Management Products. As of March 31, 2018, the Company’s only active subsidiary is Zynex Medical, Inc. (“ZMI,” a wholly-owned Colorado corporation) through which the Company conducts most of its operations. One other subsidiary, Zynex Europe, ApS (“ZEU,” a wholly-owned Denmark corporation), did not generate material revenues during the three months ended March 31, 2018 and 2017 from international sales and marketing. Zynex Monitoring Solutions, Inc. (“ZMS,” a wholly-owned Colorado corporation) has developed a blood volume monitoring device, but it is awaiting approval by the U.S. Food and Drug Administration (“FDA”) as well as CE Marking in Europe, therefore, ZMS has achieved no revenues to date.

The term “the Company” refers to Zynex, Inc. and its active and inactive subsidiaries.

Nature of Business

ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMI devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (“IFC”), neuromuscular electrical stimulation (“NMES”) and transcutaneous electrical nerve stimulation (“TENS”). All our medical devices are intended to be patient friendly and designed for home use. The ZMI devices are small, portable, battery operated and include an electrical pulse generator which is connected to the body via electrodes. All of our medical devices are marketed in the U.S. and are subject to FDA regulation and approval. Our products require a physician’s prescription before they can be dispensed in the U.S. ZMI’s primary product is the NexWave device. The NexWave is marketed to physicians and therapists by our field sales representatives. The NexWave requires consumable supplies, such as electrodes and batteries, which are shipped to patients on a recurring monthly basis, as needed.

During the three months ended March 31, 2018 and 2017, the Company generated substantially all of its revenue (99.99%) in North America from sales and supplies of its devices to patients and health care providers.

Unaudited Condensed Consolidated Financial Statements

The unaudited condensed consolidated financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. A description of the Company’s accounting policies and other financial information is included in the audited consolidated financial statements as filed with the SEC in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Amounts as of December 31, 2017, are derived from those audited consolidated financial statements. These interim condensed consolidated financial statements should be read in conjunction with the annual audited financial statements, accounting policies and notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, which has previously been filed with the SEC.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of March 31, 2018 and the results of its operations and its cash flows for the periods presented. The results of operations for the three months ended March 31, 2018, are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Non-controlling Interest

Non-controlling interest in the equity of a subsidiary is accounted for and reported as stockholders’ equity. Non-controlling interest represents the 20% ownership in the Company’s majority-owned (but currently inactive) subsidiary, ZBC.

Reclassifications

Certain reclassifications have been made to the 2017 financial statements to conform to the consolidated 2018 financial statement presentation. These reclassifications had no effect on net earnings or cash flows as previously reported.

We reclassified amounts between device and supplies revenue for all of the quarters ended during 2017. The change was due to enhanced information which allowed us to perform a more detailed analysis of revenue and the related classifications. The reclassification did not change total net revenue.

Use of Estimates

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant management estimates used in the preparation of the accompanying consolidated financial statements are associated with the allowance for billing adjustments and uncollectible accounts receivable, the reserve for obsolete and damaged inventory, stock-based compensation, and valuation of long-lived assets and realizability of deferred tax assets.

Revenue Recognition, Allowance for Billing Adjustments and Collectability

On January 1, 2018 the company adopted the new accounting standard on revenue recognition issued by the Financial Accounting Standards Board (“FASB”). Pursuant to the revenue from contracts with customer’s standards the Company recognizes revenue when it transfers promised goods to customers in an amount that reflects the consideration to which the company expects to be entitled, known as the transaction price. The company elected to use the modified retrospective method which resulted in immaterial changes to previously issued financial statements and retained earnings.

Revenue is generated primarily from sales in the United States of our electrotherapy devices and associated supplies. Sales are primarily made with, and shipped, direct to the patient with a small amount of revenue generated from sales to distributors. Revenue is recognized on medical devices when we receive notice that the device has been prescribed by a doctor and delivered to the patient. Supplies revenue is recognized once delivered to the patient. Supplies needed for the device can be set up as a recurring shipment or ordered thru the customer support team or online store as needed.

Being in the healthcare industry there is often a third party involved that will pay on the patients behalf. The terms of the separate arrangement can impact certain aspects of the contracts, with patients covered by third party payors, such as performance obligations and transaction price, but for purposes of revenue recognition the contract with the customer refers to the arrangement between the Company and the patient. The company does not report any deferred revenue as each performance obligation is met upon delivery of goods to the patient. There are no substantial costs incurred through support or warranty obligations.

A significant portion of the Company’s revenues are derived, and the related receivables are due, from a commercial health insurance or government agency (collectively “Third-party Payors”). Transaction price is estimated with variable consideration using the most likely amount technique for Third-party Payor reimbursement deductions, known throughout the health care industry as “billing adjustments” whereby the Third-party Payors unilaterally reduce the amount they reimburse for the Company’s products, refund requests, and for the timing and values of amounts to be billed. Supplies are billed only upon shipment. Devices can be billed upon shipment or over billing cycles. Billing cycles can be over a variable period and are estimated in amounts such that the likelihood that a significant reversal of revenue will not occur. Roughly 15% of total revenue and 66% of device revenue are billed in cycles. Inherent in these estimates is the risk that they will have to be revised as additional information becomes available and constraints are released. Specifically, the complexity of third-party billing arrangements and the uncertainty of reimbursement amounts for certain products from payors or unanticipated requirements to refund payments previously received may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party reimbursement, as well as changes in our billing practices to increase cash collections, it is possible our forecasting model to estimate collections could change, which could have an impact on our results of operations and cash flows. Any differences between estimated settlements and final determinations are reflected as an increase or a reduction to revenue in the period when such final determinations are known.

The basis of estimates include historical rates of collection, the aging of the receivables, trends in the historical reimbursement rates by insurance groups, determined using the portfolio approach, and current relationships and experience with the Third-party Payors. A change in the way estimates are determined can result from a number of factors, including experience and training of billing personnel, changes in the reimbursement policies or practices of Third-party Payors, or changes in industry rates of reimbursement. The company monitors the variability and uncertain timing over payor groups in our portfolios. If there is a change in our payor mix over time, it could affect our net revenue and related receivables. We believe we have a sufficient history of collection experience to estimate the net collectible amounts by payor. However, changes to the allowance for billing adjustments, which are recorded as a reduction of transaction price, have historically fluctuated and may continue to fluctuate significantly from quarter to quarter and year to year.

The Company frequently receives refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in the Company’s industry. These requests are sometimes related to a limited number of patients or products; at other times, they include a significant number of refund claims in a single request. The Company reviews and evaluates these requests and determines if any refund request is appropriate. The Company also reviews these refund claims when it is rebilling or pursuing reimbursement from insurance providers. The Company frequently has significant offsets against such refund requests, and sometimes amounts are due to the Company in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests, the Company is generally unable to determine if a refund request is valid and should be accrued. Such refunds are recorded when the amount is fixed and determinable, however management maintains an allowance for estimated future refunds which we believe is sufficient to cover future claims in connection with its estimates of variable consideration recorded at the time sales are recorded.

Fair Value of Financial Instruments

The Company’s financial instruments include cash, accounts receivable, accounts payable and income taxes, for which current carrying amounts approximate fair value due to their short-term nature. Financial instruments also included the notes payable related to our private placement and capitalized leases, the carrying value of which approximates fair value because the interest rates on the outstanding borrowings are at rates that approximate market rates for borrowings with similar terms and average maturities.

Inventory

Inventory, which primarily represents parts and supplies, are valued at the lower of cost (average) or market.

The Company monitors inventory for turnover and obsolescence and records losses for excess and obsolete inventory, as appropriate. The Company provides reserves for estimated excess and obsolete inventories equal to the difference between the costs of inventories on hand and the estimated market value based upon assumptions about future demand. If future demand is less favorable than currently projected by management, additional inventory write-downs may be required.

Total gross inventories at March 31, 2018 were $0.7 million which was comprised of finished goods, work in progress, and parts and supplies as compared to December 31, 2017 of $0.4 million.

Segment Information

We define operating segments as components of our enterprise for which separate financial information is reviewed regularly by the chief operating decision-makers to evaluate performance and to make operating decisions. We have identified our Chief Executive Officer and Chief Financial Officer as our chief operating decision-makers (“CODM”).

We currently operate our business as one operating segment which includes two revenue types: Devices and Supplies.

Income Taxes

We record deferred tax assets and liabilities for the estimated future tax effects of temporary differences between the tax bases of assets and liabilities and amounts reported in the accompanying consolidated balance sheets, as well as operating loss and tax credit carry-forwards. We measure deferred tax assets and liabilities using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. We reduce deferred tax assets by a valuation allowance if, based on available evidence, it is more likely than not that these benefits will not be realized.

On December 22, 2017, the U.S. government enacted comprehensive tax legislation (the “Tax Act”), which significantly revises the ongoing U.S. corporate income tax law by lowering the U.S. federal corporate income tax rate from 35% to 21%, implementing a territorial tax system, imposing a one-time tax on foreign unremitted earnings and setting limitations on deductibility of certain costs, among other things.

The Company is subject to the provisions of the Financial Accounting Standards Board (“FASB”) ASC 740-10, Income Taxes, which requires that the effect on deferred tax assets and liabilities of a change in tax rates be recognized in the period the tax rate change was enacted. Due to the complexities involved in accounting for the recently enacted Tax Act, the U.S. Securities and Exchange Commission’s Staff Accounting Bulletin (“SAB”) 118 requires that the Company include in its financial statements the reasonable estimate of the impact of the Tax Act on earnings to the extent such estimate has been determined.

Pursuant to the SAB118, the Company is allowed a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts. The final impact on the Company from the Tax Act’s transition tax legislation may differ from the aforementioned estimates due to the complexity of calculating and supporting with primary evidence such U.S. tax attributes such as accumulated foreign earnings and profits, foreign tax paid, and other tax components involved in foreign tax credit calculations for prior years back to 1998. Such differences could be material, due to, among other things, changes in interpretations of the Tax Act, future legislative action to address questions that arise because of the Tax Act, changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the Company has utilized to calculate the transition tax's reasonable estimate. The Company will continue to evaluate the impact of the U.S. Tax Act and will record any resulting tax adjustments during 2018.

Recent Accounting Pronouncements

In August 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”), which amends and simplifies existing guidance in order to allow companies to more accurately present the economic effects of risk management activities in the financial statements. ASU 2017-12 is effective for us in the first quarter of fiscal 2020, and earlier adoption is permitted. We are currently evaluating the impact of our pending adoption of ASU 2017-12 on our consolidated financial statements.

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) ("ASU 2016-13"), Measurement of Credit Losses on Financial Instruments. The standard significantly changes how entities will measure credit losses for most financial assets and certain other instruments that aren't measured at fair value through net income. The standard will replace today's "incurred loss" approach with an "expected loss" model for instruments measured at amortized cost. For available-for-sale debt securities, entities will be required to record allowances rather than reduce the carrying amount, as they do today under the other-than-temporary impairment model. It also simplifies the accounting model for purchased credit-impaired debt securities and loans. This ASU is effective for annual periods beginning after December 15, 2019, and interim periods therein. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the impact that the adoption of ASU 2016-13 will have on our financial condition, results of operations and cash flows.

In February 2018, the FASB issued Accounting Standards Update No. 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (“ASU 2018-02”), which allows companies to reclassify stranded tax effects resulting from the 2017 Tax Cuts and Jobs Act (the Tax Act), from accumulated other comprehensive income to retained earnings. The new standard is effective for us beginning January 1, 2019, with early adoption permitted. We are currently evaluating the effects that the adoption of this guidance will have on our consolidated financial statements and the related disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). These amendments require the recognition of lease assets and lease liabilities on the balance sheet by lessees for those leases currently classified as operating leases under ASC 840 “Leases”. These amendments also require qualitative disclosures along with specific quantitative disclosures. These amendments are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. Entities are required to apply the amendments at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact that the adoption of ASU 2016-02 will have on our financial condition, results of operations and cash flows.

Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a material impact on the Company’s consolidated financial statements.

Recent Adopted Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09—“Revenue from Contracts with Customers” (Topic 606) which amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The Company adopted the new ASU as of January 1, 2018 using the modified retrospective method and resulted in no material changes to previously stated financial statements. For further details see the revenue recognition description in Note 1.

(2) BALANCE SHEET COMPONENTS

The components of certain balance sheet line items are as follows (in thousands):

Property and equipment:	March 31,2018			December 31,2017
Office furniture and equipment	$	1,033		$	998
Assembly equipment		128			128
Vehicles		76			76
Leasehold improvements		378			-
	$	1,615		$	1,202
Less accumulated depreciation		(1,040	)		(1,014	)
	$	575		$	188


Assets acquired under capital lease:		March 31,2018			December 31,2017
Original book value	$	461		$	461
Accumulated depreciation		(395	)		(379	)
Net book value	$	66		$	82

Included in total assets at March 31, 2018 are $0.2 million in assets for leasehold improvements that have been completed and are accounted for in accrued liabilities but not yet settled.

Total depreciation expense related to our property and equipment was $26,000 and $0.1 million for the three months ended March 31 2018 and 2017, respectively.

Included in computer and office & manufacturing equipment at March 31, 2018 and December 31, 2017 are assets under capital lease. Depreciation expense related to assets under capital leases was $16,000 and $23,000 for the months ended March 31, 2018 and 2017, respectively.

(3) EARNINGS PER SHARE

Basic earnings per share are computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding and the number of dilutive potential common share equivalents during the period, calculated using the treasury-stock method for outstanding stock options.

The calculation of basic and diluted earnings per share for the three months ended March 31, 2018 and 2017 are as follows:

	For the Three Months Ended March 31,
	2018		2017
Basic income per share:
Net income available to common stockholders	$	1,921	$	353
Basic weighted average shares outstanding		32,601		31,418
Basic income per share:	$	0.06	$	0.01

Diluted income per share:
Net income available to common stockholders	$	1,921	$	353
Weighted average shares outstanding		32,601		31,418
Effect of dilutive securities - options and restricted stock		1,813		618
Diluted weighted average shares outstanding		34,414		32,036
Diluted income per share:	$	0.06	$	0.01

For the three months ended March 31, 2018 and 2017, 0.2 million and 1.1 million shares, respectively, of common stock were excluded from the dilutive stock calculation because their exercise prices were greater than the average fair value of our common stock for the period.

Prior to their issuance on August 28, 2017, the dilutive securities calculation included 776,250 shares of common stock issuable related to the private placement which was completed on February 28, 2017. The common shares were issuable six months from the closing of the shareholder notes.

(4) STOCK-BASED COMPENSATION PLANS

In June 2017, our stockholders approved the 2017 Stock Incentive Plan (the “2017 Stock Plan”) with a maximum of 5,000,000 shares reserved for issuance. Awards permitted under the 2017 Stock Plan include: Stock Options and Restricted Stock. Awards issued under the 2017 Stock Plan are at the discretion of the Board of Directors. As applicable, awards are granted with an exercise price equal to the closing price of our common stock on the date of grant and generally vest over four years. At March 31, 2018, 0.6 million remain issued and outstanding.

During the three months ended March 31, 2018, no Stock Option awards were granted under the 2017 Stock Plan.

During the three months ended March 31, 2018, 65,000 shares of restricted stock were granted to the Board of Directors and management under the 2017 Stock Plan. There were no restricted shares issued during the three months ended March 31, 2017. During the three months ended March 31, 2018, no shares of restricted stock vested. No shares of restricted stock were forfeited during the three months ended March 31, 2018. The fair market value of restricted shares for share-based compensation expensing is equal to the closing price of our common stock on the date of grant. The restrictions on the stock awards are typically released quarterly or annually over four years

The Company previously reserved 3,000,000 shares of common stock for issuance under its 2005 Stock Option Plan (the “Option Plan”). The Option Plan expired as of December 31, 2014. Vesting provisions of the expired plan were to be determined by the Board of Directors. All stock options under the Option Plan expire no later than ten years from the date of grant. Options granted in 2016 and through May 2017 prior to the approval of the 2017 Stock Incentive Plan were approved by and certified by the board of directors on September 6, 2017 under the existing 2005 stock option plan. At March 31, 2018, 1.3 million remain issued and outstanding under the 2005 Stock Option Plan.

The following summarizes stock-based compensation expenses recorded in the condensed consolidated statements of operations:

During the three months ended March 31, 2018 and 2017, the Company recorded compensation expense related to stock options of approximately $63,000 and $24,000, respectively, all of which was recorded in selling, general and administrative expense on the accompanying condensed consolidated statements of operations.

During the three months ended March 31, 2018, there were no options granted, only the aforementioned restricted stock grants.

During the three months ended March 31, 2017, the Company granted options to purchase up to 0.2 million shares of common stock to employees at a weighted average exercise price of $0.21 per share. The weighted-average grant date fair value of options granted during the three months ended March 31, 2017 were $0.28.

The Company received proceeds of $0.1 million related to option exercises during the three months ended March 31, 2018. No options were exercised during the three months March 31, 2017

The Company used the Black Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions for 2017. There were no options granted during the three months ended March 31, 2018:

	For the Three Months Ended March 31,
	2018			2017
Expected term (years)		-			6.25
Risk-free interest rate		-	%		1.64	%
Expected volatility		-	%		129.04	%
Expected dividend yield		-	%		0.00	%

A summary of stock option and restricted stock activity under all equity compensation plans for the three months ended March 31, 2018, is presented below:

						Weighted-
						Average
				Weighted-		Remaining		Aggregate
	Number of			Average		Contractual		Intrinsic
	Shares			Exercise		Term		Value
	(in thousands)			Price		(Years)		(in thousands)
Outstanding at December 31, 2017		2,136		$	0.54		6.31	$	5,645
Granted		65			0.00
Forfeited		(6	)		1.28
Exercised		(237	)		0.36
Outstanding at March 31, 2018		1,958		$	0.54		6.27	$	5,579

Exercisable at March 31, 2018		1,261		$	0.40		4.99	$	3,720

As of March 31, 2018, the Company had approximately $0.6 million of unrecognized compensation expense related to stock options that will be recognized over a weighted average period of approximately 2.97 years.

(5) STOCKHOLDERS’ EQUITY

Treasury Stock

Beginning on December 6, 2017, and continuing through March 6, 2018, we had the ability through our stock purchase program to re-purchase our common stock at prevailing market prices either in the open market or through privately negotiated transactions up to $2.0 million. On March 6, 2018, we reached the limit of $2.0 million and share re-purchases were ceased.

From the inception of the plan through March 6, 2018, we purchased 495,091 shares of our common stock for $2.0 million for an average price of $4.04 per share.

Warrants

In October 2017, 150,000 common stock warrants were issued in exchange for professional services.

In connection with the agreement entered into on March 28, 2016, with Triumph Bank, the Lender suspended this monthly payment requirement for February, March and April of 2016 up to an aggregate cap of $250,000, in exchange for the issuance of a common stock warrant to purchase 50,000 shares of the Company’s common stock.

A summary of stock warrant activity for the three months ended March 31, 2018 are presented below:

	Number of Warrants (in thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2017		200	$	1.86		5.80	$	264
Granted		-	$	-
Exercised		-		-
Forfeited		-	$	-
Outstanding at March 31, 2018		200	$	1.86		5.62	$	305

There were no warrants granted during the three months ended March 31, 2018 and 2017.

(6) INCOME TAXES

The company recorded an income tax (benefit) provision of ($0.1 million) and $9,000 for the three months ended March 31, 2018 and 2017, respectively. The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to various factors.

ASC 740, Income Taxes, provides for the recognition of deferred tax assets if realization of such assets is more likely than not. As of December 31, 2017, our deferred tax assets were fully offset by a valuation allowance. Based upon the weight of available evidence, which includes recent operating performance, and forecasting our future results, we released a portion of the valuation allowance against our deferred tax assets during the period ending March 31, 2018. Since the deferred tax assets are expected to be utilized in the current year and in connection with interim reporting requirements, we have adjusted our annual effective tax rate to recognize the benefit ratably over all quarters of 2018. We will continue to reassess valuation allowance considerations on a quarterly basis.

No taxes were paid in the three months ended March 31, 2018 and 2017.

(7) PRIVATE PLACEMENT MEMORANDUM

Commencing in November of 2016, the Company conducted a private placement on a “best efforts, minimum-maximum” basis of 12% unsecured subordinated promissory notes, for a minimum of $1,000,000 and a maximum of $1,500,000 pursuant to Sections 4(a)(2) and 4(a)(5) of the Securities Act of 1933, as amended (the “1933 Act”) and Rule 506(b) of the 1933 Act (the “Offering”). The Offering was conducted through a FINRA registered broker, Newbridge Securities Corporation (“Newbridge”). On February 28, 2017, the Company conducted a closing under the Offering and issued promissory notes totaling $1,035,000, with a maturity date of June 28, 2018, with the remaining unpaid principal balance due. The Offering requires the Company to make monthly repayment commencing on July 1, 2017, until the Senior Lender has been paid in full, the private placement memorandum limits the funds available for repayment to the note holders to an amount equal to 5% of the Company’s collections received by the Senior Lender during that month. Newbridge was compensated in connection with sales made in the Offering consisting of (i) a cash amount equaling 10% commissions, a 3% non-accountable expense allowance, and related expenses totaling $155,000 (ii) 776,250 shares of our Common Stock were issued to the placement agent as additional commission and fees totaling $255,000, and (iii) the Company had an obligation to issue 776,250 shares of the common stock, six months after issuance of the notes to the noteholders which had initially been recorded as a liability totaling $255,000. The shares were issued on August 28, 2017. In connection with the Offering, we also paid our Lender $342,000 as repayment of principal and interest on the outstanding obligations. The common stock issued to the note holders represents additional interest expense and was initially recorded as a liability and was adjusted each reporting period based upon the fair value of the underlying stock until issued on August 28, 2017. During the three months ended March 31, 2018 and 2017, the Company recognized $107,000 and $37,000, respectively in debt issuance costs and debt discount amortization expense included in interest expense, respectively.

The table below summarizes the cash and non-cash components of the private placement memorandum (in thousands):

	March 31, 2018
Proceeds from unsecured subordinated promissory notes	$	1,035
Less debt issuance costs and discount
Payment of commission and placement agent fees and related expenses		(155	)
Principal payments on promissory notes		(981	)

Non-cash activity
Common stock issued to placement agent		(255	)
Obligation to issue common stock to private placement noteholders		(255	)
Amortization of issuance costs and debt discount		618
Unsecured subordinated promissory notes, net of issuance and debt discount		7

Current portion of unsecured subordinated promissory notes		(7	)
Long-term portion of unsecured subordinated promissory notes	$	-

(8) DEFERRED INSURANCE REIMBURSEMENT

During the first quarter of 2016, the Company collected $880,000 from a single insurance company for accounts receivable. The accounts receivable had been previously reduced to zero by the allowance for billing adjustments. Subsequent to March 31, 2016, the insurance company verbally communicated to the Company that this payment was made in error and requested it be refunded to the insurance company. The Company recorded this $880,000 insurance reimbursement as a deferred insurance liability. However, the Company is disputing the refund request and has initiated an internal review of the reimbursement to determine that the original sales arrangement was properly executed, the products had been shipped and title was transferred, the price of the products or services and the reimbursement rate is fixed and determinable, and the Company’s ultimate claim to the reimbursement is reasonably assured. The Company will record the appropriate amount as net revenue when such internal review is complete and any refund obligation is deemed remote.

(9) CAPITAL LEASES AND OTHER OBLIGATIONS

On October 20, 2017 the Company entered into a sublease agreement with CSG Systems Inc. for approximately 41,715 square feet at 9555 Maroon Circle, Englewood CO 80112. The Term of the Sublease runs through June 30, 2023, with an option to extend for an additional two years through June 30, 2025. During the first year of the Sublease, the rent per square foot is $7.50, increasing to $19.75 during the second year of the Sublease and each year thereafter for the Initial Term increasing by an additional $1 per square foot. The Company is also obligated to pay its proportionate share of building operating expenses. The Sublandlord agreed to contribute approximately $0.2 million toward tenant improvements.

Our prior headquarters lease in Lone Tree, Colorado contained a termination clause which allowed the Company to terminate the lease at any time with three months written notice. We provided notice to the landlord at the end of October 2017.

We entered into a new month to month lease at our Lone Tree, Colorado location for warehouse and production space which will be transitioned to our new Englewood, Colorado location during the second quarter of 2018. The lease is for 12,494 rentable square feet at $26.50 per square foot and can be terminated at any time with thirty days’ notice. Termination notice was given on April 3, 2018.

The Company also leases certain equipment under capital leases which expire on various dates through 2018. Imputed interest rates on the leases range from approximately 2% to 10%. At March 31, 2018, the total recorded cost of assets under capital leases was approximately $0.5 million. Accumulated depreciation related to these assets totals approximately $0.4 million.

Future minimum commitments under non-cancelable operating leases and capital leases as of December 31, 2017 are as follows (in thousands):

	Operating Leases		Capital Leases
2018	$	463	$	125
2019		830		-
2020		873		-
2021		914		-
2022		956
Thereafter		495		-
Total minimum lease payments	$	4,531		125
Less: Amount representing interest				(2	)
Principal balance of capital lease obligation				123
Less: Current portion of capital lease obligation				(123	)
Long-term portion of capital lease obligation			$	-

(10) CONCENTRATIONS

For the three months ended March 31, 2018, the Company sourced approximately 86% of the components for its electrotherapy products from two significant vendors (defined as supplying at least 10%). For the three months ended March 31, 2017 the company sourced approximately 45% from the same two significant vendors. Management believes that its relationships with suppliers are good; however, if the relationships were to be replaced, there may be a short-term disruption to operations, a period of time in which products may not be available and additional expenses may be incurred.

The Company had receivables from a private health insurance carrier at March 31, 2017 and December 31, 2017, that made up approximately 21% and 24%, respectively, of the net accounts receivable balance.

(11) LITIGATION

From time to time, the Company may become party to litigation and other claims in the ordinary course of business. To the extent that such claims and litigation arise, management would provide for them if losses are determined to be both probable and estimable.

The Company is currently not a party to any material pending legal proceedings.

(12) RELATED PARTY TRANSACTIONS

The Company employs Mr. Martin Sandgaard and Mr. Joachim Sandgaard, both sons of Thomas Sandgaard. Compensation was $54,000 and $44,000 for the three months ended March 31, 2018 and 2017, respectively. To meet Mr. Sandgaard’s obligation to his former wife under a settlement agreement, the Company, during the fourth quarter of 2015, entered into 3-year employment arrangement totaling $100,000 per year with Mr. Joachim Sandgaard.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Notice Regarding Forward-Looking Statements

This quarterly report contains statements that are forward-looking, such as statements relating to plans for future organic growth and other business development activities, as well as the impact of reimbursement trends, other capital spending and financing sources. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the Company. These risks include the ability to engage effective sales representatives, the need to obtain U.S. Food and Drug Administration (“FDA”) clearance and Certificate European (“CE”) marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers for reimbursement, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on third-party manufacturers to produce key components of our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, and other risks described herein and in our Annual Report on Form 10-K for the year ended December 31, 2017.

These interim financial statements and the information contained in this Quarterly Report on Form 10-Q should be read in conjunction with the annual audited consolidated financial statements, and notes to consolidated financial statements, included in the Company’s 2017 Annual Report on Form 10-K and subsequently filed reports, which have previously been filed with the Securities and Exchange Commission.

General

Zynex, Inc. (a Nevada corporation) has its headquarters in Englewood, Colorado. We operate in one primary business segment, Electrotherapy and Pain Management Products. As of March 31, 2018, the Company’s only active subsidiary is Zynex Medical, Inc. (“ZMI,” a wholly-owned Colorado corporation) through which the Company conducts most of its operations. One other subsidiary, Zynex Europe, ApS (“ZEU,” a wholly-owned Denmark corporation), did not generate material revenues during the three months ended March 31, 2018 and 2017 from international sales and marketing. Zynex Monitoring Solutions, Inc. (“ZMS,” a wholly-owned Colorado corporation) has developed a blood volume monitoring device, but it is awaiting approval by the U.S. Food and Drug Administration (“FDA”) as well as CE Marking in Europe, therefore, ZMS has achieved no revenues to date.

RESULTS OF OPERATIONS

Summary

Net revenue was $6.9 million and $3.4 million for the three months ended March 31, 2018 and 2017, respectively. Net revenue increased 100% for the three months ended March 31, 2018. Net income was $1.9 million and $0.4 million for the three months ended March 31, 2018 and 2017, respectively, a 444% increase. We generated cash flows from operating activities of $1.0 million during the three months ended March 31, 2018.

Net Revenue

Net revenues are comprised of device and supply sales, whereas the transaction price is reduced by estimated Third-party Payors reimbursement deductions, if needed. The allowance on transaction price adjustments are adjusted on an ongoing basis in conjunction with the processing of Third-party Payor insurance claims and other customer collection history. Device revenue is primarily comprised of our Transcutaneous Electrical Nerve Stimulation (“TENS”) products and also includes our cervical traction, lumbar support and hot/cold therapy products. Supply revenue includes consumable supplies related primarily to our TENS products.

We also sell consumable supplies for all patients using our electrotherapy devices, consisting primarily of surface electrodes and batteries. Revenue for the electrotherapy products is reported net, after adjustments for estimated insurance company reimbursement deductions and refund allowance. The deductions are known throughout the health care industry as “billing adjustments” whereby the healthcare insurers unilaterally reduce the amount they reimburse for our products as compared to the sales prices charged by us. The deductions from gross revenue also take into account the estimated denials, net of resubmitted billings of claims for products placed with patients which may affect collectability. Seasonality associated with annual insurance deductibles can impact general trends in collection rates. See Note 1 to these Condensed Consolidated Financial Statements for a more complete explanation of our revenue recognition policies.

We continually pursue improvements to our processes of billing insurance providers. We review all claims which are initially denied or not received. As these situations are identified and resolved, the appropriate party is appropriately rebilled (resubmitted) or, for those claims not previously billed, billed.

We frequently receive, and expect to continue to receive, refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in our industry. These requests are sometimes related to a few patients and other times include a significant number of refund claims in a single request. We review and evaluate these requests and determine if any refund is appropriate. We also review claims where we are rebilling or pursuing additional reimbursement from that insurance provider. We frequently have significant offsets against such refund requests which may result in amounts that are due to us in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests we are generally unable to determine if a refund request is valid.

As of March 31, 2018, we believe we have an adequate allowance for billing adjustments relating to known insurance disputes and refund requests. However, no assurances can be given with respect to such estimates of reimbursements and offsets or the ultimate outcome of any refund requests.

Device Revenue

Device revenue is related to the purchase of our products. Device revenue increased $0.2 million or 15% to $1.6 million for the three months ended March 31, 2018, from $1.4 million for the three months ended March 31, 2017. The increase in device revenue is primarily related to growth in our sales force which has resulted in more device sales.

Supplies Revenue

Supplies revenue is related to the sale of supplies, typically electrodes and batteries, for our products. Supplies revenue increased $3.2 million or 158% to $5.3 million for the three months ended March 31, 2018, from $2.1 million for the three months ended March 31, 2017. The increase in supplies revenue is primarily related to an increased customer base from increased sales in 2016 and 2017, plus improvements in our billing and collection procedures.

Operating Expenses

Cost of Revenue – Device and Supply

Cost of Revenue – device and supply consist primarily of device and supply costs, operations labor and overhead, shipping and depreciation. Cost of revenue for the three months ended March 31, 2018 and 2017, increased 34% to $1.2 million from $0.9 million, respectively. The increase in cost of revenue is primarily due to the increase in device and supply orders. As a percentage of revenue, cost of revenue –device and supply decreased to 18% for the three months ended March 31, 2018 from 27% for the three months ended March 31, 2017. The decrease as a percentage of revenue is primarily due to the increase in revenue during the period from improved collections on gross billings and changes in our product mix between supplies and devices.

Selling, General and Administrative Expenses

Selling, general and administrative expenses primarily consist of employee related costs, including commissions and other direct costs associated with these personnel including facilities and travel expenses and professional fees, depreciation and amortization. Selling, general and administrative expense for the three months ended March 31, 2018 and 2017 increased 82% to $3.7 million from $2.0 million, respectively. The increase in selling, general and administrative expense is primarily due to increased compensation expense related to headcount growth, increased incentive compensation and commissions and increased rent and relocation related to our new facility. As a percentage of revenue, selling, general and administrative expense decreased to 54% for the three months ended March 31, 2018 from 59% for the three months ended March 31, 2017. The decrease as a percentage of revenue is due to the increase in revenue during the period which more than offset the aforementioned increase in expenses.

Other (Expense)

Other expense is composed primarily interest expense and debt issuance costs. For the three months ended March 31, 2018 and 2017, other expense was $0.1 million. The expense during the periods is amortization of debt issuance costs and debt discount related the private placement completed in during the first quarter of 2017 (Note 7).

Income Taxes

The provision for income taxes is recorded at the end of each interim period based on the Company’s best estimate of its effective income tax rate expected to be applicable for the full fiscal year. The Company’s effective income tax rate was 6% and 2% for the three months ended March 31, 2018 and 2017, respectively. Discrete items recognized during the three months ended March 31, 2018 results in a tax benefit of approximately $0.1 million. The Company recorded income tax expense of $9,000 for the three months ended March 31, 2017.

LIQUIDITY AND CAPITAL RESOURCES

We have historically financed operations through cash flows from operations, debt and equity transactions. At March 31, 2018, our principal source of liquidity was $4.4 million in cash and $2.7 million in accounts receivables, net of allowances. The decreased cash balance at March 31, 2018 was due cash used in investing of $0.2 million related primarily to leasehold improvements at our new corporate headquarters and cash used in financing of $2.0 million which was comprised of $1.8 million of common stock re-purchases and $0.3 million of payments on our subordinated notes payable. Partially offsetting the cash used in investing and financing activities was the cash generated from operations of $1.0 million during the first three months of 2018. Our anticipated uses of cash in the future will be to fund the expansion of our business.

Net cash provided by operating activities for the three months ended March 31, 2018 and 2017 was $1.0 million and $23,000, respectively. The increase in cash provided by operating activities for the three months ended March 31, 2018 was primarily due to the significant increase in profitability in 2018.

Net cash used in investing activities for each of the three month periods ended March 31, 2018 and 2017 was $0.2 million and $57,000, respectively. Cash used in investing activities for the three months ended March 31, 2018 is primarily related to leasehold improvements at our new corporate headquarters.

Net cash provided by (used in) financing activities for the three months ended March 31, 2018 and 2017 was ($2.0 million) and $0.2 million, respectively. The cash used in financing activities for the three months ended March 31, 2018 was primarily due to the re-purchases of our common stock of $1.8 million and $0.3 million of principal payments on our subordinated notes payable. The cash provided by financing activities for the three months ended March 31, 2017 was primarily related to the proceeds of our subordinated notes payable, partially offset by repayments on our credit facility with Triumph Bank and fees paid on the closing of our subordinated notes payable.

We believe our cash and cash equivalents, together with anticipated cash flow from operations will be sufficient to meet our working capital, debt extinguishment and capital expenditure requirements for at least the next twelve months. In making this assessment, we considered the following:

Our cash and cash equivalents balance at March 31, 2018 of $4.4 million;

Our working capital balance of $4.6 million;

Our profitability during the last 7 quarters; and

Our planned capital expenditures of less than $1.0 million during 2018.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.

On January 1, 2018 the company adopted Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU 2014-09),. Pursuant to the revenue from contracts with customer’s standards the Company recognizes revenue when it transfers promised goods to customers in an amount that reflects the consideration to which the company expects to be entitled, known as the transaction price. The company elected to use the modified retrospective method which resulted in immaterial changes to previously issued financial statements and retained earnings.

Please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and Note 2 to the Consolidated Financial Statements located within our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on February 28, 2018.

OFF BALANCE SHEET ARRANGEMENTS

The Company had no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

In the ordinary course of business, we are exposed to certain market risks, including changes in interest rates. Uncertainties that are either non-financial or non-quantifiable such as political, economic, tax, other regulatory, or credit risks are not included in the following assessment of market risks.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer (CEO) and chief financial officer (CFO), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our CEO and CFO have concluded that as of March 31, 2018, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (SEC), and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Changes in Internal Control Over Financial Reporting

There were no changes that materially affected or are reasonably likely to affect our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are not a party to any material pending legal proceedings.

ITEM 1A. RISK FACTORS

There have been no material changes in the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC on February 28, 2018.

This Quarterly Report on Form 10-Q should be read in conjunction with the risk factors defined in our Annual Report on Form 10-K for the year ended December 31, 2017 under “Item 1A. Risk Factors.”

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the period covered by this Form 10-Q, there were no sales of unregistered securities

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

N/A

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

Exhibit Number		Description

31.1*		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002

31.2*		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002

32.1*		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Calculation Linkbase Document

101.DEF *		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB *		XBRL Taxonomy Label Linkbase Document

101.PRE *		XBRL Presentation Linkbase Document

Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ZYNEX, INC.

Dated: May 8, 2018	/s/ DANIEL J. MOORHEAD
	Daniel J. Moorhead
	Chief Financial Officer and Principal Financial Officer

EX-31.1 2 tv491631_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, Thomas Sandgaard, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Zynex, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 8, 2018

/s/ THOMAS SANDGAARD
Thomas Sandgaard
Chairman, President, Chief Executive Officer and Principal Executive Officer

EX-31.2 3 tv491631_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, Daniel J. Moorhead, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Zynex, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 8, 2018

/s/ DANIEL J. MOORHEAD
Daniel J. Moorhead
Chief Financial Officer and Principal Financial Officer

EX-32.1 4 tv491631_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies, for the purposes of Section 1350 of Chapter 63 of Title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Zynex, Inc. (“Zynex”), that to his knowledge:

This Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of Zynex for the period covered by this Report.

This Certification is executed as of May 8, 2018.

/s/ THOMAS SANDGAARD
Thomas Sandgaard
Chairman, President, Chief Executive Officer and Principal Executive Officer

EX-32.2 5 tv491631_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

This Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of Zynex for the period covered by this Report.

This Certification is executed as of May 8, 2018.

/s/ DANIEL J. MOORHEAD
Daniel J. Moorhead
Chief Financial Officer and Principal Financial Officer

The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of Zynex, Inc. under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

EX-101.INS 6 zyxi-20180331.xml XBRL INSTANCE DOCUMENT 0000846475 2017-01-01 2017-03-31 0000846475 2017-01-01 2017-12-31 0000846475 2018-01-01 2018-03-31 0000846475 2015-02-07 2018-03-06 0000846475 2016-03-31 0000846475 2018-03-31 0000846475 2018-05-04 0000846475 2017-09-21 2017-10-20 0000846475 2017-10-01 2017-10-31 0000846475 2017-10-20 0000846475 2017-12-31 0000846475 2016-12-31 0000846475 2017-03-31 0000846475 us-gaap:NorthAmericaMember 2018-01-01 2018-03-31 0000846475 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2017-08-01 2017-08-28 0000846475 zyxi:StockIncentivePlan2017Member 2018-03-31 0000846475 us-gaap:RestrictedStockMember us-gaap:ManagementMember 2018-01-01 2018-03-31 0000846475 zyxi:TwoThousandAndFiveStockOptionPlanMember 2018-03-31 0000846475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-03-31 0000846475 zyxi:NewbridgeSecuritiesCorporationMember 2018-01-01 2018-03-31 0000846475 zyxi:NewbridgeSecuritiesCorporationMember us-gaap:UnsecuredDebtMember 2017-02-28 0000846475 zyxi:NewbridgeSecuritiesCorporationMember 2017-02-01 2017-02-28 0000846475 zyxi:NewbridgeSecuritiesCorporationMember 2017-02-28 0000846475 zyxi:NewbridgeSecuritiesCorporationMember us-gaap:UnsecuredDebtMember us-gaap:MinimumMember 2016-11-30 0000846475 zyxi:NewbridgeSecuritiesCorporationMember us-gaap:MaximumMember us-gaap:UnsecuredDebtMember 2016-11-30 0000846475 us-gaap:SupplierConcentrationRiskMember zyxi:TwoVendorMember 2018-01-01 2018-03-31 0000846475 us-gaap:SupplierConcentrationRiskMember us-gaap:MinimumMember 2018-01-01 2018-03-31 0000846475 zyxi:TwoVendorMember us-gaap:SupplierConcentrationRiskMember 2017-01-01 2017-03-31 0000846475 us-gaap:AccountsReceivableMember 2017-01-01 2017-03-31 0000846475 us-gaap:AccountsReceivableMember 2017-01-01 2017-12-31 0000846475 zyxi:EmploymentArrangementMember us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember 2015-10-01 2015-12-31 0000846475 us-gaap:FurnitureAndFixturesMember 2018-03-31 0000846475 us-gaap:FurnitureAndFixturesMember 2017-12-31 0000846475 us-gaap:EquipmentMember 2018-03-31 0000846475 us-gaap:EquipmentMember 2017-12-31 0000846475 us-gaap:VehiclesMember 2018-03-31 0000846475 us-gaap:VehiclesMember 2017-12-31 0000846475 us-gaap:LeaseholdImprovementsMember 2018-03-31 0000846475 us-gaap:LeaseholdImprovementsMember 2017-12-31 0000846475 us-gaap:AssetsHeldUnderCapitalLeasesMember 2018-01-01 2018-03-31 0000846475 us-gaap:AssetsHeldUnderCapitalLeasesMember 2017-01-01 2017-03-31 0000846475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-03-31 0000846475 zyxi:TriumphbankMember 2016-02-27 2016-03-28 0000846475 zyxi:TriumphbankMember 2016-03-28 0000846475 us-gaap:WarrantMember 2017-12-31 0000846475 us-gaap:WarrantMember 2018-01-01 2018-03-31 0000846475 us-gaap:WarrantMember 2018-03-31 0000846475 us-gaap:AccountsPayableMember 2018-03-31 0000846475 us-gaap:WarrantMember 2017-01-01 2017-12-31 0000846475 us-gaap:ScenarioPlanMember 2018-01-01 2018-12-31 0000846475 us-gaap:LeaseholdImprovementsMember 2018-01-01 2018-03-31 0000846475 us-gaap:MinimumMember 2018-01-01 2018-03-31 0000846475 us-gaap:MaximumMember 2018-01-01 2018-03-31 0000846475 zyxi:PrivatePlacementMemorandumMember 2018-01-01 2018-03-31 0000846475 zyxi:PrivatePlacementMemorandumMember 2018-03-31 0000846475 zyxi:NewbridgeSecuritiesCorporationMember 2017-01-01 2017-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares utr:acre xbrli:pure 10-Q false 2018-03-31 2018 Q1 ZYNEX INC 0000846475 --12-31 Smaller Reporting Company ZYXI 33116334

4366000

5565000

2668000

2185000

710000

423000

615000

198000

8359000

8371000

575000

188000

375000

370000

9309000

8929000

93000

123000

2112000

2243000

661000

538000

3753000

4015000

12000

4094000

4027000

5215000

4902000

-89000

5304000

4991000

-490000

-2411000

7761000

7612000

33000

880000

9309000

8929000

880000

7000

231000

3685000

2030000

1955000

483000

115000

121000

1921000

353000

1921000

353000

1840000

362000

0.06

0.01

0.06

0.01

32601000

31418000

34414000

32036000

-81000

9000

6876000

3436000

4921000

2953000

-160000

-57000

-1199000

215000

8000

121000

247000

462000

993000

23000

-600000

1035000

155000

30000

31000

-2032000

249000

160000

57000

331000

0.9999

0.2

1813000

618000

200000

1100000

776250

5000000

65000

3000000

63000

200000

0.28

P0Y

P6Y3M

0.0164

1.2904

2136000

65000

6000

0.54

1.28

237000

1958000

1261000

0.36

0.54

0.4

P6Y3M7D

P4Y11M26D

5579000

3720000

5645000

P6Y3M22D

600000

P2Y11M19D

107000

1035000

0.05 155000 776250 255000

776250

255000

342000

1000000

1500000

0.1 0.03

0.86

0.1

0.45

0.21

0.24

P3Y

100000000

54000000 44000000

329000

2000000

243000

0.001

10000000

0.001

100000000

33101834

32606743

32864877

32778040

495091

86837

1588000

1384000

5288000

2052000

1236000

923000

1757000

86000

1033000

998000

128000

76000

378000

1615000

1202000

1040000

1014000

461000

395000

379000

66000

82000

26000

100000

16000

23000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The calculation of basic and diluted earnings per share for the three months ended March 31, 2018 and 2017 are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div> For the Three Months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Basic income per share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="75%"> <div>Net income available to common stockholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,921</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>353</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Basic weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>32,601</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>31,418</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Basic income per share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.06</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Diluted income per share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Net income available to common stockholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,921</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>353</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>32,601</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>31,418</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Effect of dilutive securities - options and restricted stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,813</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>618</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Diluted weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34,414</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>32,036</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Diluted income per share:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.06</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company used the Black Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> for 2017. There were no options granted during the three months ended March 31,2018</font>:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> For the Three Months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="7%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="7%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">6.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">1.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">129.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Expected dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> A summary of stock option <font style="WIDOWS: 2; TEXT-TRANSFORM: none; FONT-STYLE: normal; TEXT-INDENT: 0px; LETTER-SPACING: normal; DISPLAY: inline !important; FONT-FAMILY: 'Times New Roman', Times, serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; COLOR: rgb(0,0,0); FONT-SIZE: 13px; FONT-WEIGHT: 400; WORD-SPACING: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> and restricted stock</font> activity under all equity compensation plans for the three months ended March 31, 2018, is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Outstanding at December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,136</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,645</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(6)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(237)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,958</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,579</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Exercisable at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,261</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,720</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

24000

100000

880000

41715

200000

first year of the Sublease, the rent per square foot is $7.50, increasing to $19.75 during the second year of the Sublease and each year thereafter for the Initial Term increasing by an additional $1 per square foot.

June 30, 2025

495091

4.04

150000

250000

50000

2000000

200000

1.86

264000

305000

0.9999

461000

395000

600000

P5Y9M18D

P5Y7M13D

253000 0

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>(1)  <u>BASIS OF PRESENTATION</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u>Organization</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Zynex, Inc. (a Nevada corporation) has its headquarters in Englewood, Colorado.  We operate one primary business segment, medical devices which include Electrotherapy and Pain Management Products. As of March 31, 2018, the Company’s only active subsidiary is Zynex Medical, Inc. (“ZMI,” a wholly-owned Colorado corporation) through which the Company conducts most of its operations. One other subsidiary, Zynex Europe, ApS (“ZEU,” a wholly-owned Denmark corporation), did not generate material revenues during the three months ended March 31, 2018 and 2017 from international sales and marketing. Zynex Monitoring Solutions, Inc. (“ZMS,” a wholly-owned Colorado corporation) has developed a blood volume monitoring device, but it is awaiting approval by the U.S. Food and Drug Administration (“FDA”) as well as CE Marking in Europe, therefore, ZMS has achieved no revenues to date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The term “the Company” refers to Zynex, Inc. and its active and inactive subsidiaries.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u>Nature of Business</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMI devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (“IFC”), neuromuscular electrical stimulation (“NMES”) and transcutaneous electrical nerve stimulation (“TENS”). All our medical devices are intended to be patient friendly and designed for home use. The ZMI devices are small, portable, battery operated and include an electrical pulse generator which is connected to the body via electrodes. All of our medical devices are marketed in the U.S. and are subject to FDA regulation and approval.  Our products require a physician’s prescription before they can be dispensed in the U.S. ZMI’s primary product is the NexWave device.  The NexWave is marketed to physicians and therapists by our field sales representatives.   The NexWave requires consumable supplies, such as electrodes and batteries, which are shipped to patients on a recurring monthly basis, as needed.  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the three months ended March 31, 2018 and 2017, the Company generated substantially all of its revenue (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">99.99</font>%) in North America from sales and supplies of its devices to patients and health care providers.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Unaudited Condensed Consolidated Financial Statements</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The unaudited condensed consolidated financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. A description of the Company’s accounting policies and other financial information is included in the audited consolidated financial statements as filed with the SEC in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Amounts as of December 31, 2017, are derived from those audited consolidated financial statements. These interim condensed consolidated financial statements should be read in conjunction with the annual audited financial statements, accounting policies and notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, which has previously been filed with the SEC.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of March 31, 2018 and the results of its operations and its cash flows for the periods presented.  The results of operations for the three months ended March 31, 2018, are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b> </b></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Principles of Consolidation</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Non-controlling Interest</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Non-controlling interest in the equity of a subsidiary is accounted for and reported as stockholders’ equity. Non-controlling interest represents the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20</font>% ownership in the Company’s majority-owned (but currently inactive) subsidiary, ZBC.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Reclassifications</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Certain reclassifications have been made to the 2017 financial statements to conform to the consolidated 2018 financial statement presentation. These reclassifications had no effect on net earnings or cash flows as previously reported.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We reclassified amounts between device and supplies revenue for all of the quarters ended during 2017. The change was due to enhanced information which allowed us to perform a more detailed analysis of revenue and the related classifications. The reclassification did not change total net revenue.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Use of Estimates</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant management estimates used in the preparation of the accompanying consolidated financial statements are associated with the allowance for billing adjustments and uncollectible accounts receivable, the reserve for obsolete and damaged inventory, stock-based compensation, and valuation of long-lived assets and realizability of deferred tax assets.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Revenue Recognition, Allowance for Billing Adjustments and Collectability</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On January 1, 2018 the company adopted the new accounting standard on revenue recognition issued by the Financial Accounting Standards Board (“FASB”). Pursuant to the revenue from contracts with customer’s standards the Company recognizes revenue when it transfers promised goods to customers in an amount that reflects the consideration to which the company expects to be entitled, known as the transaction price. The company elected to use the modified retrospective method which resulted in immaterial changes to previously issued financial statements and retained earnings.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Revenue is generated primarily from sales in the United States of our electrotherapy devices and associated supplies. Sales are primarily made with, and shipped, direct to the patient with a small amount of revenue generated from sales to distributors. Revenue is recognized on medical devices when we receive notice that the device has been prescribed by a doctor and delivered to the patient. Supplies revenue is recognized once delivered to the patient. Supplies needed for the device can be set up as a recurring shipment or ordered thru the customer support team or online store as needed.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Being in the healthcare industry there is often a third party involved that will pay on the patients behalf. The terms of the separate arrangement can impact certain aspects of the contracts, with patients covered by third party payors, such as performance obligations and transaction price, but for purposes of revenue recognition the contract with the customer refers to the arrangement between the Company and the patient. The company does not report any deferred revenue as each performance obligation is met upon delivery of goods to the patient. There are no substantial costs incurred through support or warranty obligations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">A significant portion of the Company’s revenues are derived, and the related receivables are due, from a commercial health insurance or government agency (collectively “Third-party Payors”). Transaction price is estimated with variable consideration using the most likely amount technique for Third-party Payor reimbursement deductions, known throughout the health care industry as “billing adjustments” whereby the Third-party Payors unilaterally reduce the amount they reimburse for the Company’s products, refund requests, and for the timing and values of amounts to be billed. Supplies are billed only upon shipment. Devices can be billed upon shipment or over billing cycles. Billing cycles can be over a variable period and are estimated in amounts such that the likelihood that a significant reversal of revenue will not occur. Roughly <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15</font>% of total revenue and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 66</font>% of device revenue are billed in cycles. Inherent in these estimates is the risk that they will have to be revised as additional information becomes available and constraints are released. Specifically, the complexity of third-party billing arrangements and the uncertainty of reimbursement amounts for certain products from payors or unanticipated requirements to refund payments previously received may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party reimbursement, as well as changes in our billing practices to increase cash collections, it is possible our forecasting model to estimate collections could change, which could have an impact on our results of operations and cash flows. Any differences between estimated settlements and final determinations are reflected as an increase or a reduction to revenue in the period when such final determinations are known.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The basis of estimates include historical rates of collection, the aging of the receivables, trends in the historical reimbursement rates by insurance groups, determined using the portfolio approach, and current relationships and experience with the Third-party Payors. A change in the way estimates are determined can result from a number of factors, including experience and training of billing personnel, changes in the reimbursement policies or practices of Third-party Payors, or changes in industry rates of reimbursement. The company monitors the variability and uncertain timing over payor groups in our portfolios. If there is a change in our payor mix over time, it could affect our net revenue and related receivables. We believe we have a sufficient history of collection experience to estimate the net collectible amounts by payor. However, changes to the allowance for billing adjustments, which are recorded as a reduction of transaction price, have historically fluctuated and may continue to fluctuate significantly from quarter to quarter and year to year.</div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company frequently receives refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in the Company’s industry. These requests are sometimes related to a limited number of patients or products; at other times, they include a significant number of refund claims in a single request. The Company reviews and evaluates these requests and determines if any refund request is appropriate. The Company also reviews these refund claims when it is rebilling or pursuing reimbursement from insurance providers. The Company frequently has significant offsets against such refund requests, and sometimes amounts are due to the Company in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests, the Company is generally unable to determine if a refund request is valid and should be accrued. Such refunds are recorded when the amount is fixed and determinable, however management maintains an allowance for estimated future refunds which we believe is sufficient to cover future claims in connection with its estimates of variable consideration recorded at the time sales are recorded.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Fair Value of Financial Instruments</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company’s financial instruments include cash, accounts receivable, accounts payable and income taxes, for which current carrying amounts approximate fair value due to their short-term nature. Financial instruments also included the notes payable related to our private placement and capitalized leases, the carrying value of which approximates fair value because the interest rates on the outstanding borrowings are at rates that approximate market rates for borrowings with similar terms and average maturities.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Inventory</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Inventory, which primarily represents parts and supplies, are valued at the lower of cost (average) or market.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company monitors inventory for turnover and obsolescence and records losses for excess and obsolete inventory, as appropriate. The Company provides reserves for estimated excess and obsolete inventories equal to the difference between the costs of inventories on hand and the estimated market value based upon assumptions about future demand. If future demand is less favorable than currently projected by management, additional inventory write-downs may be required.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Total gross inventories at March 31, 2018 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.7</font> million which was comprised of finished goods, work in progress, and parts and supplies as compared to December 31, 2017 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.4</font> million.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Segment Information </u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> We define operating segments as components of our enterprise for which separate financial information is reviewed regularly by the chief operating decision-makers to evaluate performance and to make operating decisions. We have identified our Chief Executive Officer and Chief Financial Officer as our chief operating decision-makers (“CODM”).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> We currently operate our business as one operating segment which includes two revenue types:  Devices and Supplies. </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><u><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</font></u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We record deferred tax assets and liabilities for the estimated future tax effects of temporary differences between the tax bases of assets and liabilities and amounts reported in the accompanying consolidated balance sheets, as well as operating loss and tax credit carry-forwards. We measure deferred tax assets and liabilities using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled.  We reduce deferred tax assets by a valuation allowance if, based on available evidence, it is more likely than not that these benefits will not be realized.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 22, 2017, the U.S. government enacted comprehensive tax legislation (the “Tax Act”), which significantly revises the ongoing U.S. corporate income tax law by lowering the U.S. federal corporate income tax rate from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 21</font>%, implementing a territorial tax system, imposing a one-time tax on foreign unremitted earnings and setting limitations on deductibility of certain costs, among other things.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company is subject to the provisions of the Financial Accounting Standards Board (“FASB”) ASC 740-10, Income Taxes, which requires that the effect on deferred tax assets and liabilities of a change in tax rates be recognized in the period the tax rate change was enacted. Due to the complexities involved in accounting for the recently enacted Tax Act, the U.S. Securities and Exchange Commission’s Staff Accounting Bulletin (“SAB”) 118 requires that the Company include in its financial statements the reasonable estimate of the impact of the Tax Act on earnings to the extent such estimate has been determined.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Pursuant to the SAB118, the Company is allowed a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts. The final impact on the Company from the Tax Act’s transition tax legislation may differ from the aforementioned estimates due to the complexity of calculating and supporting with primary evidence such U.S. tax attributes such as accumulated foreign earnings and profits, foreign tax paid, and other tax components involved in foreign tax credit calculations for prior years back to 1998. Such differences could be material, due to, among other things, changes in interpretations of the Tax Act, future legislative action to address questions that arise because of the Tax Act, changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the Company has utilized to calculate the transition tax's reasonable estimate. The Company will continue to evaluate the impact of the U.S. Tax Act and will record any resulting tax adjustments during 2018.</font><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Recent Accounting Pronouncements</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In August 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”), which amends and simplifies existing guidance in order to allow companies to more accurately present the economic effects of risk management activities in the financial statements. ASU 2017-12 is effective for us in the first quarter of fiscal 2020, and earlier adoption is permitted. We are currently evaluating the impact of our pending adoption of ASU 2017-12 on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) ("ASU 2016-13"), Measurement of Credit Losses on Financial Instruments. The standard significantly changes how entities will measure credit losses for most financial assets and certain other instruments that aren't measured at fair value through net income. The standard will replace today's "incurred loss" approach with an "expected loss" model for instruments measured at amortized cost. For available-for-sale debt securities, entities will be required to record allowances rather than reduce the carrying amount, as they do today under the other-than-temporary impairment model. It also simplifies the accounting model for purchased credit-impaired debt securities and loans. This ASU is effective for annual periods beginning after December 15, 2019, and interim periods therein. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the impact that the adoption of ASU 2016-13 will have on our financial condition, results of operations and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In February 2018, the FASB issued Accounting Standards Update No. 2018-02,<i> </i> Income StatementReporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (“ASU 2018-02”),<i> </i> which allows companies to reclassify stranded tax effects resulting from the 2017 Tax Cuts and Jobs Act (the Tax Act), from accumulated other comprehensive income to retained earnings. The new standard is effective for us beginning January 1, 2019, with early adoption permitted. We are currently evaluating the effects that the adoption of this guidance will have on our consolidated financial statements and the related disclosures.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). These amendments require the recognition of lease assets and lease liabilities on the balance sheet by lessees for those leases currently classified as operating leases under ASC 840 “Leases”. These amendments also require qualitative disclosures along with specific quantitative disclosures. These amendments are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. Entities are required to apply the amendments at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact that the adoption of ASU 2016-02 will have on our financial condition, results of operations and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a material impact on the Company’s consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u>Recent Adopted Accounting Pronouncements</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In May 2014, the FASB issued ASU No. 2014-09“Revenue from Contracts with Customers” (Topic 606) which amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract.  The Company adopted the new ASU as of January 1, 2018 using the modified retrospective method and resulted in no material changes to previously stated financial statements. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">For further details see the revenue recognition description in Note 1.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Principles of Consolidation</font></u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Non-controlling Interest</font></u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Non-controlling interest in the equity of a subsidiary is accounted for and reported as stockholders’ equity. Non-controlling interest represents the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20</font>% ownership in the Company’s majority-owned (but currently inactive) subsidiary, ZBC.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Reclassifications</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Certain reclassifications have been made to the 2017 financial statements to conform to the consolidated 2018 financial statement presentation. These reclassifications had no effect on net earnings or cash flows as previously reported.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We reclassified amounts between device and supplies revenue for all of the quarters ended during 2017. The change was due to enhanced information which allowed us to perform a more detailed analysis of revenue and the related classifications. The reclassification did not change total net revenue.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant management estimates used in the preparation of the accompanying consolidated financial statements are associated with the allowance for billing adjustments and uncollectible accounts receivable, the reserve for obsolete and damaged inventory, stock-based compensation, and valuation of long-lived assets and realizability of deferred tax assets.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition, Allowance for Billing Adjustments and Collectability</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On January 1, 2018 the company adopted the new accounting standard on revenue recognition issued by the Financial Accounting Standards Board (“FASB”). Pursuant to the revenue from contracts with customer’s standards the Company recognizes revenue when it transfers promised goods to customers in an amount that reflects the consideration to which the company expects to be entitled, known as the transaction price. The company elected to use the modified retrospective method which resulted in immaterial changes to previously issued financial statements and retained earnings.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Revenue is generated primarily from sales in the United States of our electrotherapy devices and associated supplies. Sales are primarily made with, and shipped, direct to the patient with a small amount of revenue generated from sales to distributors. Revenue is recognized on medical devices when we receive notice that the device has been prescribed by a doctor and delivered to the patient. Supplies revenue is recognized once delivered to the patient. Supplies needed for the device can be set up as a recurring shipment or ordered thru the customer support team or online store as needed.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Being in the healthcare industry there is often a third party involved that will pay on the patients behalf. The terms of the separate arrangement can impact certain aspects of the contracts, with patients covered by third party payors, such as performance obligations and transaction price, but for purposes of revenue recognition the contract with the customer refers to the arrangement between the Company and the patient. The company does not report any deferred revenue as each performance obligation is met upon delivery of goods to the patient. There are no substantial costs incurred through support or warranty obligations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">A significant portion of the Company’s revenues are derived, and the related receivables are due, from a commercial health insurance or government agency (collectively “Third-party Payors”). Transaction price is estimated with variable consideration using the most likely amount technique for Third-party Payor reimbursement deductions, known throughout the health care industry as “billing adjustments” whereby the Third-party Payors unilaterally reduce the amount they reimburse for the Company’s products, refund requests, and for the timing and values of amounts to be billed. Supplies are billed only upon shipment. Devices can be billed upon shipment or over billing cycles. Billing cycles can be over a variable period and are estimated in amounts such that the likelihood that a significant reversal of revenue will not occur. Roughly <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15</font>% of total revenue and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 66</font>% of device revenue are billed in cycles. Inherent in these estimates is the risk that they will have to be revised as additional information becomes available and constraints are released. Specifically, the complexity of third-party billing arrangements and the uncertainty of reimbursement amounts for certain products from payors or unanticipated requirements to refund payments previously received may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party reimbursement, as well as changes in our billing practices to increase cash collections, it is possible our forecasting model to estimate collections could change, which could have an impact on our results of operations and cash flows. Any differences between estimated settlements and final determinations are reflected as an increase or a reduction to revenue in the period when such final determinations are known.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The basis of estimates include historical rates of collection, the aging of the receivables, trends in the historical reimbursement rates by insurance groups, determined using the portfolio approach, and current relationships and experience with the Third-party Payors. A change in the way estimates are determined can result from a number of factors, including experience and training of billing personnel, changes in the reimbursement policies or practices of Third-party Payors, or changes in industry rates of reimbursement. The company monitors the variability and uncertain timing over payor groups in our portfolios. If there is a change in our payor mix over time, it could affect our net revenue and related receivables. We believe we have a sufficient history of collection experience to estimate the net collectible amounts by payor. However, changes to the allowance for billing adjustments, which are recorded as a reduction of transaction price, have historically fluctuated and may continue to fluctuate significantly from quarter to quarter and year to year.</div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company frequently receives refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in the Company’s industry. These requests are sometimes related to a limited number of patients or products; at other times, they include a significant number of refund claims in a single request. The Company reviews and evaluates these requests and determines if any refund request is appropriate. The Company also reviews these refund claims when it is rebilling or pursuing reimbursement from insurance providers. The Company frequently has significant offsets against such refund requests, and sometimes amounts are due to the Company in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests, the Company is generally unable to determine if a refund request is valid and should be accrued. Such refunds are recorded when the amount is fixed and determinable, however management maintains an allowance for estimated future refunds which we believe is sufficient to cover future claims in connection with its estimates of variable consideration recorded at the time sales are recorded.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Instruments</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company’s financial instruments include cash, accounts receivable, accounts payable and income taxes, for which current carrying amounts approximate fair value due to their short-term nature. Financial instruments also included the notes payable related to our private placement and capitalized leases, the carrying value of which approximates fair value because the interest rates on the outstanding borrowings are at rates that approximate market rates for borrowings with similar terms and average maturities.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Inventory</font></u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Inventory, which primarily represents parts and supplies, are valued at the lower of cost (average) or market.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company monitors inventory for turnover and obsolescence and records losses for excess and obsolete inventory, as appropriate. The Company provides reserves for estimated excess and obsolete inventories equal to the difference between the costs of inventories on hand and the estimated market value based upon assumptions about future demand. If future demand is less favorable than currently projected by management, additional inventory write-downs may be required.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Total gross inventories at March 31, 2018 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.7</font> million which was comprised of finished goods, work in progress, and parts and supplies as compared to December 31, 2017 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.4</font> million.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Segment Information </font></u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> We define operating segments as components of our enterprise for which separate financial information is reviewed regularly by the chief operating decision-makers to evaluate performance and to make operating decisions. We have identified our Chief Executive Officer and Chief Financial Officer as our chief operating decision-makers (“CODM”).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> We currently operate our business as one operating segment which includes two revenue types:  Devices and Supplies. </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><u><font style="FONT-SIZE: 10pt">Income Taxes</font></u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We record deferred tax assets and liabilities for the estimated future tax effects of temporary differences between the tax bases of assets and liabilities and amounts reported in the accompanying consolidated balance sheets, as well as operating loss and tax credit carry-forwards. We measure deferred tax assets and liabilities using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled.  We reduce deferred tax assets by a valuation allowance if, based on available evidence, it is more likely than not that these benefits will not be realized.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 22, 2017, the U.S. government enacted comprehensive tax legislation (the “Tax Act”), which significantly revises the ongoing U.S. corporate income tax law by lowering the U.S. federal corporate income tax rate from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 21</font>%, implementing a territorial tax system, imposing a one-time tax on foreign unremitted earnings and setting limitations on deductibility of certain costs, among other things.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company is subject to the provisions of the Financial Accounting Standards Board (“FASB”) ASC 740-10, Income Taxes, which requires that the effect on deferred tax assets and liabilities of a change in tax rates be recognized in the period the tax rate change was enacted. Due to the complexities involved in accounting for the recently enacted Tax Act, the U.S. Securities and Exchange Commission’s Staff Accounting Bulletin (“SAB”) 118 requires that the Company include in its financial statements the reasonable estimate of the impact of the Tax Act on earnings to the extent such estimate has been determined.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Pursuant to the SAB118, the Company is allowed a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts. The final impact on the Company from the Tax Act’s transition tax legislation may differ from the aforementioned estimates due to the complexity of calculating and supporting with primary evidence such U.S. tax attributes such as accumulated foreign earnings and profits, foreign tax paid, and other tax components involved in foreign tax credit calculations for prior years back to 1998. Such differences could be material, due to, among other things, changes in interpretations of the Tax Act, future legislative action to address questions that arise because of the Tax Act, changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the Company has utilized to calculate the transition tax's reasonable estimate. The Company will continue to evaluate the impact of the U.S. Tax Act and will record any resulting tax adjustments during 2018.</font><font style="FONT-SIZE: 10pt"> </font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In August 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”), which amends and simplifies existing guidance in order to allow companies to more accurately present the economic effects of risk management activities in the financial statements. ASU 2017-12 is effective for us in the first quarter of fiscal 2020, and earlier adoption is permitted. We are currently evaluating the impact of our pending adoption of ASU 2017-12 on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) ("ASU 2016-13"), Measurement of Credit Losses on Financial Instruments. The standard significantly changes how entities will measure credit losses for most financial assets and certain other instruments that aren't measured at fair value through net income. The standard will replace today's "incurred loss" approach with an "expected loss" model for instruments measured at amortized cost. For available-for-sale debt securities, entities will be required to record allowances rather than reduce the carrying amount, as they do today under the other-than-temporary impairment model. It also simplifies the accounting model for purchased credit-impaired debt securities and loans. This ASU is effective for annual periods beginning after December 15, 2019, and interim periods therein. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the impact that the adoption of ASU 2016-13 will have on our financial condition, results of operations and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In February 2018, the FASB issued Accounting Standards Update No. 2018-02,<i> </i> Income StatementReporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (“ASU 2018-02”),<i> </i> which allows companies to reclassify stranded tax effects resulting from the 2017 Tax Cuts and Jobs Act (the Tax Act), from accumulated other comprehensive income to retained earnings. The new standard is effective for us beginning January 1, 2019, with early adoption permitted. We are currently evaluating the effects that the adoption of this guidance will have on our consolidated financial statements and the related disclosures.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). These amendments require the recognition of lease assets and lease liabilities on the balance sheet by lessees for those leases currently classified as operating leases under ASC 840 “Leases”. These amendments also require qualitative disclosures along with specific quantitative disclosures. These amendments are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. Entities are required to apply the amendments at the beginning of the earliest period presented using a modified retrospective approach. We are currently evaluating the impact that the adoption of ASU 2016-02 will have on our financial condition, results of operations and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a material impact on the Company’s consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><u>Recent Adopted Accounting Pronouncements</u></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In May 2014, the FASB issued ASU No. 2014-09“Revenue from Contracts with Customers” (Topic 606) which amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract.  The Company adopted the new ASU as of January 1, 2018 using the modified retrospective method and resulted in no material changes to previously stated financial statements. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">For further details see the revenue recognition description in Note 1.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.35

0.15 0.66

0.21

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The components of certain balance sheet line items are as follows (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 3in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Property and equipment:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Office furniture and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,033</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>998</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Assembly equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>128</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>128</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Vehicles</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>76</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>76</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>378</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,615</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Less accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,040)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,014)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>188</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Assets acquired under capital lease:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Original book value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>461</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>461</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(395)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(379)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Net book value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>82</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

200000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of stock warrant activity for the three months ended March 31, 2018 are presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 35pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>Number of Warrants<br/> (in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>Aggregate<br/> Intrinsic<br/> Value<br/> (in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Outstanding at December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>1.86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>5.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>264</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>1.86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>5.62</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>305</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

830000

873000

914000

956000

495000

4531000

125000

123000

2000

1300000

0.02 0.1

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Future minimum commitments under non-cancelable operating leases and capital leases as of December 31, 2017 are as follows (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Operating Leases</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Capital<br/> Leases</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>463</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>830</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>873</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>914</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>956</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>495</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Total minimum lease payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>4,531</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Less: Amount representing interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="8%"> <div>(2)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Principal balance of capital lease obligation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>123</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Less: Current portion of capital lease obligation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(123)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Long-term portion of capital lease obligation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

463000

1035000

155000

981000

255000

-255000

618000

7000

461000

37000

2000000

0.21

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>(4) <u>STOCK-BASED COMPENSATION PLANS</u></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In June 2017, our stockholders approved the 2017 Stock Incentive Plan (the “2017 Stock Plan”) with a maximum of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> shares reserved for issuance.  Awards permitted under the 2017 Stock Plan include:  Stock Options and Restricted Stock.  Awards issued under the 2017 Stock Plan are at the discretion of the Board of Directors.  As applicable, awards are granted with an exercise price equal to the closing price of our common stock on the date of grant and generally vest over four years.  At March 31, 2018, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.6</font> million remain issued and outstanding.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the three months ended March 31, 2018, no Stock Option awards were granted under the 2017 Stock Plan.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the three months ended March 31, 2018, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 65,000</font> shares of restricted stock were granted to the Board of Directors and management under the 2017 Stock Plan.  There were no restricted shares issued during the three months ended March 31, 2017. During the three months ended March 31, 2018, no shares of restricted stock vested. No shares of restricted stock were forfeited during the three months ended March 31, 2018.  The fair market value of restricted shares for share-based compensation expensing is equal to the closing price of our common stock on the date of grant. The restrictions on the stock awards are typically released quarterly or annually over four years</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company previously reserved <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> shares of common stock for issuance under its 2005 Stock Option Plan (the “Option Plan”). The Option Plan expired as of December 31, 2014. Vesting provisions of the expired plan were to be determined by the Board of Directors. All stock options under the Option Plan expire no later than ten years from the date of grant. Options granted in 2016 and through May 2017 prior to the approval of the 2017 Stock Incentive Plan were approved by and certified by the board of directors on September 6, 2017 under the existing 2005 stock option plan. At March 31, 2018, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.3</font> million remain issued and outstanding under the 2005 Stock Option Plan.</div>  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The following summarizes stock-based compensation expenses recorded in the condensed consolidated <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> statements</font> of operations:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> During the three months ended March 31, 2018 and 2017, the Company recorded compensation expense related to stock options of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">63,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24,000</font>, respectively, all of which was recorded in selling, general and administrative expense on the accompanying condensed consolidated <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> statements</font> of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> During the three months ended March 31, 2018, there were no options granted, only the aforementioned restricted stock grants.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> During the three months ended March 31, 2017, the Company granted options to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0.2</font> million shares of common stock to employees at a weighted average exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.21</font> per share. The weighted-average grant date fair value of options granted during the three months ended March 31, 2017 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.28</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company received proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1</font> million related to option exercises during the three months ended March 31, 2018. No options were exercised during the three months March 31, 2017</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company used the Black Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> for 2017. There were no options granted during the three months ended March 31,2018</font>:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> For the Three Months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="7%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="7%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">6.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">1.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">129.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Expected dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> A summary of stock option <font style="WIDOWS: 2; TEXT-TRANSFORM: none; FONT-STYLE: normal; TEXT-INDENT: 0px; LETTER-SPACING: normal; DISPLAY: inline !important; FONT-FAMILY: 'Times New Roman', Times, serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; COLOR: rgb(0,0,0); FONT-SIZE: 13px; FONT-WEIGHT: 400; WORD-SPACING: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> and restricted stock</font> activity under all equity compensation plans for the three months ended March 31, 2018, is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Outstanding at December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,136</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,645</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(6)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(237)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Outstanding at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,958</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">6.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,579</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Exercisable at March 31, 2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,261</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,720</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">  </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> As of March 31, 2018, the Company had approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.6</font> million of unrecognized compensation expense related to stock options that will be recognized over a weighted average period of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.97</font> years. </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

There is no difference between net income and comprehensive income

EX-101.SCH 7 zyxi-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - BALANCE SHEET COMPONENTS link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - EARNINGS PER SHARE link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - STOCK-BASED COMPENSATION PLANS link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - PRIVATE PLACEMENT MEMORANDUM link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - DEFERRED INSURANCE REIMBURSEMENT link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - CAPITAL LEASES AND OTHER OBLIGATIONS link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - CONCENTRATIONS link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - LITIGATION link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - BALANCE SHEET COMPONENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - STOCK-BASED COMPENSATION PLANS (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - PRIVATE PLACEMENT MEMORANDUM (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - CAPITAL LEASES AND OTHER OBLIGATIONS (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - BASIS OF PRESENTATION (Details Textual) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - BALANCE SHEET COMPONENTS (Details) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - BALANCE SHEET COMPONENTS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - EARNINGS PER SHARE (Details) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - EARNINGS PER SHARE (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - STOCK-BASED COMPENSATION PLANS (Details) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - STOCK-BASED COMPENSATION PLANS (Details 1) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - STOCK-BASED COMPENSATION PLANS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - STOCKHOLDERS' EQUITY (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - INCOME TAXES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - PRIVATE PLACEMENT MEMORANDUM (Details) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - PRIVATE PLACEMENT MEMORANDUM (Details Textual) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - DEFERRED INSURANCE REIMBURSEMENT (Details Textual) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - CAPITAL LEASES AND OTHER OBLIGATIONS (Details) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - CAPITAL LEASES AND OTHER OBLIGATIONS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - CONCENTRATIONS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - RELATED PARTY TRANSACTIONS (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 zyxi-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 zyxi-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 zyxi-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] Statement [Table] Class of Stock [Domain] Statement [Line Items] Class of Stock [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash Cash Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Accounts Receivable, Net, Current Accounts receivable, net Inventory, Net Inventory, net Prepaid Expense, Current Prepaid expenses and other assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and Equipment, Net Deposits Assets, Noncurrent Deposits Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities, Current [Abstract] Current liabilities: Unsecured Debt, Current Current portion of unsecured subordinated promissory notes Current portion of unsecured subordinated promissory notes Capital Lease Obligations, Current Current portion of capital leases Less: Current portion of capital lease obligation Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Employee-related Liabilities, Current Accrued payroll and related taxes Liability for Claims and Claims Adjustment Expense, Total Deferred insurance reimbursement Liability for Claims and Claims Adjustment Expense, Total Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2018 and December 31, 2017 Common Stock, Value, Issued Common stock, $0.001 par value; 100,000,000 shares authorized; 33,101,834 issued and 32,606,743 outstanding as of March 31, 2018 and 32,864,877 issued and 32,778,040 outstanding as of December 31, 2017 Additional Paid in Capital, Common Stock Additional paid-in capital Treasury Stock, Value Treasury stock 495,091 and 86,837 shares, at March 31, 2018 and December 31, 2017, respectively, at cost Retained Earnings (Accumulated Deficit), Total Accumulated deficit Stockholders' Equity Attributable to Parent, Total Total Zynex, Inc. stockholders' equity Stockholders' Equity Attributable to Noncontrolling Interest Non-controlling interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Total Total stockholders' equity Balance Balance Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Revenue, Net [Abstract] NET REVENUE Operating Expenses [Abstract] COSTS OF REVENUE AND OPERATING EXPENSES Cost of Goods and Services Sold, Total Costs of revenue - device & supply Selling, General and Administrative Expense, Total Selling, general and administrative expense Nonoperating Income (Expense) [Abstract] Other expense Interest Expense, Total Interest expense Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest, Total Income from operations before income taxes Income Tax Expense (Benefit) Income tax expense (benefit) Income Tax Expense (Benefit) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net Income Net income Net Income (Loss) Attributable to Noncontrolling Interest, Total Plus: net loss - noncontrolling interest Net Income (Loss) Attributable to Parent, Total Net income - attributable to Zynex, Inc. Net Income (loss) Net income available to common stockholders Net income available to common stockholders Earnings Per Share, Basic, Total Basic Basic income per share: Earnings Per Share, Diluted, Total Diluted Diluted income per share: Earnings Per Share, Basic and Diluted [Abstract] Net income per share attributable to Zynex, Inc.: Weighted Average Number of Shares Outstanding, Basic Weighted average basic shares outstanding Basic weighted average shares outstanding Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Diluted Weighted average diluted shares outstanding Diluted weighted average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted - average number of common shares outstanding: Sales Revenue, Goods, Net Devices Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by in operating activities: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from (Repayments of) Lines of Credit Net (repayments) borrowings on line of credit Repayments of Notes Payable Principal payments on subordinated Principal payments on promissory notes Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Cash and Cash Equivalents, Period Increase (Decrease), Total Net (decrease) increase in cash and cash equivalents Interest Paid, Net Interest paid Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] BASIS OF PRESENTATION Earnings Per Share [Abstract] Earnings Per Share [Text Block] EARNINGS PER SHARE Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Summary of status of the Company's non-vested share awards Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION PLANS Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] INCOME TAXES Leases, Capital [Abstract] Capital Leases in Financial Statements of Lessee Disclosure [Text Block] CAPITAL LEASES AND OTHER OBLIGATIONS Risks and Uncertainties [Abstract] Concentration Risk Disclosure [Text Block] CONCENTRATIONS Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] LITIGATION Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Calculation of Basic and Diluted Earnings (Loss) Per Share Concentration Risk Benchmark [Axis] Concentration Risk, Percentage Percentage of sales Concentration Risk Type [Axis] Concentration Risk Benchmark [Domain] Accounts Receivable [Member] Net Accounts Receivable Property, Plant and Equipment, Type [Axis] Capital Leased Assets, Gross Cost of assets under capital lease Original book value Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation Accumulated depreciation Accumulated depreciation Imputed Interest Rate On Capital Lease Imputed interest rate on lease Imputed interest rate on capital lease. Range [Axis] Property, Plant and Equipment, Type [Domain] Lease Arrangement, Type [Axis] Range [Domain] Maximum [Member] Maximum Minimum [Member] Minimum Lease Arrangement, Type [Domain] Concentration Risk Type [Domain] Supplier Concentration Risk [Member] Income Taxes [Table] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Taxes [Line Items] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Two Thousand And Five Stock Option Plan [Member] 2005 Stock Option Plan Income Statement Location [Axis] Income Statement Location [Domain] Selling, General and Administrative Expenses [Member] Selling, General And Administrative Expenses Title of Individual [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Shares under option, granted Non-vested Shares Under Option, Granted Number of Shares, Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Granted Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation expense related to stock options Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Weighted-average period of unrecognized compensation expense related to stock options Earnings Per Share, Basic [Abstract] Basic income per share: Earnings Per Share, Diluted [Abstract] Diluted income per share: Weighted Average Number Diluted Shares Outstanding Adjustment, Total Effect of dilutive securities - options and restricted stock Equity Components [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Fair value of stock option grants Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Contractual term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] Summary of stock option activity under the option Plan Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Balance Beginning Balance Ending Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Number of Shares, Forfeited Number of Warrants, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Non-vested Shares Under Option, Exercised Number of Shares, Exercised Number of Shares, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Number of Shares, Exercisable at March 31, 2018 Number of Warrants, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Outstanding Beginning Weighted Average Exercise Price, Outstanding Ending Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Forfeited Weighted Average Exercise Price, Forfeited Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Exercised Weighted Average Grant Date Fair Value, Exercised Accounting Policies [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Remaining Contractual Life (Years) Consolidation, Policy [Policy Text Block] Principles of Consolidation Non-controlling Interest [Policy Text Block] Non-controlling Interest Noncontrolling interest policy. Reclassification, Policy [Policy Text Block] Reclassifications Use of Estimates, Policy [Policy Text Block] Use of Estimates Revenue Recognition, Policy [Policy Text Block] Revenue Recognition, Allowance for Contractual Adjustments and Collectability Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Inventory, Policy [Policy Text Block] Inventory Segment Reporting, Policy [Policy Text Block] Segment Information Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life Exercisable Weighted Average Remaining Contractual Life Exercisable (years) Weighted Average Remaining Contractual Life Exercisable (years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair Value of Stock Options Grants Insurance [Abstract] Insurance Disclosure [Text Block] DEFERRED INSURANCE REIMBURSEMENT Legal Entity [Axis] Entity [Domain] Liabilities, Current Total current liabilities ORGANIZATION, NATURE OF BUSINESS AND UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS [Table] Noncontrolling Interest, Ownership Percentage by Parent Subsequent Event Type [Axis] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Axis] Related Party [Axis] Related Party Transaction [Domain] Related Party Compensation Compensation paid Related party compensation. Related Party Transaction, Amounts of Transaction Lump sum payment Related Party Transaction Agreement Term Agreement term Related party transaction agreement term. Equity [Abstract] Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS’ EQUITY Employment Arrangement [Member] Employment Arrangement Related Party Transaction [Line Items] Related Party [Domain] Immediate Family Member of Management or Principal Owner [Member] Immediate Family Members of Management or Principal Owner Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Future Minimum Commitments Under Non-Cancelable Operating Leases and Capital Leases Payables and Accruals [Abstract] Capital Leases, Future Minimum Payments Due, Next Twelve Months 2018 Capital Leases, Future Minimum Payments Due in Two Years 2019 Capital Leases, Future Minimum Payments Due in Three Years 2020 EX-101.PRE 11 zyxi-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2018	May 04, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Entity Registrant Name	ZYNEX INC
Entity Central Index Key	0000846475
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ZYXI
Entity Common Stock, Shares Outstanding		33,116,334

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash	$ 4,366	$ 5,565
Accounts receivable, net	2,668	2,185
Inventory, net	710	423
Prepaid expenses and other assets	615	198
Total current assets	8,359	8,371
Property and equipment, net	575	188
Deposits	375	370
Total assets	9,309	8,929
Current liabilities:
Current portion of unsecured subordinated promissory notes	7	231
Current portion of capital leases	93	123
Accounts payable and accrued expenses	2,112	2,243
Accrued payroll and related taxes	661	538
Deferred insurance reimbursement	880	880
Total current liabilities	3,753	4,015
Long-term liabilities:
Deferred rent	329	0
Warranty liability	12	12
Total liabilities	4,094	4,027
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2018 and December 31, 2017	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 33,101,834 issued and 32,606,743 outstanding as of March 31, 2018 and 32,864,877 issued and 32,778,040 outstanding as of December 31, 2017	33	33
Additional paid-in capital	7,761	7,612
Treasury stock 495,091 and 86,837 shares, at March 31, 2018 and December 31, 2017, respectively, at cost	(2,000)	(243)
Accumulated deficit	(490)	(2,411)
Total Zynex, Inc. stockholders' equity	5,304	4,991
Non-controlling interest	(89)	(89)
Total stockholders' equity	5,215	4,902
Total liabilities and stockholders' equity	$ 9,309	$ 8,929

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	33,101,834	32,864,877
Common Stock, Shares, Outstanding	32,606,743	32,778,040
Treasury Stock, Shares	495,091	86,837

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands

3 Months Ended

Mar. 31, 2018

Mar. 31, 2017

NET REVENUE

Devices

$ 1,588

$ 1,384

Supplies

5,288

2,052

Total Net revenue

6,876

3,436

COSTS OF REVENUE AND OPERATING EXPENSES

Costs of revenue - device & supply

1,236

923

Selling, general and administrative expense

3,685

2,030

Total costs of revenue and operating expenses

4,921

2,953

Income from operations

1,955

483

Other expense

Interest expense

(115)

(121)

Income from operations before income taxes

1,840

362

Income tax expense (benefit)

(81)

Net Income

1,921

353

Plus: net loss - noncontrolling interest

Net income - attributable to Zynex, Inc.

^[1]

$ 1,921

$ 353

Net income per share attributable to Zynex, Inc.:

Basic

$ 0.06

$ 0.01

Diluted

$ 0.06

$ 0.01

Weighted average basic shares outstanding

32,601

31,418

Weighted average diluted shares outstanding

34,414

32,036

[1]	There is no difference between net income and comprehensive income

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided by operating activities	$ 993	$ 23
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(160)	(57)
Net cash used in investing activities	(160)	(57)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net (repayments) borrowings on line of credit	0	(600)
Principal payments on subordinated	(331)
Proceeds from unsecured subordinated promissory notes	0	1,035
Payment of commission and placement agent fees and related expenses	0	(155)
Payments on capital lease obligations	(30)	(31)
Purchase of treasury stock	(1,757)	0
Proceeds from the issuance of stock	86	0
Net cash (used in) provided by financing activities	(2,032)	249
Net (decrease) increase in cash and cash equivalents	(1,199)	215
Cash and cash equivalents at beginning of period	5,565	247
Cash and cash equivalents at end of period	4,366	462
Supplemental disclosure of cash and non-cash transactions:
Interest paid	8	121
Property and Equipment purchased and included in accrued liabilities but not settled	$ 253	$ 0

XML 17 R6.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

(1) BASIS OF PRESENTATION

Organization

The term “the Company” refers to Zynex, Inc. and its active and inactive subsidiaries.

Nature of Business

Unaudited Condensed Consolidated Financial Statements

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Non-controlling Interest

Reclassifications

Use of Estimates

Revenue Recognition, Allowance for Billing Adjustments and Collectability

Fair Value of Financial Instruments

Inventory

Inventory, which primarily represents parts and supplies, are valued at the lower of cost (average) or market.

Total gross inventories at March 31, 2018 were $0.7 million which was comprised of finished goods, work in progress, and parts and supplies as compared to December 31, 2017 of $0.4 million.

Segment Information

We currently operate our business as one operating segment which includes two revenue types: Devices and Supplies.

Income Taxes

Recent Accounting Pronouncements

Recent Adopted Accounting Pronouncements

XML 18 R7.htm IDEA: XBRL DOCUMENT

BALANCE SHEET COMPONENTS

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BALANCE SHEET COMPONENTS

(2) BALANCE SHEET COMPONENTS

The components of certain balance sheet line items are as follows (in thousands):

Property and equipment:	March 31,2018		December 31,2017
Office furniture and equipment	$	1,033	$	998
Assembly equipment		128		128
Vehicles		76		76
Leasehold improvements		378		-
	$	1,615	$	1,202
Less accumulated depreciation		(1,040)		(1,014)
	$	575	$	188

Assets acquired under capital lease:	March 31,2018		December 31,2017
Original book value	$	461	$	461
Accumulated depreciation		(395)		(379)
Net book value	$	66	$	82

Included in total assets at March 31, 2018 are $0.2 million in assets for leasehold improvements that have been completed and are accounted for in accrued liabilities but not yet settled.

Total depreciation expense related to our property and equipment was $26,000 and $0.1 million for the three months ended March 31 2018 and 2017, respectively.

XML 19 R8.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

EARNINGS PER SHARE

(3) EARNINGS PER SHARE

The calculation of basic and diluted earnings per share for the three months ended March 31, 2018 and 2017 are as follows:

	For the Three Months Ended March 31,
	2018		2017
Basic income per share:
Net income available to common stockholders	$	1,921	$	353
Basic weighted average shares outstanding		32,601		31,418
Basic income per share:	$	0.06	$	0.01

Diluted income per share:
Net income available to common stockholders	$	1,921	$	353
Weighted average shares outstanding		32,601		31,418
Effect of dilutive securities - options and restricted stock		1,813		618
Diluted weighted average shares outstanding		34,414		32,036
Diluted income per share:	$	0.06	$	0.01

XML 20 R9.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS

3 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION PLANS

(4) STOCK-BASED COMPENSATION PLANS

During the three months ended March 31, 2018, no Stock Option awards were granted under the 2017 Stock Plan.

The following summarizes stock-based compensation expenses recorded in the condensed consolidated statements of operations:

During the three months ended March 31, 2018, there were no options granted, only the aforementioned restricted stock grants.

The Company received proceeds of $0.1 million related to option exercises during the three months ended March 31, 2018. No options were exercised during the three months March 31, 2017

	For the Three Months Ended March 31,
	2018			2017
Expected term (years)		-			6.25
Risk-free interest rate		-	%		1.64	%
Expected volatility		-	%		129.04	%
Expected dividend yield		-	%		0.00	%

A summary of stock option and restricted stock activity under all equity compensation plans for the three months ended March 31, 2018, is presented below:

					Weighted-
					Average
			Weighted-		Remaining		Aggregate
	Number of		Average		Contractual		Intrinsic
	Shares		Exercise		Term		Value
	(in thousands)		Price		(Years)		(in thousands)
Outstanding at December 31, 2017		2,136	$	0.54		6.31	$	5,645
Granted		65		0.00
Forfeited		(6)		1.28
Exercised		(237)		0.36
Outstanding at March 31, 2018		1,958	$	0.54		6.27	$	5,579

Exercisable at March 31, 2018		1,261	$	0.40		4.99	$	3,720

XML 21 R10.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2018

Equity [Abstract]

STOCKHOLDERS’ EQUITY

(5) STOCKHOLDERS’ EQUITY

Treasury Stock

From the inception of the plan through March 6, 2018, we purchased 495,091 shares of our common stock for $2.0 million for an average price of $4.04 per share.

Warrants

In October 2017, 150,000 common stock warrants were issued in exchange for professional services.

A summary of stock warrant activity for the three months ended March 31, 2018 are presented below:

	Number of Warrants (in thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2017		200	$	1.86		5.80	$	264
Granted		-	$	-
Exercised		-		-
Forfeited		-	$	-
Outstanding at March 31, 2018		200	$	1.86		5.62	$	305

There were no warrants granted during the three months ended March 31, 2018 and 2017.

XML 22 R11.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

Mar. 31, 2018

Income Tax Disclosure [Abstract]

INCOME TAXES

(6) INCOME TAXES

No taxes were paid in the three months ended March 31, 2018 and 2017.

XML 23 R12.htm IDEA: XBRL DOCUMENT

PRIVATE PLACEMENT MEMORANDUM

3 Months Ended

Mar. 31, 2018

Private Placement Memorandum Disclosure [Abstract]

PRIVATE PLACEMENT MEMORANDUM

(7) PRIVATE PLACEMENT MEMORANDUM

The table below summarizes the cash and non-cash components of the private placement memorandum (in thousands):

	March 31, 2018
Proceeds from unsecured subordinated promissory notes	$	1,035
Less debt issuance costs and discount
Payment of commission and placement agent fees and related expenses		(155)
Principal payments on promissory notes		(981)

Non-cash activity
Common stock issued to placement agent		(255)
Obligation to issue common stock to private placement noteholders		(255)
Amortization of issuance costs and debt discount		618
Unsecured subordinated promissory notes, net of issuance and debt discount		7

Current portion of unsecured subordinated promissory notes		(7)
Long-term portion of unsecured subordinated promissory notes	$	-

XML 24 R13.htm IDEA: XBRL DOCUMENT

DEFERRED INSURANCE REIMBURSEMENT

3 Months Ended

Mar. 31, 2018

Insurance [Abstract]

DEFERRED INSURANCE REIMBURSEMENT

(8) DEFERRED INSURANCE REIMBURSEMENT

XML 25 R14.htm IDEA: XBRL DOCUMENT

CAPITAL LEASES AND OTHER OBLIGATIONS

3 Months Ended

Mar. 31, 2018

Leases, Capital [Abstract]

CAPITAL LEASES AND OTHER OBLIGATIONS

(9) CAPITAL LEASES AND OTHER OBLIGATIONS

Future minimum commitments under non-cancelable operating leases and capital leases as of December 31, 2017 are as follows (in thousands):

	Operating Leases		Capital Leases
2018	$	463	$	125
2019		830		-
2020		873		-
2021		914		-
2022		956
Thereafter		495		-
Total minimum lease payments	$	4,531		125
Less: Amount representing interest				(2)
Principal balance of capital lease obligation				123
Less: Current portion of capital lease obligation				(123)
Long-term portion of capital lease obligation			$	-

XML 26 R15.htm IDEA: XBRL DOCUMENT

CONCENTRATIONS

3 Months Ended

Mar. 31, 2018

Risks and Uncertainties [Abstract]

CONCENTRATIONS

(10) CONCENTRATIONS

XML 27 R16.htm IDEA: XBRL DOCUMENT

LITIGATION

3 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

LITIGATION

(11) LITIGATION

The Company is currently not a party to any material pending legal proceedings.

XML 28 R17.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2018

RELATED PARTY TRANSACTIONS

(12) RELATED PARTY TRANSACTIONS

XML 29 R18.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Policies)

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Non-controlling Interest

Non-controlling Interest

Reclassifications

Reclassifications

Use of Estimates

Use of Estimates

Revenue Recognition, Allowance for Contractual Adjustments and Collectability

Revenue Recognition, Allowance for Billing Adjustments and Collectability

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Inventory

Inventory

Inventory, which primarily represents parts and supplies, are valued at the lower of cost (average) or market.

Total gross inventories at March 31, 2018 were $0.7 million which was comprised of finished goods, work in progress, and parts and supplies as compared to December 31, 2017 of $0.4 million.

Segment Information

Segment Information

We currently operate our business as one operating segment which includes two revenue types: Devices and Supplies.

Income Taxes

Income Taxes

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Recent Adopted Accounting Pronouncements

XML 30 R19.htm IDEA: XBRL DOCUMENT

BALANCE SHEET COMPONENTS (Tables)

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Balance Sheet

The components of certain balance sheet line items are as follows (in thousands):

Property and equipment:	March 31,2018		December 31,2017
Office furniture and equipment	$	1,033	$	998
Assembly equipment		128		128
Vehicles		76		76
Leasehold improvements		378		-
	$	1,615	$	1,202
Less accumulated depreciation		(1,040)		(1,014)
	$	575	$	188

Assets acquired under capital lease:	March 31,2018		December 31,2017
Original book value	$	461	$	461
Accumulated depreciation		(395)		(379)
Net book value	$	66	$	82

XML 31 R20.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Calculation of Basic and Diluted Earnings (Loss) Per Share

The calculation of basic and diluted earnings per share for the three months ended March 31, 2018 and 2017 are as follows:

	For the Three Months Ended March 31,
	2018		2017
Basic income per share:
Net income available to common stockholders	$	1,921	$	353
Basic weighted average shares outstanding		32,601		31,418
Basic income per share:	$	0.06	$	0.01

Diluted income per share:
Net income available to common stockholders	$	1,921	$	353
Weighted average shares outstanding		32,601		31,418
Effect of dilutive securities - options and restricted stock		1,813		618
Diluted weighted average shares outstanding		34,414		32,036
Diluted income per share:	$	0.06	$	0.01

XML 32 R21.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Fair Value of Stock Options Grants

	For the Three Months Ended March 31,
	2018			2017
Expected term (years)		-			6.25
Risk-free interest rate		-	%		1.64	%
Expected volatility		-	%		129.04	%
Expected dividend yield		-	%		0.00	%

Summary of Stock Option Activity Under the Option Plan

A summary of stock option and restricted stock activity under all equity compensation plans for the three months ended March 31, 2018, is presented below:

					Weighted-
					Average
			Weighted-		Remaining		Aggregate
	Number of		Average		Contractual		Intrinsic
	Shares		Exercise		Term		Value
	(in thousands)		Price		(Years)		(in thousands)
Outstanding at December 31, 2017		2,136	$	0.54		6.31	$	5,645
Granted		65		0.00
Forfeited		(6)		1.28
Exercised		(237)		0.36
Outstanding at March 31, 2018		1,958	$	0.54		6.27	$	5,579

Exercisable at March 31, 2018		1,261	$	0.40		4.99	$	3,720

XML 33 R22.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2018

Summary of stock warrant activity

A summary of stock warrant activity for the three months ended March 31, 2018 are presented below:

	Number of Warrants (in thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2017		200	$	1.86		5.80	$	264
Granted		-	$	-
Exercised		-		-
Forfeited		-	$	-
Outstanding at March 31, 2018		200	$	1.86		5.62	$	305

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 34 R23.htm IDEA: XBRL DOCUMENT

PRIVATE PLACEMENT MEMORANDUM (Tables)

3 Months Ended

Mar. 31, 2018

Private Placement Memorandum Disclosure [Abstract]

Schedule of Cash and Non-Cash Components Of The Private Placement Memorandum

The table below summarizes the cash and non-cash components of the private placement memorandum (in thousands):

	March 31, 2018
Proceeds from unsecured subordinated promissory notes	$	1,035
Less debt issuance costs and discount
Payment of commission and placement agent fees and related expenses		(155)
Principal payments on promissory notes		(981)

Non-cash activity
Common stock issued to placement agent		(255)
Obligation to issue common stock to private placement noteholders		(255)
Amortization of issuance costs and debt discount		618
Unsecured subordinated promissory notes, net of issuance and debt discount		7

Current portion of unsecured subordinated promissory notes		(7)
Long-term portion of unsecured subordinated promissory notes	$	-

XML 35 R24.htm IDEA: XBRL DOCUMENT

CAPITAL LEASES AND OTHER OBLIGATIONS (Tables)

3 Months Ended

Mar. 31, 2018

Leases, Capital [Abstract]

Future Minimum Commitments Under Non-Cancelable Operating Leases and Capital Leases

Future minimum commitments under non-cancelable operating leases and capital leases as of December 31, 2017 are as follows (in thousands):

	Operating Leases		Capital Leases
2018	$	463	$	125
2019		830		-
2020		873		-
2021		914		-
2022		956
Thereafter		495		-
Total minimum lease payments	$	4,531		125
Less: Amount representing interest				(2)
Principal balance of capital lease obligation				123
Less: Current portion of capital lease obligation				(123)
Long-term portion of capital lease obligation			$	-

XML 36 R25.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Details Textual) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	20.00%
Percentage Of Revenues		99.99%
Percentage Billing Cycle on Total Revenue	15.00%
Percentage Billing Cycle on Device Revenue	66.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				35.00%
Inventory, Net	$ 710			$ 423
Scenario, Plan [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%
North America [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage Of Revenues	99.99%

XML 37 R26.htm IDEA: XBRL DOCUMENT

BALANCE SHEET COMPONENTS (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment, Gross	$ 1,615	$ 1,202
Less accumulated depreciation	(1,040)	(1,014)
Property and Equipment, Net	575	188
Capital Leases, Balance Sheet, Assets by Major Class, Net [Abstract]
Original book value	461	461
Accumulated depreciation	(395)	(379)
Net book value	66	82
Office furniture and equipment
Property, Plant and Equipment, Gross	1,033	998
Capital Leases, Balance Sheet, Assets by Major Class, Net [Abstract]
Original book value	461	461
Assembly equipment
Property, Plant and Equipment, Gross	128	128
Vehicles
Property, Plant and Equipment, Gross	76	76
Leasehold improvements
Property, Plant and Equipment, Gross	$ 378	$ 0

XML 38 R27.htm IDEA: XBRL DOCUMENT

BALANCE SHEET COMPONENTS (Details Textual) - USD ($)	3 Months Ended
BALANCE SHEET COMPONENTS (Details Textual) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Depreciation	$ 26,000	$ 100,000
Property and equipment Purchased Not Settled	253,000	0
Assets Held under Capital Leases [Member]
Depreciation	16,000	$ 23,000
Leasehold Improvements [Member]
Property and equipment Purchased Not Settled	$ 200,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands

3 Months Ended

Mar. 31, 2018

Mar. 31, 2017

Basic income per share:

Net income available to common stockholders

^[1]

$ 1,921

$ 353

Basic weighted average shares outstanding

32,601

31,418

Basic income per share:

$ 0.06

$ 0.01

Diluted income per share:

Net income available to common stockholders

^[1]

$ 1,921

$ 353

Weighted average shares outstanding

32,601

31,418

Effect of dilutive securities - options and restricted stock

1,813

618

Diluted weighted average shares outstanding

34,414

32,036

Diluted income per share:

$ 0.06

$ 0.01

[1]	There is no difference between net income and comprehensive income

XML 40 R29.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Details Textual) - shares	1 Months Ended	3 Months Ended
EARNINGS PER SHARE (Details Textual) - shares	Aug. 28, 2017	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		200,000	1,100,000
Weighted Average Number Diluted Shares Outstanding Adjustment, Total		1,813,000	618,000
Common Stock [Member] \| Private Placement [Member]
Weighted Average Number Diluted Shares Outstanding Adjustment, Total	776,250

XML 41 R30.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS (Details)	3 Months Ended
STOCK-BASED COMPENSATION PLANS (Details)	Mar. 31, 2018	Mar. 31, 2017
Fair value of stock option grants
Expected term (years)	0 years	6 years 3 months
Risk-free interest rate	0.00%	1.64%
Expected volatility	0.00%	129.04%
Expected dividend yield	0.00%	0.00%

XML 42 R31.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS (Details 1) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Summary of stock option activity under the option Plan
Balance Beginning	2,136
Number of Shares, Granted	65	200
Number of Shares, Forfeited	(6)
Number of Shares, Exercised	(237)
Balance Ending	1,958		2,136
Number of Shares, Exercisable at March 31, 2018	1,261
Weighted Average Exercise Price, Outstanding Beginning	$ 0.54
Weighted Average Exercise Price, Granted	0	$ 0.21
Weighted Average Exercise Price, Forfeited	1.28
Weighted Average Exercise Price, Exercised	0.36
Weighted Average Exercise Price, Outstanding Ending	0.54		$ 0.54
Weighted Average Exercise Price, Exercisable	$ 0.4
Weighted Average Remaining Contractual Life, Outstanding	6 years 3 months 7 days		6 years 3 months 22 days
Weighted Average Remaining Contractual Life Exercisable	4 years 11 months 26 days
Aggregate Intrinsic Value, Outstanding	$ 5,579		$ 5,645
Aggregate Intrinsic Value, Exercisable	$ 3,720

XML 43 R32.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares under option, granted	65,000	200,000
Weighted Average Exercise Price, Granted	$ 0	$ 0.21
Unrecognized compensation expense related to stock options	$ 600,000
Weighted-average period of unrecognized compensation expense related to stock options	2 years 11 months 19 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.28
Proceeds from Stock Options Exercised	$ 100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	1,958,000		2,136,000
Management [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	65,000
Selling, General And Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 63,000	$ 24,000
2005 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	1,300,000
Stock Incentive Plan 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	5,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	600,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Balance Beginning	2,136
Shares under option, granted	65	200
Number of Shares, Exercised	237
Number of Warrants, Forfeited	6
Balance Ending	1,958		2,136
Weighted Average Exercise Price, Outstanding Beginning	$ 0.54
Weighted Average Exercise Price, Granted	0	$ 0.21
Weighted Average Exercise Price, Exercised	0.36
Weighted Average Exercise Price, Forfeited	1.28
Weighted Average Exercise Price, Outstanding Ending	$ 0.54		$ 0.54
Weighted Average Remaining Contractual Life (Years)	6 years 3 months 7 days		6 years 3 months 22 days
Warrant [Member]
Balance Beginning	200
Shares under option, granted	0
Number of Shares, Exercised	0
Number of Warrants, Forfeited	0
Balance Ending	200		200
Weighted Average Exercise Price, Outstanding Beginning	$ 1.86
Weighted Average Exercise Price, Granted	0
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Forfeited	0
Weighted Average Exercise Price, Outstanding Ending	$ 1.86		$ 1.86
Weighted Average Remaining Contractual Life (Years)	5 years 7 months 13 days		5 years 9 months 18 days
Aggregate Intrinsic Value Exercisable Balance	$ 264
Aggregate Intrinsic Value Exercisable Balance	$ 305		$ 264

XML 45 R34.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	1 Months Ended		37 Months Ended
STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	Oct. 31, 2017	Mar. 28, 2016	Mar. 06, 2018	Mar. 31, 2018
Stock Repurchase Program, Authorized Amount				$ 2,000,000
Stock Repurchased During Period, Shares			495,091
Treasury Stock Acquired, Average Cost Per Share			$ 4.04
Common Stock Warrants Issued For Professional Services	150,000
Stock Repurchased During Period, Value			$ 2,000,000
TriumphBank [Member]
Debt Conversion, Original Debt, Amount		$ 250,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		50,000

XML 46 R35.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details Textual) - USD ($) $ in Thousands	3 Months Ended
INCOME TAXES (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Income Taxes [Line Items]
Income Tax Expense (Benefit)	$ (81)	$ 9

XML 47 R36.htm IDEA: XBRL DOCUMENT

PRIVATE PLACEMENT MEMORANDUM (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Proceeds from unsecured subordinated promissory notes	$ 0	$ 1,035
Less debt issuance costs and discount Payment of commission and placement agent fees and related expenses	0	$ (155)
Principal payments on promissory notes	(331)
Non-cash activity
Current portion of unsecured subordinated promissory notes	(7)		$ (231)
Private Placement Memorandum [Member]
Proceeds from unsecured subordinated promissory notes	1,035
Less debt issuance costs and discount Payment of commission and placement agent fees and related expenses	(155)
Principal payments on promissory notes	(981)
Non-cash activity
Common stock issued to placement agent	(255)
Obligation to issue common stock to private placement noteholders	(255)
Amortization of issuance costs and debt discount	618
Unsecured subordinated promissory notes, net of issuance and debt discount	7
Current portion of unsecured subordinated promissory notes	(7)
Long-term portion of unsecured subordinated promissory notes	$ 0

XML 48 R37.htm IDEA: XBRL DOCUMENT

PRIVATE PLACEMENT MEMORANDUM (Details Textual) - Newbridge Securities Corporation [Member] - USD ($)	1 Months Ended	3 Months Ended
	Feb. 28, 2017	Mar. 31, 2018	Mar. 31, 2017	Nov. 30, 2016
Non Accountable Expense Allowance	$ 155,000
Commission And Fees To Placement Agent	$ 255,000
Stock to be Issued For Services	776,250
Stock Issued During Period, Shares, Issued for Services	776,250
Notes Payable, Noncurrent	$ 255,000
Repayments of Unsecured Debt	$ 342,000
Amortization of Debt Issuance Costs and Discounts		$ 107,000	$ 37,000
Percentage Of Commissions In Cash	10.00%
Non Accountable Expense Allowance Percentage	3.00%
Unsecured Debt [Member]
Funds Available For Repayment Of Note,Percentage	5.00%
Debt Instrument, Face Amount	$ 1,035,000
Unsecured Debt [Member] \| Minimum [Member]
Debt Instrument, Face Amount				$ 1,000,000
Unsecured Debt [Member] \| Maximum [Member]
Debt Instrument, Face Amount				$ 1,500,000

XML 49 R38.htm IDEA: XBRL DOCUMENT

DEFERRED INSURANCE REIMBURSEMENT (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2016
Liability for Claims and Claims Adjustment Expense, Total	$ 880	$ 880	$ 880

XML 50 R39.htm IDEA: XBRL DOCUMENT

CAPITAL LEASES AND OTHER OBLIGATIONS (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Operating Leases
2018		$ 463
2019		830
2020		873
2021		914
2022		956
Thereafter		495
Total minimum lease payments		4,531
Capital Leases
2018		125
2019		0
2020		0
2021		0
2022
Thereafter		0
Total minimum lease payments		125
Less: Amount representing interest		(2)
Principal balance of capital lease obligation		123
Less: Current portion of capital lease obligation	$ (93)	(123)
Long-term portion of capital lease obligation		$ 0

XML 51 R40.htm IDEA: XBRL DOCUMENT

CAPITAL LEASES AND OTHER OBLIGATIONS (Details Textual) $ in Thousands	1 Months Ended	3 Months Ended
	Oct. 20, 2017 USD ($) a	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Debt Instrument [Line Items]
Cost of assets under capital lease		$ 461	$ 461
Accumulated depreciation		395	379
Land Subject to Ground Leases \| a	41,715
Tenant Improvements	$ 200
Lessee Operating Sublease Rent Description	first year of the Sublease, the rent per square foot is $7.50, increasing to $19.75 during the second year of the Sublease and each year thereafter for the Initial Term increasing by an additional $1 per square foot.
Lessee, Operating Sublease, Option to Extend	June 30, 2025
Accounts Payable [Member]
Debt Instrument [Line Items]
Accumulated depreciation		$ 395
Maximum
Debt Instrument [Line Items]
Imputed interest rate on lease		10.00%
Minimum
Debt Instrument [Line Items]
Imputed interest rate on lease		2.00%
Office furniture and equipment
Debt Instrument [Line Items]
Cost of assets under capital lease		$ 461	$ 461

XML 52 R41.htm IDEA: XBRL DOCUMENT

CONCENTRATIONS (Details Textual)	3 Months Ended		12 Months Ended
CONCENTRATIONS (Details Textual)	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Supplier Concentration Risk [Member] \| Minimum [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Net Accounts Receivable
Concentration Risk [Line Items]
Concentration Risk, Percentage		21.00%	24.00%
Two Vendor [Member] \| Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	86.00%	45.00%

XML 53 R42.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2015
Related Party Transaction [Line Items]
Compensation paid	$ 54,000	$ 44,000
Employment Arrangement \| Immediate Family Members of Management or Principal Owner
Related Party Transaction [Line Items]
Lump sum payment			$ 100,000
Agreement term			3 years

EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( -R"J$P?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ W(*H3&;S"V"" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " #<@JA,_<,.?N\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+!:L,P#(9?9?B>R$Y9Z4R:RT9/'0Q6V-C-V&IK&L?&UDCZ]G.R M-F5L#["CI=^?/H%J':3V$5^B#QC)8KH;7-LEJ<.:'8F"!$CZB$ZE,B>ZW-S[ MZ!3E9SQ 4/JD#@@5YTMP2,HH4C "BS 365,;+75$13Y>\$;/^/ 9VPEF-&"+ M#CM*($H!K!DGAO/0UG #C##"Z-)W &UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " #<@JA,W@_*8V0" 4" & 'AL+W=OXXB<2ZAH>*)=="J M+U?&&RK5DM\BT7&@%T-JZ@C'<18UM&K#(C=[1U[D["[KJH4C#\2]:2C_O8>: M]=L0A>\;+]6ME'HC*O*.WN ;R._=D:M5-%FY5 VTHF)MP.&Z#7?H^8 233"( M'Q7T8C8/="@GQE[UXO-E&\;:(ZCA++4)JH8''*"NM27EQZ_1:#AI:N)\_F[] MHPE>!7.B @ZL_EE=9+D-UV%P@2N]U_*%]9]@#"@-@S'Z+_" 6L&U)TKCS&IA M?H/S74C6C%:4*PU]&\:J-6,_?$G02/,3\$C $P%G_R60D4 F B(F^,$S$^H' M*FF1<]8'?+BMCNJD0,]$'>99;YJS,]]4M$+M/HHXCQ[:S(C8#P@\0Z )$2G; MDP#V">RQ0\?_"AQ^ ML@1^L01D;4K8F7* M?H!D<\A"JFR\$AM7(K$D/)#4+X%B?T'%KH7,+JG8.:UUDB6K):6%TD6NDIU: M/LS"K2!O_>X0=BW8^>7!X(4$0_XB1L2U8*>8#X,75/RUCMQ2QL1ZC4;,_&X( M02@CQ'Y6HMD;VP"_F78D@C.[MZ87SG:GEK?#YHW^"Q_ZY5?*;U4K@A.3ZJ4W M[_&5,0G*H?A)N5*J%CTM:KA*/5VI.1_ZU+"0K!M[<#3]$2C^ %!+ P04 M" #<@JA,76_ MP>-.X1@P*?XI[:6_.P_&4I[;]OMX\?FP#N/1D:WL?AB;*-SAS>YL58TM.1__ MS8V&MYQCX/WY>^M_3,6[8IZ+WN[:ZM_R,)S6818&!WLL7JOA6WOYT\X%F3"8 MJ_]BWVSEY*,3EV/?5OWT&^Q?^Z&MYU:A6]C>W,DNU5@O>2I6(G*,Q-$KG\-Q,HFL I7MW')W*\$N/5%*_OXU-2Q%62 M3I)FDFB5)*0.+C(F\52B12>:.\F(DZO$W"7!)"&BG2""S./$B$X,=Y(3)X8E M22$F1KA&HY)])**/A/E0),R3Y2T4?*?0#QD;(49:2"# M$3@9%27CK%GV++7"->## ,AD!(Y&1=$($O: O6T$%6J?&YF.P/&H*!Z!LR]) M@)KA(J,\TQ!D0@)'I*:(!,Z_+*.L_H5HZ46F)'!,:HI)X AT5&!#AJMT#+Z) M)),2,C85-7I:D!D'''*:0@X$@M%WY4X0>7H69<@AAYRFD$..+S;Z/]8LGZ67DLWGK4?AZ6FL)0TOBPR"%'QD>29I2CS"SF_-"4& M:I1.96\BY92@KD",I31E$)57B'=4R MN9"3R]!E%7(F/;@O7O:,))GO!8,RNI"O\B@BM\B7< \Z9VX$%6KP+ 10YB!R M#AI&'XXXHV(VY[E*Y[G'C9)9J#@+#260XIQ[R"B5?R%:>I%IJ#@-#>6/XIPS MR#Y1!)5[FIY1K&0:*DXZPSYED7VF"DMA024LA:.[?8)QX^9KT;V431\\M\/0 MUM/&P+%M!^M:C#^YRDZV.-PN*GL&PO=V]R:W-H965T&ULC97;CILP$(9?!?$ L3F;B" U5%4KM5*T5=MK)W$"6L#4=I+MV];(;9:^\)$0X;TW=\HU;"M&M >"'DC28KVA'6KERHJS! M0@[9&?".$7S41DT-? ACT."J=?-,S^U8GM&+J*N6[)C#+TV#V;\MJ>EMXWKN M^\1+=2Z%F@!YUN$S^4G$KV['Y B,7HY50UI>T=9AY+1Q/WGKPH/*0"M^5^3& M)WU'I;*G]%4-OATW+E1$I"8'H5Q@V5Q)0>I:>9(G[AA3&4[[[]Z_Z.1E M,GO,24'K/]51E!L7N6*1,8XT)KKOW.X M<$&;P8M$:?!;WU:M;F_]2IP,9G8#?S#P1P,OO&L0# :!80!Z,IWJ9RQPGC%Z MD]ER.7O-(Y2!J_(S2+:]Q)](_+FBL"BB40)D M_!'"MT+XVCZ<0J0&1"]!6M)J"5Q!Z!D@CU0SEL#*$BQ88FBP]))H$L6#_6?@ M/"&<$856HG!)9.2]#1>!3)1[BAE#9&6(E@S&)=A&#QGN*68,L94A7C($!D/\ MU"UYI)JQ)%:69,D2&BS)AX=O[LLSRAD3LC*A)5-D,*%%I"#PH(<" [ZP"'T4 MARA)[$2IE2A=$L4&46H)%,,X"8VC+6S")$$P_&"/9&VQOG=PR928#QYJY"OFLZ\?W1*D@TB5<26>EK,?CH"8G MH;J)[+.^*/4#0;NAX(*QZN?_ 5!+ P04 " #<@JA,J/ #*'\# #X#@ M& 'AL+W=OY15WMZJDZS-G;UJJER;87,(VE,C\YTE565 PS .JKRH M_?72SCTTZZ4ZZ[*HY4/CM>>JRIL_][)4EY5/_+>)Q^)PU-U$L%Z>\H/\+O6/ MTT-C1L&XRJZH9-T6JO8:N5_Y=V2QH5%'L(B?A;RTDVNO2^5)J>=N\&6W\L-. MD2SE5G=+Y.;O16:R++N5C([?PZ+^&+,C3J_?5O]DDS?)/.6MS%3YJ]CIX\H7 MOK>3^_Q"=$A-CJ\K6_GK;-Z[B#0*:VR3YQS"NC0V8Y!^%@ZCYPN&62E)P6$6" MKT!Q)Z30"=VW:39@TFE=;T/W_8"CYCZ5<">DT E%ZJHA_Z4&1=S(ZMV#WM6@%G/C,M&D'F M[RA?9)0C=XP^<\?V(<%[Z+XG_)8WAZ)NO2>E37-B6XB]4EJ:M,);D];1M*'C MH)1[W5TFYKKI>[%^H-5IZ#.#L=E=_P502P,$% @ W(*H3%LYO,4J P M,0T !@ !X;"]W;W)KP]V&TI9@$3\S>6E&]T%;RK-2+^W@ZVX9 MDE:1S.56MR&$N9SE1N9Y&\GH^-T'#8><+7%\_Q;]LRW>%/,L&KE1^:]LIX_+ MP=T)LB^^4V5(_"2U6BUI=@KI[6I5H-P7< M,;.8VW;2KIW]SU3;F-GS:LX6T;F-TT/6'82.(# @(A-\R$"Q#&OJT>EU@HV/ M2.9X!H;6P"R?C6N(<7Z,\F/+C\=\[JQ!!TDMI.P@[CIM? QEN R.RN!^&0G. M3U!^XI>1.F5T$#Z2> ,)<>I 0#S%A:2HD-07,G.$I/\C! %-"9FA0F;^BDYL MK#G*GWN% '%$KN>>2+<,'W&3C,)TK\1(Q-O*LP80> )*)N M(OBP9@0"A/$)+:AQW -%M'CF1#_6XD-N@$]IP2T&&*(E=K4PY %X:C#0U$/" M_0I\PP+B.E8/NJXZY:DKQX=-;4WRS!)7B8^94H+['_@&",1U M0$#$\X:X:'T7C"6,&W%D!L59PK15\YXQ9XNT;!)507 W%[942[T,!,-7DX,9) M$>,$USBI[XK.AM@@$*!34G#?I(AO@NN;/>BJ6^%N1X. W%ICM,?!?U(2N;X%EITP;;9G6OE)9& M(;DU"W4TYY=AD,N];F]3'H_OV2P%'6H7TAMO%[ M?G:M/_3H%'<>=>TS/8&>!U!2K)T MM[MCB@M-RSS&3J;,<7!2:#@98@>EN/E]!(EC01-Z#3R)MG,AP,J\YRU\!_>C M/QGOL86E%@JT%:B)@::@]\GAF(7\F/!3P&A7-@F=G!%?@O.E+N@N" ()E0L, MW!\7> I Y&7\6OFI$O) %S;5_;'V+OOYYP9&8:?8]#U><'%(_FRH$XRCB/R_>^NBE3)(L9Y= -.<4N?MOT;-ZW0EIS1^9N-\V\0'7@INQN_0IU_ M8(LCH7'!_.!M,ZW9Y#CLYQ?$EF=<_@%02P,$% @ W(*H3/.SL\BP 0 MT@, !@ !X;"]W;W)K&>:<.3,>9X.QKZX% M\.1=2>URVGK?[1ES90N*NRO3@<8_M;&*>W1MPUQG@5<1I"1+-YL;IKC0M,AB M[&B+S/1>"@U'2URO%+>_#R#-D-.$7@+/HFE]"+ BZW@#+^!_=$>+'IM9*J% M.V$TL5#G]#[9'W8A/R;\%#"XA4U")R=C7H/SM45)!S7OIG\WP!%,_UY1,S7^# M,TA,#TJP1FFDBU]2]LX;-;&@%,7?QU/H> X3_P6V#D@G0/H)P,9"4?D7[GF1 M63,0.\Z^X^&*DWV*LRE#,(XB_D/Q#J/G(DEN,W8.1%/.8I"%O,5(%MXC8Y4II> MQTU>1.>%O4_CG?Q)'[?].[>-T(Z;C?.OC?& 4C97N$(M/K#9D5#[8-ZB M;<%_ Z^?L"]CI6:_4%F.&<,Q>&;$3S8EL 1UZUZFQ.6^?Z M V.V;$$+>X,]=/ZF1J.%\Z9IF.T-B"J2M&(\23XR+61'BRSZ3J;(<'!*=G R MQ Y:"_-V!(5C3E-Z=3S*IG7!P8JL%PW\!/>K/QEOL46EDAHZ*[$C!NJWE%10BT&Y1QR_P5S/!TKFXG_ !92'ATQ\C!*5 MC2LI!^M0SRH^%2U>IUUV<1^GF]V5MDW@,X$OA-M(8%.@F/D7X421&1R)F7K? MB_#$Z8'[WI3!&5L1[WSRUGLO19I^SM@E",V8XX3A:\R"8%Y]"<&W0ASY/W2^ M3=]M9KB+]-TZ.D^V!?:; OLHL/]OB1L8_G>1;-53#::)TV1)B4,7)WGE70;V MCL8=/T_X@3",[2\[H_,O&_M>(#GPJR8T?H=9_L,504+MP_.3/9AJSR7#8 MSS^(+=^X^ -02P,$% @ W(*H3+"Q,%ZS 0 T@, !@ !X;"]W;W)K MH7P,;O^=F8?$3[[#H 3UZT,JZ@G??]D3%7=:"% MN\$>3+AIT&KA@VE;YGH+HDX@K1C?[=XS+:2A99Y\9UOF.'@E#9PM<8/6POXZ M@<*QH'OZZGB2;>>C@Y5Y+UKX"OY;?[;!8@M++348)]$0"TU![_?'4Q;C4\!W M":-;G4FLY(+X'(U/=4%W41 HJ'QD$&&[P@,H%8F"C)\S)UU21N#Z_,K^(=4> M:KD(!P^H?LC:=P6]HZ2&1@S*/^'X$>9ZWE$R%_\9KJ!">%02F8)4K1XF79ITCY.-[?9#-L&\!G %\!=RL.F1$GYH_"BS"V.Q$Z][T5\XOV1 MA]Y4T9E:D>Z">!>\UW+/> M$OSPE\+#-D&V29 E@NS-$K=BLG^2L%5/-=@V39,C%0XF3?+*NPSL/4]O\B=\ MFO8OPK;2.')!'UXV];]!]!"D[&[""'7A@RV&@L;'XVTXVVG,)L-C/_\@MGSC M\C=02P,$% @ W(*H3$\G(@"V 0 T@, !D !X;"]W;W)K&UL;5/;;MLP#/T501]0Q4K:!H%MH.DP=, &!"VV/2LV?4%U M<24Y[OZ^E.RZ;N<72:1X#@\I*AV,?78-@">O2FJ7T<;[[L"8*QI0PEV9#C3> M5,8JX=&T-7.=!5%&D)*,;S8W3(E6TSR-OI/-4]-[V6HX6>)ZI83]=P1IAHPF M]-WQV-:-#PZ6IYVHX0G\[^YDT6(S2]DJT*XUFEBH,GJ7'(Z[$!\#_K0PN,69 MA$K.QCP'XT>9T4T0!!(*'Q@$;A>X!RD#$]$>.+DP+$W17#& M5L0[%._0>\D3?IVR2R":8HYC#%_&S!$,V><4?"W%D?\'Y^OP[:K";81O/RF\ M62?8K1+L(L'N$\'MEQ+78O9?DK!%3Q78.DZ3(X7I=9SDA7<>V#L>W^0C?)SV M7\+6K7;D;#R^;.Q_98P'E+*YPA%J$/-AH3*A^,MGNTX9J/A33?](#9_X_P- M4$L#!!0 ( -R"J$Q9MA:)M $ -(# 9 >&PO=V]R:W-H965TI.G*MI1-5;52*ZU2-7EF[;&- AX' M\#K]^P)V'*NU\@+,<,Z9"T,VHGFV+8 CKUIU-J>M<_V!,5NVH(6]PAXZ?U.C MT<)YTS3,]@9$%4E:,9XD-TP+V=$BB[Z3*3()!-ZX*#%5DO&O@%[G=_,MYBBTHE-7168D<,U#F]VQV.^X"/@$<)HUV=2:CD MC/@ M9.7:G-Y24D$M!N4>57PJ6KQ. MN^SB/DXW:3K3M@E$O"%&UL?5-A;]P@#/TKB!]0+B3=JE,2J==JVJ1-.G7:]IE+G 05X@S(I?OW M Y)FV1;U"V#C]_QL3#ZA>;8=@",O6O6VH)USPY$Q6W6@A;W! 7I_TZ#1PGG3 MM,P.!D0=05HQ?CB\8UK(GI9Y])U-F>/HE.SA;(@=M1;FUPD43@5-Z*OC2;:= M"PY6YH-HX2NX;\/9>(NM++74T%N)/3'0%/0^.9ZR$!\#ODN8[.9,0B47Q.=@ M?*H+>@B"0$'E H/PVQ4>0*E Y&7\7#CIFC( M^=7]@^Q=E_+15AX0/5#UJXK MZ!TE-31B5.X)IX^PU'-+R5+\9[B"\N%!B<]1H;)Q)=5H'>J%Q4O1XF7>91_W M:;ZY31;8/H O +X"[F(>-B>*RA^%$V5N<")F[OT@PA,G1^Y[4P5G;$6\\^*M M]U[+).4YNP:B)>8TQ_!MS!K!//N:@N^E./'_X'P?GNXJ3",\_4MAND^0[1)D MD2![L\2]F.R?)&S34PVFC=-D285C'R=YXUT']I['-_D3/D_[%V%:V5MR0>=? M-O:_073@I1QN_ AU_H.MAH+&A>-[?S;SF,V&PV'Y06S]QN5O4$L#!!0 ( M -R"J$P$;!;:M $ -(# 9 >&PO=V]R:W-H965T0;)JV M45\ &Y_C8V/RT;H7WP$$\JJ5\07M0NB/C/FJ RW\C>W!X$UCG18!3=TD(:6>?*=79G;(2AIX.R('[06[N<)E!T+NJ=OCF?9=B$Z6)GW MHH4O$+[V9X<66UAJJ<%X:0UQT!3T<7\\'6)\"O@F8?2K,XF57*Q]B<;'NJ"[ M* @45"$R"-RN\ 1*12*4\6/FI$O*"%R?W]C?I]JQEHOP\&35=UF'KJ /E-30 MB$&%9SM^@+F>6TKFXC_!%12&1R68H[+*IY54@P]6SRPH18O7:9-TDV4S M;!O 9P!? \I#YL2)>7O1!!E[NQ(W-3[7L0GWA\Y]J:*SM2*=(?B/7JOY3Z[ MS=DU$LTQIRF&KV.6"(;L2PJ^E>+$_X'S;7BVJ3!+\.P/A7?;!(=-@D,B./RW MQ*V8^[^2L%5/-;@V39,GE1U,FN25=QG81Y[>Y'?X-.V?A6NE\>1B [YLZG]C M;0"4LKO!$>KP@RV&@B;$XSV>W31FDQ%L/_\@MGSC\A=02P,$% @ W(*H M3)2G$9*U 0 T@, !D !X;"]W;W)K&UL?5/; M;MP@$/T5Q <$+W:3[6;ML8W"Q06\3O^^@!W';:R\ #/, M.7-F&/)1FV?; 3CT(H6R!>ZR5[D'YFT8;R9PW34ML;X#5$20% MH4ER323C"I=Y])U,F>O!":[@9) =I&3FSQ&$'@N\PZ^.!]YV+CA(F?>LA9_@ M?O4GXRVRL-1<@K)<*V2@*?#M[G#,0GP,>.0PVM49A4K.6C\'XUM=X"0( @&5 M"PS,;Q>X R$"D9?Q>^;$2\H 7)]?V>]C[;Z6,[-PI\43KUU7X#U&-31L$.Y! MCU]AKN<31G/QW^$"PH<')3Y'I86-*ZH&Z[2<6;P4R5ZFG:NXC]-->C/#M@%T M!M %L(]YR)0H*O_"'"MSHT=DIM[W+#SQ[D!];ZK@C*V(=UZ\]=Y+N4OW.;D$ MHCGF.,70=0N?IOT',RU7%IVU\R\;^]]H[&UL?5-ACYP@ M$/TKA!]PK.BUEXV:W%[3M$F;;*YI[S.KHY(#QP*NUW]?0,_:UO8+,,.\-V^& M(9_0/-L.P)$7K7I;T,ZYX M,"UD3\L\^LZFS'%T2O9P-L2.6@OSXP0*IX(F]-7Q*-O.!0L*>D=)#8T8E7O$Z0,L M]=Q2LA3_":Z@?'A0XG-4J&Q<235:AWIA\5*T>)EWV<=]FF_2VP6V#^ +@*^ MNYB'S8FB\G?"B3(W.!$S]WX0X8F3(_>]J8(SMB+>>?'6>Z]EDB4YNP:B)>8T MQ_!MS!K!//N:@N^E./&_X'P?GNXJ3",\_4WA/PBR78(L$F3_+7$O)OTC"=OT M5(-IXS194N'8QTG>>->!O>?Q37Z%S]/^69A6]I9&PO=V]R:W-H965T29M<<7!1@7\#K]^P)V'+>U^@+,,.?,F6%(!S1O MM@%PY%U);3/:.-<=&+-% TK8*^Q ^YL*C1+.FZ9FMC,@R@A2DO'-YIHIT6J: MI]%W,GF*O9.MAI,AME=*F%]'D#AD=$L_'$]MW;C@8'G:B1I^@'ON3L9;;&8I M6P7:MJB)@2JC=]O#,0GQ,>"EA<$NSB14QL^)D\XI W!Y_F#_$FOWM9R%A7N4KVWIFHS>4E)")7KIGG#X"E,]>TJF MXA_A M*'!R4^1X'2QI44O76H)A8O18GW<6]UW(?Q9L\GV#J 3P ^ VYC'C8F MBLH?A!-Y:G @9NQ])\(3;P_<]Z8(SMB*>.?%6^^]Y-LD2=DE$$TQQS&&+V/F M".;9YQ1\+<61_P/GZ_#=JL)=A._^4+A?)TA6"9)(D/RWQ+68Z[^2L$5/%9@Z M3I,E!?8Z3O+".P_L77Q$]AD^3OMW8>I66W)&YU\V]K]"=."E;*[\"#7^@\V& MA,J%XXT_FW',1L-A-_T@-G_C_#=02P,$% @ W(*H3/"] :2U 0 T@, M !D !X;"]W;W)K&UL?5/;;MLP#/T501]0)8[7 M9H%MH.E0;, &!!W6/BLV;0O5Q9/DN/O[4;+K>JO1%TFD> X/*2H;C'UV+8 G M+TIJE]/6^^[ F"M;4-Q=F0XTWM3&*N[1M USG05>19"2+-ELKIGB0M,BB[Z3 M+3+3>RDTG"QQO5+<_CF"-$-.M_35\2":U@<'*[*.-_ 3_*_N9-%B,TLE%&@G MC"86ZIS>;@_'-,3'@$45%#S7OH',WR%J9Y/E$S%?X<+ M2 P/2C!'::2+*RE[YXV:6%"*XB_C+G3UYDU@S$CKWO>'CB[2'!WI3!&5L1[U"\0^^EV*8W&;L$HBGF.,8DRY@Y@B'[ MG")92W%,WL&3=?AN5>$NPG?_*-RO$Z2K!&DD2#\L<2WF\W])V**G"FP3I\F1 MTO0Z3O+".P_L;1+?Y"U\G/8?W#9".W(V'E\V]K\VQ@-*V5SA"+7XP69#0NW# M\0;/=ARST?"FFWX0F[]Q\1=02P,$% @ W(*H3)UUT/ Q @ ; < !D M !X;"]W;W)K&UL=571CILP$/P5Q ><,22!1 0I MN:IJI5:*KFK[[)!-0&=C:COA^O>U#4=S9'G!]C([L_;:NWDGU:NN $SP)GBC MMV%E3+LA1)<5"*:?9 N-_7.62C!CE^I"=*N G;R3X"2.HA41K&["(O>V@RIR M>36\;N"@ GT5@JF_>^"RVX8T?#>\U)?*. ,I\I9=X >8G^U!V14964ZU@$;7 ML@D4G+?ACF[V-'$.'O&KAD[?S0.WE:.4KV[Q];0-(Q<1<"B-HV!VN,$S<.Z8 M;!Q_!M)PU'2.]_-W]L]^\W8S1Z;A6?+?]RC1(Q)[.,']QAW3] ($^^>?(AP1G^!$BP\P>(#03S9(H9)<)$E*K)$ M"!83$0RSQ$56J,@*(5A-1#!,BHNDJ$B*$&03$0RSQD4R5"1[)%A-KQV&F4G\ M&A59(P33Q&.8F<33"']!$4(Q33T*FLD]G7FI%*&89A\%S:2?HL]U1V.$8GH! M4-#,#:#XNZ;)(T7Z4'HPT/02D+MB)T!=?)G702FOC>\Q=]:QE>QB7RS_P_L^ M])VI2]WHX"B-+;F^,)ZE-&!CB9[L^ZULZQL7',[&35,[5WW][Q=&MD-O(V.# M+?X!4$L#!!0 ( -R"J$QE &8IL@$ -(# 9 >&PO=V]R:W-H965T MTE0K0,HFBEJIE5:IVCY[80 K M-J:V6=*_[]BPE&YYP3/#.6CL6^N!?#D7:O.Y;3UOC\PYLH6M'!WIH<. M_]3&:N'1M0USO05119)6C.]V'Y@6LJ-%%F,G6V1F\$IV<++$#5H+^_L(RHPY M3>@U\"J;UH< *[)>-/ -_/?^9-%CBTHE-71.FHY8J'/ZF!R.:> 9NP2A&7.<,'R-61 ,U9<4?"O%D?]'Y]OT_6:%^TC?K[,G]]L" MZ:9 &@72?UKHQ0>V. IJ'\P'M.VT9I/C33^_(+8\X^(/4$L# M!!0 ( -R"J$R&D^-JMP$ -(# 9 >&PO=V]R:W-H965T[EG',_N*0#FE?; #CRIE5K,]HXUQT9LT4#6M@;[*#U-Q4:+9PW M3*=G"V1#;:RW,[Q,H'#*ZH>^.9UDW M+CA8GG:BAN_@?G1GXRTVJY120VLEML1 E='[S?&T"_@(>)$PV,69A$HNB*_! M^%)F- D)@8+"!07AMRL\@%)!R*?Q:]*D<\A 7)[?U9]B[;Z6B[#P@.JG+%V3 MT3M*2JA$K]PS#I]AJF=/R53\5[B"\O"0B8]1H+)Q)45O'>I)Q:>BQ=NXRS;N MPWBS_S31U@E$O"9'>*S% 0 -P0 !D !X;"]W;W)K&UL;51A;]L@$/TKB!]0;)(L:61;:CI-F[1*4:=MGXE]ME'!>(#C]M\7 ML.MY&5\,=[Q[[^[@G(U*OY@6P*)7*3J3X];:_DB(*5N0S-RI'CIW4BLMF76F M;HCI-; J!$E!:))\(I+Q#A=9$UUD:G!"M[!62,S2,GTVPF$&G..']'C:>7P _.(PFM4>^4HN2KUX MXUN5X\0G! )*ZQF86Z[P"$)X(I?&GYD3+Y(^<+W_8/\2:G>U7)B!1R5^\\JV M.3Y@5$'-!F&?U?@5YGIV&,W%?XB,2P]RV@JPN3H)NPI,UJ%1#%\9EY5VF MXH&&B_\+GT;JB>F&=P9=E'7/)UQRK90%ETIRYW)IW10OAH#:^NW>[?7TEB?# MJGX>4[+\*XIW4$L#!!0 ( -R"J$R)$=+LJ@$ )$# 9 >&PO=V]R M:W-H965TF<17P" M_) PNI5-8B=7Q.?H?*X+NHN"0$'E8P81CAL\@E(Q49#Q:\Y)EY*1N+9?LW], MO8=>KL+!(ZJ?LO9=08^4U-"(0?DG'#_!W,\])7/S7^ &*L"CDE"C0N72EU2# M\ZCG+$&*%B_3*4TZQ^DF.\RT;0*?"7PA'%,=-A5*RC\(+\KQ%^\ M/_$PFRH&TRC271#O0O16[H]9SFXQT8PY3QB^QBP(%K(O)?A6B3/_C\ZWZ=FF MPBS1#_\H/+Q1N(6Y?U.$K4:BP;9I&1RI<#!I$5?19=\>>!KI7_BTK%^%;:5Q MY(H^_)@TO@;10Y"RNPL;T(7WL3@*&A_-]\&VTY9,CL=^?@!L>87E'U!+ P04 M " #<@JA,;BPBRK-\=&7-% TJX&].!QIO*6"4\FK9F MKK,@RDA2DO'-YI8IT6J:I]%WMGEJ>B];#6=+7*^4L']/(,V0T2U].# M@^5I)VKX!?YW=[9HL5FE;!5HUQI-+%09O=L>3[N CX _+0QN<2:ADHLQS\'X M7F9T$Q(""84/"@*W*]R#E$$(TWB9-.D<,A"7YS?U;[%VK.4B'-P;^=26OLGH M@9(2*M%+_VB&!YCJ^4+)5/P/N()$>,@$8Q1&NKB2HG?>J$D%4U'B==Q;'?=A MO-GO)]HZ@4\$/A,.,0X; \7,OPHO\M2:@=BQ]YT(3[P];;PVW*KD%HPIQ&#%]B9@1#]3D$7PMQXO_1^3H]67C?VOC/& J6QN<(0:_&"S(:'RX;C'LQW';#2\Z:8?Q.9OG/\#4$L#!!0 M ( -R"J$R-F3G$L@$ -(# 9 >&PO=V]R:W-H965T#L6^N!?#D0TGM0,H@A&6\3YIT3AF(2_NJ_AQ[QU[.W,&3D;]%Y=N0" ^58([22!>_I.R=-VI2P5(4_QA/H>,Y3/I7 MVCHAG0CI#8&-B6+E7[CG16;-0.PX^XZ'*]X<4IQ-&8)Q%/$?%N\P>BDV#_N, M78+0A#F.F'2)F1$,U><4Z5J*8_H?/5VG;U"?_X..V?^>V$=J1L_%XLW'^ MM3$>L)3D#E>HQ0&PO=V]R:W-H965TJNKAB_L0HAV[C@\+TB-^1-M22._'"BKL9!3=G1XRPC> M:U)=.9[K1DZ-R\;.4FU[9EE*3Z(J&_+,+'ZJ:\S^K$A%NX6-[(OAI3P60AF< M+&WQD7PGXD?[S.3,&57V94T:7M+&8N2PL)=HOD6A(FC$SY)T_&9LJ51VE+ZJ MR9?]PG951*0BN5 26+[.9$VJ2BG).'X/HO;H4Q%OQQ?U3SIYF:/>9# F%MC5D_Y6<227A*A+I(Z<5UT\K/W%!ZT%%AE+C MM_Y=-OK=#?H7&DSP!H(W$OKB3!+\@>!?"<&[A& @!%="]"XA' BAX<'I<]?% MW&"!LY31SF+]?FBQVG9H'LKERI51KX[^)NO)I?6@D 03,A>\QL<8T&A,CHZ3;1TS@362+ M7/C,NT H$_L+3?PVT,?/ 0*/_!)Y_Z[Z!@3-)OS )Q;Y@,3$1D?PF47!?V0+ MGTCT@2.Y D%FJ,[-K[TF[*C[++=R>FJ$BO'&.O;RI:=:@V%?H?D: ?:-ZOVZ ME5SE^XO#-\R.9<.M'16R(>FV<:!4$!F[^R1C+^1=99Q4Y"#4,)9CUC?L?B)H M.UQ&G/%&E/T%4$L#!!0 ( -R"J$P(D\\UJ0( (\* 9 >&PO=V]R M:W-H965TV$[=O7-BP*]I#NS8+-F?$W]N2LUSUE+[PD1#BO3=WRC5L*T:T\ MCQ]+TF#^1#O2RB]GRAHLY)!=/-XQ@D\ZJ*F]P/<3K\%5ZV[7>F[/MFMZ%775 MDCUS^+5I,/N[(S7M-RYRWR:>JTLIU(2W77?X0GX0\;/;,SGRIBRGJB$MKVCK M,'+>N!_1JD"9"M"*7Q7I^=V[HTHY4/JB!E]/&]=71*0F1Z%28/FXD8+4MHG+/!VS6COL.&T.JR: JU"N9E'-:GW3G^3U7(Y>]L&R%][ M-Y5HU.P&37"OF2L*0!%/$D\"3!0!2!'H^&A&@0R*09-J3:LU*$&Q 0*( C^ M44(0)010C')W@R:^6^4#\B-CVPI0A2(8)@)A(@ F-& B:YDX-;?%UJ L@T%B M$"36"<(9R$(E"9@@ 2HQ*'>)11DE1A<4CS4SD!0$20&0Q !)[9,+AZ22V M*L^7:!8L#;V_61'L1P@R)+-=1]'C?OV/: X#.Q*"+&FAT1#L(P@R$NN )<( M,K.>QZ(Y#.PE*+9A G\A!>PF"+(3JQ[;*U+SM_-8,T>!_00!AA(L'3#L P@R M JN:S/K7%J;6Z=@BQT" M G!@ &0 'AL+W=O&QA$+.]IRLY,?:DC6]UX0=:$!"HI&; M:KG! 0C11$K&GY'3GU+JP/G^A?V+J5W5S6<\97(!S9\ MA;&>Q/?&XK_##8B":R4J1\6(,+]>=162T9%%2:'XV:YM9];!GB3Q&.8.B,: M: I0N?\7$(\!\6O QA1OE9E2/V.)RYRSP>/V8_58WXEP%ZMF5MII>F?.5+5" M>6]E%$4YNFFB$;.WF&B&"2<$4NQ3BLB58A^MPA<)#FM$^LF=(786$9OXS9LB MXD41%K,UF,YBTB (%DK6J# (YK W:C9.-1N'FLU"C<4DO6Z>8K4-,ZB;(G 39!SY,MM;IN@!H M]KXH\(L91<*KV+63^B;/O-.TNX_T^USX]VH*VJ'U2F-'Z _,+VTGO!.3ZO6; M-WIF3()2&=RI=C=J:D\&@;/4VZW:&PO=V]R:W-H965TM2A8HUU;=^_?7%F2Q#'M^ M@7;ZWLR;86B;WAA_$V=*I?->%I58N&%AWX^\DN25NTR-;8;%&J"0;SF]"9Z8T>G MLF/L34^^'1:NKQ71@NZE=D'4ZTHS6A3:D]+QIW7J=C$UL3^^>_]BDE?)[(B@ M&2M^YP=Y7KBQZQSHD5P*^<)N7VF;T-1UVNR_TRLM%%PK43'VK!#FZ>PO0K*R M]:*DE.2]>>>5>=]:_W<:3, M 7>$:/8I(6@)04=08C\CA"TA_""8\GM-*J8V M&R+),N7LYO#F\]9$=Q&:AZKZ>VTTQ39KJCQ"6:]+C&>I=]6.6DS68' /@SJ$ MI[QW(3 4(L,#.GX,L!DBH@2.$(!)!(8?/"01PPY"T$%H'(0/#I)'D>LA)HZL M0C60F8%43:$2C*QDAZ!@&L!BIZ#8Z5!LX%M*&LRT'P1'OBT%0*$0C50N L5$ M0.5B2TR#27IA_(EOU6X#@D;Z; 9*F0V[(!AQ$(,.XB>Z8(@9=$'\3!<,0:-= MD(!B$Z +K/\J2Y[J @ UW@7(A[<1'Y 3V/N(/XB$8F2A-@ J&E4SLJDA0$UH MJT'#O,,0A;8< (;](!H1!&Z!*X0!0<@6A)_Y3V#42)\C>[]\7(4W0_3_G6X- M8!)L:?!Z9U!)^X0:ZS/,,N>Z;L%8%^A8)ZI%(8'X:>\$LZ.276JFK/OR)BD*BU_HC[S6=V?NDE!CU(/9VK,FTM$ M,Y&L;B](7G=+6_X#4$L#!!0 ( -R"J$R@N!4#% ( -H% 9 >&PO M=V]R:W-H965TU#6'#9=OF >SAG#-G)O;$'>.OH@*0UALEC4CL2LIV MAY#(*J!8/+ 6&O6E8)QBJ;:\1*+E@'-#H@1YCA,ABNO&3F,3._$T9A=)Z@9. MW!(72C'_O0?"NL1V[5O@N2XKJ0,HC5M0/]H35SLTJN0UA4;4K+$X%(G] MY.Z.D<8;P$L-G;A;6[J2,V.O>O,E3VQ'&P("F=0*6+VN< !"M)"R\6O0M,>4 MFGB_OJE_,K6K6LY8P(&1GW4NJ\3>VE8.!;X0^9I91LLWO^[+=:'R-T%JON9#IIFFV^J/4)%KZGGAS&Z:J$! ML^\QW@0333&')<8=$4@Y&&UX:S;VWDJ*S2S%"F:*."X1T>.Z"W^U&;[A!Q,7 MVYF+'A,:3--C'/V;65G"7'>*F_@)5OT$*WX>9WZ"9:*MZR\-+7&1N_W03[CJ M)USZ"3X0B%8%HG\7M(\61C>;R OG>=#=":? 2S,]A)6Q2R/U&;B+C@/JR=,W M9!8_J,'5SYEWF7[J?<.\K!MAG9E4]\_&UL?53;CILP$/T5Q >L"9=D-R)(FU15 M*[52M%6WSPX,%ZV-J>V$[=_7-BPA9+0OV!Z?<^:,L2?MA7Q3-8#VWCEKUZVA*B\!D[5@^B@-3NED)QJLY0549T$6C@29R0,@C7AM&G]+'6QH\Q2<=:L M:>$H/77FG,I_>V"BW_DK_R/PTE2UM@&2I1VMX!?HW]U1FA695(J&0ZL:T7H2 MRIW_O-H>-A;O *\-]&HV]VPE)R'>[.)[L?,#:P@8Y-HJ4#-O&?MB)5R,-)X0C(9P()O=GA&@D1%>" M.TTR.'.E?J&:9JD4O2>'G]51>R=6V\@<9FZ#[NS@E"^-52BY6:,3L M!TPXPUP1Q*A/*4(LQ3Z\HX>W"0[WB/43GB%"BX@WB.]-;QM: MT55F:(P_J:R:5GDGH]4?X" "J"P &0 'AL+W=OX]BO>0765Q1!=VD:*OZ6K.:W58C"MXVGZGB2>B-:+\_TR'XP^?/\*-0J&K+LJX:U7<7; M0+##*GQ BRTJ=(!!_*K8K1O=![J49\Y?].+K?A7&6A&KV4[J%%1=KFS#ZEIG M4CK^V*3AP*D#Q_=OV3^;XE4QS[1C&U[_KO;RM KG8;!G!WJIY1._?6&VH"P, M;/7?V)75"JZ5*(X=KSOS&^PNG>2-S:*D-/2UOU:MN=YL_K3NU>USC#R^BJ$UE,V6/P"(/N$5L 420#)E(*!AD8DE%B+X$C8N,C2.&H M ))DL(@$[$5BXI.[^(DJ4C!!:A*D=PE2IYD])C.8ML>@A, L&RUXJFC09!X0!K1X9M>#=.WO[9WA^003["0H 9@2 MERGQF>+9U'%!L.4@P'.(ZSD6Y#"YUK2UL/]\WK Y(<"=7.LI+0BA.Z8I(MA] M$& _Q+4?$)2[94.@J><-VQ0"?,K]/)40*)]P7 0;%0*<*O?>IAZ4CYJ;9;G[ ML810))WX7B+8K!#@5KGW0A4>49)CM^YH-+ T3!S-,-@%.WYII?ZFCW:'@?,! MZX''V2_18M./C>]I^BGV.Q7'JNV"9R[5.&6&G@/GDBF1ZIB'P4D-SL.B9@>I M;W-U+_KIL5](?K:3<32,Y^M_4$L#!!0 ( -R"J$Q 1QR<^ ( #8, 9 M >&PO=V]R:W-H965TDP9G0W1=BFS,S9R8^PS"_Q++.3^I(J_8D_#DJ2RI^+-B!;\L?.)?#Y[SPU&9@V YK^F!?6?J1_TD M]"[HO.SRDE4RYY4GV'[A/Y+9!F)C8!$_/,UJPHC"?-XW?KU.]B&L/^^NK]DTU>)_-")5OSXE>^4\>%G_G>CNWI MJ5#/_/*9M0DEOM=F_Y6=6:'AAHF.L>6%M)_>]B05+ULOFDI)WYIG7MGGI?5_ M-<,-H#6 S@#2NP91:Q!U!B2^:Q"W!K%C$#2IV-ILJ*++N> 73S2OMZ;F%I%9 MK*N_-8>VV/8[71ZI3\]+F$3SX&PAG2(0'OO0@ 68@4#<[@-L!XB MTNDM9(,X27 2$9IG9.VCFSQCW$&,.HBM@_C&0>(4JL$D%E,U>21A&#K9#E%: MIGW8#9L$99,,V:3$8=-@)KTX+I,&,>TC'F#DW:8HCQ2I2NKP2 <\TCOY3M X M$R3.Q(F#83(\2(8&R1 'SCU<9UC)1J),T2C3893,>3&KZ:!DY$[)2(A+.T0B MN9>D!?5O(YDFV>#6;A @D"@=)S72;PA""D9&ULC9?O;ILP%,5?!?$ M!9M_(4HB-8FF3=JDJM.ZSS1Q$E3 &3A)]_:SP65@']I^*>"A#C//:_9G5B9-7?\S"KYRX'792;D8WWTFG/-LGT;5!8> M]?W8*[.\+=NRA7BWX111YQ1YJI[F495;_7;."WY8N<=\&'O/C2:@!;[4X M9T?VDXE?YX=:/GG]+/N\9%63\\JIV6'IWI/YEB8JH%4\Y>S6#.X=5ZK X?W;[%_:XF4QSUG#-KSX MG>_%:>G.7&?/#MFE$(_\]I7I@B+7T=5_9U=62+G*1'KL>-&T?YW=I1&\U+/( M5,KLM;OF57N]Z?G?PG U0&T#Z#1NP&!#@CZ !*^&Q#J@-!P\+I2VK799B); M+6I^<^IN>\^9>HO(/)2KOU.#[6*WO\GE:>3H=45GZ<*[JHFT9MUIZ$!#QHHM M4*1!K_%D!GT:%*6QIM8$=&RQL16QD><63!+A) *X%D$;'X[B0V,M.DW4:JI. M0X(8NX30);1=DLAP"2V7V)!L;(D\[#B/".81@6H3(X_(-@D2;!)#D]@V27W# M)+:+Q18)M$A '3/#(K$L2&J*MK9H>FMG,)69G4IL5MMITH&+?S=XRT8N*71) M@8MQ(->I58N1QR8%>5""\R ^9H'0B=1DX3:TKF: 4 4[4="*V$[FC MLPDG"*)[0H&3"0$MFMQ$#<4/5.-T,)((8%)J;C82Q8F9#1)-K0TF%P'H2NG$ M%!@Z!%''6EZ G2FV$@AB#TF0XG-E2D73!4"L&)!5(L^ MXX*I0@!6+(X2FRO#G=%OVONB\=< )@M%9#%+UJ)T=-QG$V"A&"P4@<4\7UKT MB;6E&"H40<4$I19]Q@6S@J(3;D*2VA\P4RX8 A1 P *D%DUNC?Y>^T U3@<# MA0*@6("$HL#,!HDF:$TQ=2CZW#&IHT7)\'C$4SZ8.Q1PQ_9)+)_ C\RB;9&= MC#=H)DI6']M&K7%V_%()];T]&.V;P7NJFA%C?$WFFZZE^S]-UV'^R.IC7C7. M,Q>RU6D;D@/G@LD0CV<"XSQO;D V7OO")$.!]MT_&56PG1+Q'B945:S)]H3SKYYD!9 MBX67Z M[B7P5A\KH0*HR'M\)-^)^-%OF9RA465?MZ3C->T<1@XK]]E?OOJ>(FC$SYH, M?#)V5"D[2M_5Y,M^Y7HJ(]*04B@)+!]GLB%-HY1D'K^MJ#MZ*N)T?%'_I(N7 MQ>PP)QO:_*KWHEJY"]?9DP,^->*-#I^)+2AV'5O]5W(FC82K3*1'21NN_YWR MQ 5MK8I,I<4?YEEW^CE8_0L-)@26$(P$Z?V($%I">"5$#PF1)4170O*0$%M" M/'- IG:]F"]8X")G='"8V0\]5MO.7\;R.R4]=4(=JDET M["7/@;J:9O&UO]R8CG"5,0WJ&V;'NN/.C@IY\>GKZ4"I(#)+[TGF5\F>.$X: M&UL?53;;MLP#/T50>^K?$G3 M-K --!Z&#=B H$.W9\6F+Z@NGJ3$W=]/%]=U$V,OEDB=Z,&7:$Z*H#3O6-'$#8DT8J3HTU54OTH(#6GL092:)H2SCM!2XR[SNH M(I,GPWH!!X7TB7.J_NZ!R3'',7YS//5M9YR#%-E 6_@)YGDX*&N16:7N.0C= M2X$4-#E^C'?EQN$]X%O,-5SB]%4_'UVHJT3DHF0S 0;^W^$="*D M[P1_FR1DYDO]3 TM,B5'I,)C#=3U1+Q+[656SNGOSI_9:K7UGHLT>LC(V0E- MF'W ) M,/".(59]#)&LA]LD5/?D8H+Q&;!_6(Z2K1:2>GRZ+B*-U@W$#!W'B,\YM/]!::\QES6018/PT&UOH]@+ M_]Z.3^CV=YDP>S^H:GNAT5$:VS;^<1LI#=@$HQO;T)T=]]E@T!BWO;-[%9H^ M&$8.TSR3^:=2_ -02P,$% @ W(*H3'^U3_ZV @ 5 H !D !X;"]W M;W)K&ULC5;;CMHP$/V5*.^[B>W<0 &)BZI6:B6T M5=MG P:B3>+4-K#]^]I.R ;;0;P0VYDYY\PP$T]^I>R=GP@1WD=5UGSFGX1H MID' =R=28?Y*&U++-P?**BSDEAT#WC""]]JI*@,8ADE0X:+VY[D^V[!Y3L^B M+&JR81X_5Q5F_Y:DI->9#_S;P5MQ/ EU$,SS!A_)3R)^-1LF=T&/LB\J4O." MUAXCAYF_ -,UR)2#MOA=D"L?K#T5RI;2=[7YMI_YH5)$2K(3"@++QX6L2%DJ M)*GC;P?J]YS*<;B^H7_1P@#47G9HT%GN>,7CW6_KT-5E4$II',_DX=ZF3K=S(] M7)Y>Y@C /+@HH,YFV=K @0WH+0*)WE- %\426NX&P$1O[ZQ,F2: 1TQS(B,W4"I+;,Q%"9VBI3HWA2.UUP+)#, MJ2-SI"MQ TR< ),GZF]B13)>72!TMW/X1'UU1O%3Y0-&OAO@B0+JC.Z()ME( MXH'SZ[$ \/D: N[>!W;S(Y":6I&M%8XFQ=WCYUJH&VIPVH]&"ZBN9N-\"::K=L#YA&GGK1^8'8N:>ULJ MY,6OK^<#I8)(A>&K3,%)CGC]IB0'H9:I7+-VSFDW@C;=#!?T@^3\/U!+ P04 M " #<@JA,U9"P&<@" "J"@ &0 'AL+W=OZZJ1R_"H5#N/(KD]LIK*&]ZR1O^R MYZ*F2@_%(9*M8'1GC>HJPG&<134MFW"UL',/8K7@)U65#7L0@3S5-15_UZSB MEV6(PK>)Q_)P5&8B6BU:>F _F7IJ'X0>18.775FS1I:\"03;+\-;-+]'A3&P MBE\EN\C1>V"6\LSYBQE\VRW#V$3$*K95Q@75CS/;L*HRGG0_2YWZK@,BS#8L3T]5>J17[ZR?D%I&/2K_\[.K-)R$XEF M;'DE[?]@>Y**U[T7'4I-7[MGV=CGI??_9@8;X-X #P::_9$!Z0W(_QHDO4'R M;I!\:)#V!JEC$'5KMYMY1Q5=+02_!*([#RTUQP[-4_VYMF;2?AW[F]Y/J6?/ M*X+Q(CH;1[UFW6GP2(-)=JW9^!HT*"(=P1 &AL)88\^<8.(@?(T3Z)VOR&;7 MDGL(E,"1$G##B'607#E(G0WK-+G5--UFI&DN" @H"<0]VLBO"2@FTX<; MP54! 64AF7(!)SP",MX-][X778=K_R98<-(C(.N3B0L(P?F,H(3VPO4S&J50 MN-'H_JV9.-AF2 9;?FJ4N7Y</#=8O-_>W,;]#\KFN;WMUT7=P/*@YE(X-G MKG1W8._P/>>*Z3CC&_WYCKIQ' 85VROSFNMWT75/W4#QMN\,HZ$]7?T#4$L# M!!0 ( -R"J$Q.UM)JM $ @$ 9 >&PO=V]R:W-H965T^!JJO$"OR<> MV6&P/D&::J0'> +[>]QI%Y%9I6,"I&%*(@U]C;\MUMON7U4TP](]=QBE(K_!2?@#NZ=N#M:Q4WXHO9HK!))Q5D1]"6N M3(9UBB?+NT2[3L@3(9\)B_)30I$(Q5<)92*4%P022PF]V5)+FTJK">GX=T?J M']%B7;KNMSX9FAW.7'N,RYZ:HLPKQT?9PRL&M/&ULC5;1CILP$/P5Q/L=K($ IR12DZIJI5:*KFK[[$N]K&RXE M>%WE)=AF=F<6=LC.+UR\RB-C*GAKZE8NPJ-2W5,4R>V1-50^\HZU^LZ>BX8J MO16'2':"T9T-:NJ(Q/$L:FC5ALNY/=N(Y9R?5%VU;",">6H:*OZL6,TOBQ#" M]X/GZG!4YB!:SCMZ8-^9^M%MA-Y%URR[JF&MK'@;"+9?A!_@:4UL@$7\K-A% MCM:!*>6%\U>S^;);A+%1Q&JV528%U9NO56NOE_Y.3H8P/( , >0: .E_ Y(A()D$1+TR6^I'JNAR M+O@E$/W;ZJAI"GA*],/(($39#8!)E-T/8"8B@F*GM0/@*ELP1G25&6%&,I M)RPNJ$ABG"5#63*$A<03%A=4Y)Y:9BC+#&.!"8L+*B'%67*4)<=8IMWC@LK, M\_8+E*6P"=*;]LDG)(5#DI:>'BU1DA(AF798Z9)D"> L$..&C!$OE)X4'D_# M/6Y 4.!S+>"V!7*/(1"4QP^ FQLP=SN.0% ^&MS=@-G;L02"\M'@]@;4W\X7 M-7/:;=32MSRXP6%VARO =;BO&MS@D-]A"W =[F\UW.* >#QS6L U^0/QT. F M!\3EF=,"KLV!>#Z^!'20^L!M#X#^NA3"9B!M!-S7XU^ ># *+&(0)' MS;15HM'48<; ;U0M^*@GS^NF9GMEEKE>BW[\ MZC>*=\-H&5WGV^5?4$L#!!0 ( -R"J$SC^&TTNP( ,,* 9 >&PO M=V]R:W-H965TE5R#=UXEP[[UF:JYE[ MTKJ8>)[:G7C&U(LH>&Z^'(3,F#9+>?14(3G;VZ L]8CO1U[&DMR=3^W>1LZG MXJS3).<;Z:ASEC'Y9\E3<9VYX-XV7I/C29<;WGQ:L"/_SO6/8B/-RFM8]DG& M%[[B M:5HR&1V_:U*WR5D&MM]O[)]L\::8+5-\)=)?R5Z?9N[(=?;\P,ZI?A77S[PN M*'2=NOJO_,)3 R^5F!P[D2K[U]F=E199S6*D9.R]>B:Y?5ZK+_$M# \@=0!I M D:/ V@=0)N JIN# 4$=$'0"O*H4VYLUTVP^E>+JR.KG+5AYBF 2F.[ORDW; M;/O-M$>9W8RY$Q*B M0L*>$ +=7ZW"A*TD=-QI^QK!Q&-<2(0*B?H=B?S.$8MZ20*((<33Q&B:&$G3 M:>HR[C75W)!XDA&:9(0D(9TD&(;B2<9HDC%"T/4DAAEH%_BX\WV$(AJ@&+@\ MX'FW &K\!9 GCFD-B@?.Z7T>W-= D6H';@; G0W!!ZK%/0E]4])HU*T6 =&! M P2XY0#SW(!I ;<3Q!^H%C<+8$[H58N X@%/ NX7Z)N!P(!4@IN!^,]72W S M$'CBYJ]!CZ_^_X J,5[K/WS&Y=%.3\K9B7-N1[?6;C.A+8B=$/[!J_'N&Y/' M)%?.5F@S9]AIX""$YD:+_V(.X\E,E,TBY0==OL;F759C5;70HJA'1J^96^=_ M 5!+ P04 " #<@JA,E'\"SC," 4!P &0 'AL+W=OV.FS 0?!7$ QR?(2$B2!>BJI5:*;JJU]\.V01T!E/; M"=>WKVTX0LCFFC_!7F9F9]=AG;2,OXD"0%KO%:W%RBZD;):.(_("*B*>6 .U M>G-@O")2;?G1$0T'LC>DBCJ^ZT9.1V9W\$7LIC(77 29.&'.$GR%_-EJN=,ZCLRPIJ4;+:XG!8V<_>P8>].;;_N5[6I'0"&76H*HQQDRH%0K*1]_>E%[R*F)X_6'^A=3 MO"IF1P1DC/XN][)8V0O;VL.!G*A\8>U7Z N:V59?_7\)_D!0N3\C!#TAN!#"3PEA3P@OA,AT MJRO%]&9#)$D3SEJ+=\?;$/TO\I:AZGZN@Z;9YIUJCU#1L^XP M_@@S06P01!P,&$^+A MB J$1B"X$KC3AADJ,$,Y@(56/R_S.P6 MX[N+R8%C.A%N)$:-Q(C '!?P7/S[<1]OAG?G$_0>.'44-.E'AH+BB1EG-!HJ MX$6M]>Y"F_*%K5L!>>O#!&Q-\-4-YF_L*_.9ZK)P5O [PI:.=I[II(#YR_&^';, M_, D!!0*912(7JZP!4J-D$[CM=?TAY"&.-[?U+_:VG4M!R)AR^F?ZJC*S$]\ M[P@GS]+V^^.]P!:KA)A,=H^!4VJ]77*3BK%?1J3#RUJU5;=>V MU[_1W(2P)X0#0ZVVV(^8D6 M:ZR[7QBG;;8]T^V1VGO-HR1(T=4(]9A-APE'F,6 0%I]"!&Z0FS".WHX#;"] M1ZR^3"&[>TB4?)!%Y"PTL@+11"!T"V"G +8">"(0S3K586*+J2UFB8-@UL_M M/0I/4)-DELYDEHYDL%M@Y118_7\[8J= [,A@.;NT^*[011!\6&GBC),XXJQF M<5R8>!8$C5X$ W&VTT9Z!;_4ROQ8(^\PT!Y#\Z)F_HT>=-U<>I?IIN0/(LY5 M+;T#5_J]VE=UXER!3C%XT#=6ZL$\&!1.RFQCO1?=>.H,Q9M^\J)A_.?_ %!+ M P04 " #<@JA,KIM;.[4V #X!0$ % 'AL+W-H87)E9%-T&UL[7UI<^/&M>CG^WY%E^_<1*J":)+:[<15'(EC*YF1%%%C9ZGW 22;(FP2 M8 !0&KGRX]_9>@$:H*BQ\^Z]"2OQC$8 >CG[UJ=_5Q2E^K1JK M+[\L)G.]C(M.MM(I/)EE^3(NX9_YPY?%*M?QM)AK72X77_:[W9,OEW&2?J'6 M:?+WM;[(UFGY^R\.S\Z^^.9W1?+-[\IO+K/)>JG34@W2J1JF95(^JZN4QTRR M5!VH8A[GNOC=E^4WO_L2O^'O#M6'+"WG!7PSU=/ZTP]QWE&'O4CUN[VS\.&S MZAXU/[/+\=?PM_=)JM55J9?%_VW]X/YYI>L/>]V#/]5_-X"WI_3%NT7\4'\Z MBQ=%,(R=XU;G289@FJK+N S>,[O^/__Q'QOW]BXI)O%"_47'N7H'OPR 6W]3 MYFU\]T^]^F\$BW?Z(2G*/(9AKN-EL-B__N5Z^&=U=7W1\OD%S)_#W%> WT_J MC_JY_M[%.L_KNVF#S,%!KW]PV+;2=\E"Y^H"OGO(\F">T3)>X/,[OAY.4M=%R$'UC$K.)G MQ I!(9Y,\K5V<&[XB)[#-WFV6- WN5[0"LOX4_C!I9[I'#>3I,4:N'^BX?UD M.5[GA49H;\:;![KZB^^S].&@U/ER(WSM]'G#7#_$.YOHU MT)#Y+1 58I08R@D9H&DD(= AD[E5G?02" B]' /CM0H)EE\;%K9Q98>'4:_; MB\X.C_RE'?:CD^Y)='ITN-TJX?VSDZ/H[/2T-LKIZ5G4/>HVC/+BQ@;3:8*\ M!22!PN@ Q*BP6"C[@>76P*H$!'5T?AQUSWNTA+,3V-JI;#Q2<;D5C",@X&*E M)V7RJ!?/]-DD*P**!O9<+]?,CE,]2R9)"X/]]3G5GR+0IB#LBP:"JW]UG:4' M2-O(] BQ) 76T^$">/1M1@Q8BS:^S9?;Z;N]VQAY?J[+!.R!?=!_;]27+=:C MXR91NO"MRG+X%T'R>Z1;M'I8&;_XM:CL@27J;;^X(DK=]NU-)D'%A'C5;AJM MC_:M-+T>M6RD^=T-V[!L5/ED2WH8W<-?'X;70 LW[]3-[?!N<'\%+WB6D)& MGCD4O6 >^:Y$(""NA_?J;OC]\/KC,%1$C\DD7/MHO5HM&O0*<\>U+H'OP2Y: MAVBZ&?'&9#XUN+XTF[S^5@W_?(L@&84H*$H2=C(L &-**U._B9>KK\'D@/6$ M-J\FKH\4*#:-5CB9"M-EDI))CT+)6 PM^KP^+6D;,+YBLJ#;K T03]E2JQF8 M/N;M+ W>NB$SL&7^*Q%4[<^;IE!C#?Z>!DJ@IXV6S95]9L96>V. SRPI]P/" MT.A"XOL!H'/Z@T% &"FV#1D8(R\C8MD$A!\LEB7H0SX028(M/[X$^ )<%&CW39 ;"5*,=.M;ED]8I 5_VSR;<$JRS.2 4R3II MQ-I6(N=B,/I.O7M_\\/VSI?WR;N[FP\>0P\N[J^^O[J_&HX"\"/^)N!YH8OP MF$P!).-GC[EB-!J:C=?:;%?7WP]'+\UVNP9K!?P)Y.95HP/5NKYU07X _/\1 M*/IU:WMW=0W:?0M([*&G^$P6^;X"_RG/GF FH(\4C(V4ECT!71H:1KA,% 5Z;PC0U0)^I)\4&>$P,K$N_H!T")X& J I/M'X(MK38_V0 MI"DN BF;0ERO^EZC2FO[DO0\(1-P,4V*"4A[H!7VTF70%&UL_ =&R0J$!* I MH'&KT- %V1C1&!J&5"O!+3M! +K%>LJL:/Q]WPX'J8^DJ@I=EHN0ZM\.1E%O$"ZK/%G&P#?C=0&R!O1Y MH1\XIK0$D8-Q2;:V"O4T3\#I$U2HX0)39= M3\JBHP8-/F]$?"B1R-_\YUF_=_HU\O_BF5E*HU JDFF"JP--2'!0'WA1!A[X M7;_[]5\_7$7T8^]K%<-"P1)Y/LB>4B 3L_$JQ,IYGJT?YK(G;R$8#J%%JR48 M@+AJ!*PSLSKJ!B4RV6]N?9&L;KA&:H[48#5R:QM^;%O;I4X!]C]5EA8!KTV) MF-ER!30MX8\<"4U,T4)-USER/:X;=J+A%4XE:$PE-'GG:/JS\"/K+(TE*%" M,& )C0O1J.$Z!M)9FI09S3/*P&[!W0=@'[T.[$BH0$YZ 5 "SE;C!1"G>H3A ME[0',R&37$1\G92(_?@I3EC_KE ,P])!"./^/W9&'?4.AZ$H1+Y^4 //S <& M,JM]=SF0Q>YC^.1)8S"P4.!_ \!^8LO58A 13 8UH/;#B!8>3^8)K!V1XS ! M=B;("-T! PEP@;$]F:U&W @BD!)U#@H+F!PN* M0CV E8XLG1<4D^-2,OGBB+@(W(\1)26"'/@20[$@^$EQIVH*V):=T@[9$2)# MA%5U964BQXT:AH\R#J%::8 X T)?&-$+D$8-!\9?3)8U[]G?1B3;RY;/V0,( MPCD,IB?S%*C_ :0",1L9[V7BQ8@-15Z]NS 4B2%\(#V< 8;.6Z!FO[S^,!PY M8H9=D0(&_,6I!D/=_SQ%5=,XR#WX V80D-& [6R=!\12P0W@88PD EH7S3N@ MRW2Z8.G/9"CXFZ-K H83\T4=U04FI"**^W-R90R^F\Z-"U!5^O"SOYW5>@'4 M)[(19A*M5*#@3N$M7B1BSUHTRQ["A8:4+\49.W/@C MC(3C@RP!VGHP$*4W1#"!AH#!5Z+[X"VP:= [54 4 -+T16'O+= @'?.]:?_H!G$[9&B/!_ Y>L;N$G=A5 M,>.P/D\P]H$N&>QDENC%5!0%."K6"GI$? MHQLKQHC5O.07H8N.W(MDSL23$%HY*K2GSL\[Y^<$B'4:K\%+TY13F3+B)M:. M1,ZP)F/A3$9KVZ+& 3S/$99C]/)7Z!?F[&_XRP/YBLY+:0@]7R^LFV5(D@PN M?#A"D+EH]? 3F-7I PUF/#)\TA C8A8 \\Y"E9; .4OE:2 M".;KIK6/3B#)B2$)-F8=&/TIDZ(":QS6H_$7*!N83V=[ (U>L>_)$4"G[RC 42S,9!M@E@L.3<<$MF+"(83X$@T823 M. !8*=OOAZ1=P2YP;# *QE5)2H4IB-U"Q.\@5+5C<8U4R$ M3-2>M24!K(OU@K,%56_1&O<4))DMLJ?" I>C+H7C:M:FWEC>..:C%S4:DSG* M![/GA.0EF\>/VNS+3$/2:1DCXIR#@[/%:K8&*,ZX-HDH@<-(*0X^UAP:!7#* MV!4@@M&+(@1%KEDYFL YDQ1OM(+NK=6DI13B==A,DRM5=9O0Y".>G1C1'"]P M:84SG"5RY2D$D-Y+"8"M;2(0<7/K&OD]K>,I]K8#QP<: )ZB?X[J0/S M;@51Q 0-'ZJ5%RLS8K-I->1+Z]D,K>J,TQI 'RE'OW.?:ZI2Q@"-HEEN8(2B M: &3*9%4(27JQ1:UMANA@$TZW)J-G#%?28R%E0L2K!A.3QC#6!/P=#I'0II6 M5*:8L0M8-CQ9$Q"%(8 'F=Y!G9 [ED'D-:D9*5']M@T:R MR))RF*E+QG84U:/EUK%M83*#;Z3?FK5D[?NJ7TZF"B9'EF3VD>%8@/V_8B23 M@(D9Q;PM0^]+R\-[;)A;*X7)\3-CJ M/2_DEMLZ2I;A(&(FY9KB D;G%(Z32HG2>8=C&-6\$N$MD16\ .LO[+;76#]W(+L M-P_[8%!AP$9".?#:U-2>8)Z;7\2HK?I## 8/B&&CO5F3; M6)2BC?,I"BA#&;#A#- F)C+5:HF/YK(" S?$2(8HU-L,1[(1R<'HK7.%;NMN MG1%32$ D^F,,*!#*)H"6#+PK:\T5=@K?:I%U_NP)O:(-9.=..X29N# MC/$574VDV&@4RU'#J$9Y==2(0_:Y]J8B;8Z$P5PC\1-,)>02L"+I(6$[HJ"8 MHW &MY[8"1,&P'!/6D1$F2;HD9V;C%K:/0C M3-0#7=DQ\U2LIMFD%%MIJI'[ M K^>:XPL3#@ .X6A\F=V[Q19#*7&D%@Y3W(L;L84*HC5;/%("X@1S0LJ#$"D M>-M%,,_CQB6"6L"$G(A0=]=\-+]=?.<)0,GA2A'8-(,'NWZ@ME?FE-T%B4N&T/Z MS]NQL1TK_I_8"Y9F?/DTS2@X58IEH.AWKHQ;K DP+,'#:MDMA66)P-"88THE M;6:%UCC Q).:@M))L]JSQ@>6$QL M07I2F+JJQS"Y]B!:IL"*_I]P3J,$ M,;V#1\&(!H,55(\* ' P+,]A0M9X@I%L77H\KJI,#J0B.VPPQ$PV\0E)0*R. M$!!X7@W1P)%:R9T1H1M=KI_=6JW$JV/:I#&PF'NV)C4(6R\H#)4Z05FBL_Q@ M+3;F26-1L^;'G:"$L[(6=\R_Y*0_4;Z1IATEU:=&^,J;E9=(D *A6'-U\HPI M29"BE7^;(>C5V"&=C7>;W7&TD:1V[22BK*HB2DCFF&QFMZ;"-,@5.6A+7QZ1 M#$;)D$V (T%K(NYAL[UC=7)",H02&/B)L_A-J&.>H'X@99H;B\&P 1K(A,X' M*?]ASK,<%V%^-YU:T\,?JT*A//+XV6/ !Z#0%8P ;BIH!S)Z'$N@:)B!CY%Q MP@LD&I."R6T2]R/! Y(*ZT)AHM#$WYL)%D60.*^RY"=079Y?R7ZS61#BE.T[ M(U+2-<4GT;6-T6(H3 C4E.O*&D2K)*9NRA /O%!@"G$160M1%E(%F(VYH@I" MW4)D"@.%>XHHB.$&LPQNT5D9NJI4I!R"#60F6G9QQ!$372RL1\1-BE70A_.A M>6GQ!1"^FCG[(?:@3>_1M\OD$P\%PX*T3DKQ9<6!QQ>]H$*EM,\C/@K+2 ($ M33\*.V$H;(;G.Q"(3([/58KVL831%<&].&6EJOB>)LXCYD1'?9<](0-&OGV_ ME6?K9Q[1?LBG'(V+66Q:11A:(K0OQUEH\R_6& HP*6P,K'+,@@-&]K$O.(RK M(/$G?,_\B&-0Z!5^YR*GQB:9D3"F <2X+NIBVM3\&-:6NHB\$#Y%I@8# LPY M7(RSW-A9%R)%9YY\,B-7&>T5/9<4J[5A4S)=)GQRHB7Y8#C!!0=EO93^!?L, MZ:]PY_1 VBB,R%+RRS*Z2PZ[A/O7& +BE!:-$;&JL\4$%9'MAA*X319QLF2W M5Z'(6]BE54&/?J-^$OG&00K.O53V0BZ+B"P8=*;X4Q]#Q(HH2(&D;!V1-3H7 M16:G,H/[ZS3./'D[AK39-"[6^',52VW$T$I6Z)3Y\,IF,XZ[/(#HP> 5946; M+ .'0\.I8@(:MC2S)I9V3TY")X4OFBGFC]/( M9XXEI,+&9BPQU>(4- "WQ9YV0M5#2V'#&.9QA0JMI/#STB QUM5L$&8(HN9 M9-QT6-@_'1,1F!@:QGH!.SRG2*JE6N3-3ZR',&'(]JU'R D>/P$=RP=[4RK1 MZWAA0'_5Q,\V+TMJC7*V9H6>N".5G'/=G5=53QDX*H^GN 8?DV;ZM4OG%0(Z M1*VY'13^%L9Z$IMHFDLF,2HE5^N=-_6.)?!9&WF5[6 /2%Q;)$])X[HOB6H* M$.-8X<:1![*^Y7C,$H%'87Q,%]L(,6_#!;N\A!<:6T4EN!5:(?"]>2,^;F>>(QNKW^ M1P[XCI\K50*Q.\WLNU#C#CQI$K8WI4@DJ$.\G+A5^S<4Z6*U 8F*84 M1<<-7-!\PT]ZLJ98^@VJ!*%W?N:DFGU6T*_V#435.6*$@FVMJ%NBJE M$Y3D$K'9HI=8XP[$Z'BMJ# ;?H!,\U*ZTZ@=FY8T15>M63XI9E#4LJBH%&X[ ML-%!3:(+6 >?)6-]<0!;?,*T$8%F26>H]%:PX8B QDIU>9%%/N=[;*EP3)#G MD'O\B;A==+#L#-T:LBY,Z@@3I8 55R^D>P3!&OIIU05L$E M%IW5E,PBD6SXZ\<8U!2N5Z,H3B?L#F.8%F/V$A0DR87Q'1,C*E#(THG:P@5_ MN.R+5#9E(FTQ5;\?>>6GE&KW0I\&N-7CG;B3!78F,M7<^*D)B,*SP:1T1>4B MA2K.)DJ<@KT5V.A#AGBDJ\Q,Z*6 EJ;": MS$ [J5J> I(:76=<.[R )J9U[*8-M,F1NW@Q64L4R=C@4AC#>4 YG& $*&.( MJ)(83,[KZ\)F F.O&0PN!^26P[:*XV\4F920GW'SO_/Q,O'A?(TV,HV^*"R*!5H2:'!'+"YKC!J)J M*)BL15U6J_4M_XJA89&& =2)J;( .SA'\XAB#UZ5%1F?QJ^KC^A-WE#=PEOW MW6-%R:R%9$2JJZ7BP@( 7%C2L/-0KA[3.1(_S/V K*,JGX215_G<%2MV@Q+M MBD,L'?^V:)(95?>)%*\?=[5V$;US8/U SSS%/KG:S&I1FG\["-!UGXW&'VTG^'4!STP*BXUQ0XH)(R;^DY/ M*5&T=Y^MDHDZZQWO?P6[SA_H&-#5$C6PJ_D<5#6-^7A@3[K[DYM)ZT9'O*3\ M$PD& /D"'0TT#Q/NH_"P3OA,!N8?L&Z""!L%KV1 $J88LK90+J#N).>0J[=) MW *.LR7LQ[/%@0=^\B-D[GB^T3BA33",F4L2V]C[. <4F/D]UE%0@ MW>_VNRR#0&Z Q9MS29DX>2O40*4I6$4[UCD^0IO&MG+422$@+>V^S&!XJL9; M:<;)FRW.+@!]_F&=4K'O2:20V"R1\7@G![W#R"/9*R]P=: N6%B^Y_"&D-%A M_V1?[7WA#? %H/^#IS-AN=4O\9Q!TQ3,P+;6KFJQ&@$R!^*@"K)$BW5M/!:1 MY5[TA5+W#A2>-6\8E*M!B90U&^59;15"+DT92 MR(>E,+QIM4ZG8A01G ]PA /GUR&9)SG'L'&O0* EQT<]86$\7Y%%#BBN.P0C M_H"'PZKMZG[9?,]BKIL&3D1:#=A;CMV8$QFNK09;=M9=ZQV3NW8>22R9SP&9 MSTH^R]510XKB-/+_YTQW]L)T6TH4:Z(WR!)D728("@R)5''<@V=P$BXZ:#Z? M8CN,4+4^29MW>IQ3O:UK]E"1.AM4VW76H:\.NOVH/M1)PU!F$_BZ**;W%!FW M^NZHOV_J9FJJ"[_RJH;(@X]-AV-W?-?8ZZ:X#,N1J9F+[R;2+RK.(BN-2HR& MO&FPWK0-,&'$@R/Y'A+],PV54 Z_R.R%SN[94;>Z:=E-PV8DG\@[PA"Q.;'O M'TV,L)0'G-L&<4NFO0P8'Z?;"^H+N1":'P^*VNF0C\'\E M;NWV?U5N]7JVH"ENK&7C3]DH@VE+ZI\+!@L,BU%BAV61"==,)D\ ]DK$/7%B[6.T1M:@&,W>Y9( MF3V'S8TW..#$J?Z7CPN(F65'M_$;[+' K;S%"J PEHNI8_X;EE\ZAVS&YB^7 MIU+P-9?F(K_\_(!;3?/I 2D:X$"6DZ'!6FJ[]<4?!:IC/NCE"3^_*H;RLY3/ MC:R9P]564;4&BZ,A?DV4?W -'!)RI#:CQ37JQ5ZYOFS&\=KD;U6:/Z^F#XU8O*F ?1.;P@2XK5?0V5,2I0PR!C=F2QF*!Q0S9.+;3UDI9 M:@=LD*_X3&W]6(Y??;OIC =G7=T)CS13+QSQ*,H-XN(=;2(G@E=6.ORJBYL/MS?7V&QQN^Y@>_U]U3:":FX%_Y7+:Q(T M_7/;=,Z3,W>X5=@(NDZ5S]4;P$/W\!#^/C\_4P.@@>48E91]H=<_H_^^U\"J M*(=.3_#_9'K@T544W"Z8<'AZ1FV,>]%)[YC^!D<97BZJL;XIIO3QI LE-'K8 M[7J?_NX=8?_)XU/Z]HP71+V2A.39#*IT#'P9 GGR0/'4<9;])&[=&W5TTI,_ M!ZT+.SP_AF4=GI[O4Y_;ROL33EAQOCGWKFN8Q0E\^QP6[;X-J<)<7L- MF, B[LT[:O^VD"WU>$O]0_PKN'UB<'=]=?TM\,+P#AADT53+\3](@]L!4P+AZ1"F? M##O%^@=1S?%3:5S;M)JD^*IQRUU E% =#I4F\M_)"M91'H%)BFE@G^73MUVB929GS6FPI_I;Q6PRXE M3#5R[LH .;)/\NV\CW+D\/A01GRJ-P%N@"+=%-##!1W!\)_]2S. M?\T5!PV+7USK4'*G'MZ]X,N!P891UMC#BTXS$JIZT5GO4)V@C);-; 6L(YCY M"-?1/3S9 (8JN PUO*8E%$KF'LC26TH(V7(_USK6A?S/_#Q^$RB\+).K #P] M/8GZQX%8&]W?7/SQX.V FS5_P+;HW!?T%DR!H#_Z9>6$_(5WA!I<(.8D:J$N MO>CEJ+5MN/MJ<0@:>?,"_5 S0 2U5H7FN%&:V(+$>]0K'U46"@R V^TBKM8U M>&_A,YOOD).LR_A3LEPO8X;-NMBJHSARK '/#-G M#8[:RG%-KVL\%JD36FFMZL]K<$'PGJI#NY]>YY!SP1E&9TG@K9=8$HFGN]M. MT;O^!;8(-[$G(YO:ZGCI^5^AD9J=M&E-OB%0D=U48^%*2@$<8%X=LAUPQ'>P M?-XJI:TG8Q2P;>83Y$9\$*TA&1Z(+OJB>!7.ZSWFA*#,&M!5,?VLN;X Q0_\ MU\,_SFJG#^BT!Z7#N:\U0.P-V7VH%&W+DO:M;MM!EG#[2DTZM"5:6!&]1P$Z MO,SDI-,_5G=)\=/!#,>IU!S#X_\""C\Y@K_L]X\9"DPZ\T2/^^>=;N4%LF:P MB?4S]2C$E_#J'OAK(,SQ;/M["P2:-9%1? =J((K'_>9.+^6PV.#A(=WCC M6UQE@QW>CWJ'K.J.CP#.AZC0CZ.3HV/UK>#[Y)A! [B<:3I&LW>R#Q 'RC*K M@U_U#T_WX3T8JS9E#<]@-!R?N?GZIS3?\>FY&8P+[AN^ZY.;U>T<==41]DT$ MPR,Z[7=?[A!-W8+J4@%E?+]S'MQJ0@KJNYOWE\.[T6_5\$\?K^[_$K@&W*2I M5?]5!C'=F!J':M.4QZ(I&\=0U9MBU%L7:_8*!$]L\[K4W-2U9K[E-"0#[,3 MB\[:L6*-:[UMK1IV8@9@">)@R2&_ _MK3B@[6Q'QB*H)3$G*PG$A.!V! WF1 M2!:54WTK:BU%+Y#0X+GE( .@+-4/63,J,BB\)L+UC5J]7X?D6 B.PO'3D(7E% M>3BL_9+YQ?([D=8']WFR7J[F8,.G/S'YOM=D,11K;.7*QSZHAI3;E\J]#2:& MQZ>T '(FXQ7)-(C^ 8"1#A?C? (Q#*Y:J00.-"N"ONQ)_G+2RH+!6OKV!R?< M7I8V,"8X#IVS$W7<.>M2X.'(2AH,]QQX0N4 _N>D#C_=+%TJXY_T449TCVOZ M[,GLY)4*K6JM=(*K[*ZNP: =JOO!G\.;B%PYJ?*,[E<;T"!W_5DJAW[=4:G4 M+Z>UM_2X4EE$YQ[K?"EYK=>[VD,D7K6HG[]LJG9-9E*I;)LN26D>/VTN?C;] M_1MZ1*(L:9J'T(@-!I_E3&%K578'_6%SV,3%*D,GZ1874\S3Q05D3N]375OFD^*2 _/: MVN9*]HA3J$2X^#3&0#*?H%HL7+<]%FAGE!D-"O=01Q88+6Z"="5[)!VB95C3 M&1K[)DHY(Y$L$T'AP[ M),B:CB1T,]D,V ;) R]: ,_[0#QPD^RT32UZ_?_:]I:A2-J.RI"LR7K._8V. M[4_=0W:>CU6OJPY!A?,_)9P"ZJ_YWX='?1Z@>\K_/K4N.%\:-M98?NBYU5SJ M5+_LIGKV2]*R-9 M'8ZKQOQ7=2+[K"N9)$]SS*D4*GJR82G.SIGFB91Y_15N M;%)[ &;R4QJNG J6MW=^UMOGGJ4$/B["M!=%LUTI*7;T?&NKV.OC7#>N.Q+V MF<6WJX8II??JD,<%F% 3CS/@4CFKTIH@A1"TX,*0Y,=MJ18CZ?Z@X7"GZO/O M3"8V=Q<'?\8 :&\%,T!.DFDV MYT)N6-U(Y/BSSC.3%GFQ?0@>"Q@7W#(!/ZZPM^PM7#*HP3%U&$""7J?40=DV MIC.@D"*@I+!^ B;%J-D?5D#DN>TA;/HC)'+8#$_ZN_&"Z>O-+,3HI*DLU%NN MO^;6*-/PDFQ[);77BZ5VL(;;A+@^JI4>"K@3NLD*351IH:+DNJ*%G).5O\*K M]VZO[@?OU?OA8 06-5TL>O_=\$[=O'U_]2U?HAK BT=\S! M]T.:JG\L+$<%S,FPF=@=0_[OVF5U]BA^*C M?-4*IF?EL ?[+K06&\"P2*3(LD9-P34:)YH<\+*-#TBFC?M0J1:W!W& M<34)N(*&J^;<+"&Y5#7 &6,%(>ZY(21I/&;FW7(@#G7Q)'" MK,B&/MK*WXL?ZPU$D;(4@6*9;!8 50#Z0'EKNKL\,N&!%XQ$6=G1[R MCSUUWCOB'_OJ_/B$XS/,WD?GQ_"$BUJ,.<_(M48CS!$='_9H#K1AOY+[.UQW M#UL C%O%2BAG>IIZ:CJ#V'Q9* Q\* ,W&%^M7^W!9RWV5NLW30;6Q0W85-?W M=\VJ!Y,@;'=^M#6$F"1^M0KJ=?=5=:KM$]U5Y5P (Z/U4R6:LQ.DFJ/C"IFC M\>3W]A3KS%CB03]//"M"!Z)J@;[3YJ*B2,F=%%-*A-6HN*?Z1X$FO[H79=MT M?7OB]2^_,/WCJ8'?+W&^>^#>N'DE9HWR!84Y]<[SH#8W\ M@W%/=';57)0G&GF)$4 Y157KN"AM/#,ZV)N-;4LE/H)IS6W/VG,U[E@.'KNM M,TBD5M,<<5OH!_P7>\/48#M@F^%[NK/Z=G"'^1/P6T9XLW(3@XGS>DLSWON9 MAE=C&B3)OFJ?NK)IO5PMLN="?W#5WJUTM SN M@/=KYDW7R_9\V:VK3:="%._*E.U O6& _^4WQ@0W0]UJD^UVO[O=9G>[37"[39VV/K*V')IV ]L*H-T5.;LKW24]NTMZ=I?T["[IV5W2L[ND9W=)C_YOO:2G'B9\ MA[TQOS=7SC3V]MPN^'??((%VE__\.U[^$U8?2RA\.T*RK^\N$=I=(J3_&R\1 M"@X4R^4U5RZ?NAU%-WRXNZ#H7_."HO8SI]LFL?TO=O<=[>X[VMUWM+OO:'?? MT>Z^(_QR=]_1[KZCW7U'N_N.?H7[CAJJ>5$.M+99W]9XW=VBM+M%*=W=HK2[ M16EWB]+N%J7=+4J[6Y1VMRCM;E':W:*D=K+DG<'TMX] ME3(&!]]N"]J^=&E2G6-LYYBV7\YC*_.W[D0JAU/E$HCBJ]TM-[M;;CQP MO>XFF59^J=;T^7>B%-SF^_4E?7Q&&RGU[0)S#*/)/*-&'RM;J^V"$Y5*3HH7 MNM!1_3X'OHDC\A2>NR#%+RO:78R!%V,$!.)NR:A]O\2]Q5\)I^X>T0G[3MB[3MC_1IVPM^K@VVHG<='"!VEQZ7<; M9+W)W JP8/,T:+M)E:OB8_&OMF-4F=CTUIQX$[/CQAQJ)PX"W]Y9 ONKYCL\ M:AY'P,.[5J+_Y%:B+4W[+B6ZX-^?8(-\P1']?%Z_8JE M&K2&UY..%PS!\[6>(JW]=OV2*'PR_9\8L* O%JNE1J::%T$)F16 M!-]LC+^U35 ?N0%R51T15:.:D0G> 1-\B'_$OER8]:2!-K3K;(C6-?3_W&HG MU9A=,-'&P&@P9Q 9K;]A J2-#?V#2.FK*:1!HH8R+* M_::] QZ_0Y^=]7@5\:UD[[9>*4)K>[TI=-K('U^:T!0P"O;%PB2(_87EG.@% M3FH)]351T981O>89MHBKA95?[PDQR!E80O=K6W#HD-Q-L(?"367"M"3/1' M(@<&4A+V\;UWUZ(P8DW=U"XCZ.^3674I+XD2=4J7JKSX&CCZ3>^]8EF;=GQF/0#KEP-,/#[(SXK_ST3]QS@Z=>- MCKTI4@%5$ZOJ$ND*)=Z;7 LO.AX-2G;*F9^S8UX'!&) MM15YUY:+@JBOP*N*]"RJ.V?O5JVM?\(&Y*)W_R3&C2O';\53V+V!HC/P(C<> MHHC78(I!2?2PR81GR-%M^@=20[' PARP4?"8]\[M>V>O4UP5NZN%)3=B8PO]8V'9ZAWR3T6$.'?_(J:>L"!\ MAGA4J_Y5$$&^!MMHJ.X'?QYNM(E>X/]*$Y1-UHX7[Q8)K/;>&\*^5 M(P^HY!=DO#^+@'UFN]9/XSR9/E0">!?2 778DVZ5F7Q3H_;8X37V6-';JH- MM<$UU:$14$B;&?ZT=Y TT9+P!]IF[Y ?[C./'@=-M#0R!#/6OG#>+(_EQ48U M$IFGLPW#7%-%PBWW_HNP4$#.,@7!..V8=.;58J",?HF*2<)?&5*[L*1\*;06 M$D@E+^K@2<=[L.PH"-LU!@%?Q)R7N@V,BZ8!J]MN%2;OJ'7FP"8/$(\6?K@C MA'K4/G=C3I.!:)T'L"/Q3'*SD;OHP_;?SRI;O"";;ZWK&*4=SZZ3\Z*+M!O]M4?>M2G!>K5[KA2F!B62+3((G&ZI-@L5O MJM[YYN5RE';=O$5E2O-TKRA2V4K9;/OQJ_#HB/$%+*(S8:Y-%\3'F^CTK#5G MZ^I:3EO?J;#Z1L.1;'_7W*[AO$P 7.[T9SN!?9MGV)U84KO_4,&V[G6*IO+5 MAFSV>SH"[15AV;O7[W #E^YX5?W+?]5KX9LA%#6 R(2V< -#;*D5>++4ZH/- MD_YQH&Q-BV%1XJT"6@1XX'DT7>>-AG@C\8C^",)#31JK=B-TP')A HN:%M)] M;J@9Q;;#-.!K5%C3UQL9J/YZM,$LP.( "_$[V^DY@,=1$T#NGS+U/> 7R,O; MSS;;KH]TUEAS==1H.&RX,_CS5;(OQ@*2;+WV^ 5$> %#["U6?V%(MQJS!>W% M$_\!D@GO$>.P]1*[*C/4R%+UXKX4ZC!JC6QED MY[[_:V(3G)#/7TC^'/>$>O$RZF>8)\27AMCK=CZ),T(V#0P.D@@H)E#YYK2PP2/WDPH'SS*7H>!CA0MK:KH+[7'73 M)X'>,P()I8/ $#H@B2JD%);\5CMVL@5_"H'.7FXJK;"0:!.$&J^E;S-YKBW:<.]>$%%UD)];/1RN/7-U<'W$N>D MM7Z;#P(T.ZHJNOE 2<$9=HOY;<%@SX))A/HZH!22/&D^Z47VB8>Q^&:EW4\25R]E]?A0EH_L=9D7]4!; M-,WJ4M?KZ4(NT_IKN9(%_#(OJV7:P&7U2Z]7E4QG]4+*9IGK9J]WJB_3K-"N MKS9MA95^?=6>W&7RI7Z[WUZR=-IDSS))'P9:3X/G=/1@U^CFN":ZK/Z'J9S/ MLZETRNG34A;-&JJ2>=ID95$OLE6ML2)=RH&V>839Q8R)HLF:W\PMUDW!LQKK M7NW.!IH!YTW:P'^>LSI[R*7&JLL,?JCW9_D@P!&D2D.8Q(3F"Y 0D/PIDG,!A+'P$:1&0UC$A^PBR3T#VU4(.[=B- M67##PDC$P@G+(1HXMA=$(P7!V"\#3Q' M1/$G)GY,W.0>E^@>5:-[:ME<'Z(F6&+_%#A:!ND-Q>(((_<.BD;;A:.VOB5L M+,9!9/O.9(P9*6T8BKWAB!L113#H7#^>1%WB1L(=#R=1_*XD&Y0X#-7FL$,W ML3WF"G>,H)^C+G6WQB'E"D.Q+#PW@1B] M,X1!*<)0[(A(>)U40SM*[AG$"ZK=Z$/,*$T8BCVQ4[#L)"SS;)K)&F-2UC 4 M:V.?;-D)3.E;DC=,2AR&8G-\M.Y?P/HSGCY3 C$5"X06\-8LGW**J=@INQR\ M,Y;D6D2Q5"CQ 2S&I*1B'E,JIH4Q*:F8BJ6RIQ0YLDFSO-X:F91E3.5+DGVE MJ"/%F)1ZS",M3SI,\PQC4OXQ#[Y.^=?C6VE.R<=4+!^"D27R%6-2\C$/L6S9 M5]EY#V^-4 +BQQ00-S F)2!^" 'MQ30Q)J4@KEA!NSVY(X,XN1^FV$ D)<.B MY)2!N&(#X<7U5HHW3VF^%4Q*0%RQ@.A9AX,Q*0%QQ0(B,3D6$*<$Q!4+B-P8 MX.<8DW(05^P@<@['+S FY2"NV$$DIH4=9%$.LA0[:'O_XD.J8TS*099B!^W? M/NB0,2;E(*MSD+[YS#63\ZR0,Q]>4961$->/+B M57V!IBR44-JFNT9]>VLOE@3Z>2"?EY(&,O,_-+]LRNHE5'G:-W4L]VV]ZLL^YY(]GL+>]V(:TS]UFYCZ8[Q#*$%-WP(3?]@OXG7VWXR_IFN]T7X:DI MWH^A3FY*>#/#WH=CKHEAZTF Y:T(/NIH/NZ$'+ MZ: E/>A^.NB>'B1S(..RT ;.&++8!LX9LM &WAJRV ;>&[ M+0!NXNM0&_]A[,V.FSS]5:@M_+U5J"W\O56H+?R M]5:@M_+U5J"W\O56H+?R]5:@M_+U-J"W\?4VH+?Q]3:@M_W#NQ+TLH2OMP&] MC:^W ;V-K[[[>'NCM^7I[H+?GZ^U' M>LA>O77(R_&+-".Z8OJIP_8QAZL7](Z53OR6XX7KU)V68^A/A M3O[S>?P&4$L#!!0 ( -R"J$PPE#3!KP$ $ : 3 6T-O;G1E;G1? M5'EP97-=+GAM;,V9WV["(!2'7\7T=K$(=.Y/U)MMMYO)]@*L/;6-;2& 3M]^ MM.J2F2YQ49/?32D<..>#DN^FDX^M(3?8U%7CIE'AO7EDS*4%UZ M8>LF.THZW">,+57='%>4QMV$"='@91.RN# VC4+41>R$"L<+VWY8][8F:\N, M_H6F\[Q,*=/IJ@Y+8FG8RRDXJ'U-?[L%_:+KOWO@/_"3K6->>=^N4X! B'!.%(0#AN03C&(!QW M(!SW(!P/(!Q\A *"8E2.HE2.XE2.(E6.8E6.HE6.XE6.(E:.8E:!8E:!8E:! M8E:!8E:!8E:!8E:!8E:!8E:!8E:!8E:)8E:)8E:)8E:)8E:)8E:)8E:)8E:) M8E:)8E:)8M8$Q:P)BEF3*YJU:^-:E&PO=&AE M;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( -R"J$S>#\IC9 ( !0( 8 M " ?@( !X;"]W;W)K&PO=V]R M:W-H965T&UL4$L! A0#% @ W(*H3)"(9OE6 @ 0@ M !@ ( !H@\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ W(*H3*S)[JRP 0 T@, !@ ( ! M0QD 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MW(*H3+"Q,%ZS 0 T@, !@ ( !^!X 'AL+W=O.,!+,! #2 P &0 M @ %Z*@ >&PO=V]R:W-H965T&UL4$L! A0#% @ W(*H3/"] :2U 0 T@, !D M ( !3RX 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ W(*H3(:3XVJW 0 T@, !D ( ! MC#0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ W(*H3&XL(LJW 0 T@, !D ( !5SH 'AL+W=OQT" G!@ &0 M@ '&0P >&PO=V]R:W-H965T&UL4$L! A0#% @ W(*H3*"X%0,4 @ V@4 !D M ( !_T@ 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ W(*H3$!'')SX @ -@P !D ( !P5 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MW(*H3%OXKZ;< 0 8 0 !D ( !%%H 'AL+W=O&PO=V]R:W-H965T%F !X;"]W;W)K&UL4$L! A0#% @ W(*H3)1_ LXS @ % < !D M ( !TVD 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ W(*H3%M'B=^ P PAL \ M ( !\*< 'AL+W=O7!E&UL4$L%!@ S #, UPT &6O ! $! end XML 55 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 56 194 1 true 27 0 false 5 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.zynexmed.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.zynexmed.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.zynexmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.zynexmed.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.zynexmed.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 106 - Disclosure - BASIS OF PRESENTATION Sheet http://www.zynexmed.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 6 false false R7.htm 107 - Disclosure - BALANCE SHEET COMPONENTS Sheet http://www.zynexmed.com/role/BalanceSheetComponents BALANCE SHEET COMPONENTS Notes 7 false false R8.htm 108 - Disclosure - EARNINGS PER SHARE Sheet http://www.zynexmed.com/role/EarningsPerShare EARNINGS PER SHARE Notes 8 false false R9.htm 109 - Disclosure - STOCK-BASED COMPENSATION PLANS Sheet http://www.zynexmed.com/role/StockbasedCompensationPlans STOCK-BASED COMPENSATION PLANS Notes 9 false false R10.htm 110 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.zynexmed.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 10 false false R11.htm 111 - Disclosure - INCOME TAXES Sheet http://www.zynexmed.com/role/IncomeTaxes INCOME TAXES Notes 11 false false R12.htm 112 - Disclosure - PRIVATE PLACEMENT MEMORANDUM Sheet http://www.zynexmed.com/role/PrivatePlacementMemorandum PRIVATE PLACEMENT MEMORANDUM Notes 12 false false R13.htm 113 - Disclosure - DEFERRED INSURANCE REIMBURSEMENT Sheet http://www.zynexmed.com/role/DeferredInsuranceReimbursement DEFERRED INSURANCE REIMBURSEMENT Notes 13 false false R14.htm 114 - Disclosure - CAPITAL LEASES AND OTHER OBLIGATIONS Sheet http://www.zynexmed.com/role/CapitalLeasesAndOtherObligations CAPITAL LEASES AND OTHER OBLIGATIONS Notes 14 false false R15.htm 115 - Disclosure - CONCENTRATIONS Sheet http://www.zynexmed.com/role/Concentrations CONCENTRATIONS Notes 15 false false R16.htm 116 - Disclosure - LITIGATION Sheet http://www.zynexmed.com/role/Litigation LITIGATION Notes 16 false false R17.htm 117 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.zynexmed.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 17 false false R18.htm 118 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://www.zynexmed.com/role/BasisOfPresentationPolicies BASIS OF PRESENTATION (Policies) Policies 18 false false R19.htm 119 - Disclosure - BALANCE SHEET COMPONENTS (Tables) Sheet http://www.zynexmed.com/role/BalanceSheetComponentsTables BALANCE SHEET COMPONENTS (Tables) Tables http://www.zynexmed.com/role/BalanceSheetComponents 19 false false R20.htm 120 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.zynexmed.com/role/EarningsPerShareTables EARNINGS PER SHARE (Tables) Tables http://www.zynexmed.com/role/EarningsPerShare 20 false false R21.htm 121 - Disclosure - STOCK-BASED COMPENSATION PLANS (Tables) Sheet http://www.zynexmed.com/role/StockbasedCompensationPlansTables STOCK-BASED COMPENSATION PLANS (Tables) Tables http://www.zynexmed.com/role/StockbasedCompensationPlans 21 false false R22.htm 122 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.zynexmed.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.zynexmed.com/role/StockholdersEquity 22 false false R23.htm 123 - Disclosure - PRIVATE PLACEMENT MEMORANDUM (Tables) Sheet http://www.zynexmed.com/role/PrivatePlacementMemorandumTables PRIVATE PLACEMENT MEMORANDUM (Tables) Tables http://www.zynexmed.com/role/PrivatePlacementMemorandum 23 false false R24.htm 124 - Disclosure - CAPITAL LEASES AND OTHER OBLIGATIONS (Tables) Sheet http://www.zynexmed.com/role/CapitalLeasesAndOtherObligationsTables CAPITAL LEASES AND OTHER OBLIGATIONS (Tables) Tables http://www.zynexmed.com/role/CapitalLeasesAndOtherObligations 24 false false R25.htm 125 - Disclosure - BASIS OF PRESENTATION (Details Textual) Sheet http://www.zynexmed.com/role/BasisOfPresentationDetailsTextual BASIS OF PRESENTATION (Details Textual) Details http://www.zynexmed.com/role/BasisOfPresentationPolicies 25 false false R26.htm 126 - Disclosure - BALANCE SHEET COMPONENTS (Details) Sheet http://www.zynexmed.com/role/BalanceSheetComponentsDetails BALANCE SHEET COMPONENTS (Details) Details http://www.zynexmed.com/role/BalanceSheetComponentsTables 26 false false R27.htm 127 - Disclosure - BALANCE SHEET COMPONENTS (Details Textual) Sheet http://www.zynexmed.com/role/BalanceSheetComponentsDetailsTextual BALANCE SHEET COMPONENTS (Details Textual) Details http://www.zynexmed.com/role/BalanceSheetComponentsTables 27 false false R28.htm 128 - Disclosure - EARNINGS PER SHARE (Details) Sheet http://www.zynexmed.com/role/EarningsPerShareDetails EARNINGS PER SHARE (Details) Details http://www.zynexmed.com/role/EarningsPerShareTables 28 false false R29.htm 129 - Disclosure - EARNINGS PER SHARE (Details Textual) Sheet http://www.zynexmed.com/role/EarningsPerShareDetailsTextual EARNINGS PER SHARE (Details Textual) Details http://www.zynexmed.com/role/EarningsPerShareTables 29 false false R30.htm 130 - Disclosure - STOCK-BASED COMPENSATION PLANS (Details) Sheet http://www.zynexmed.com/role/StockbasedCompensationPlansDetails STOCK-BASED COMPENSATION PLANS (Details) Details http://www.zynexmed.com/role/StockbasedCompensationPlansTables 30 false false R31.htm 131 - Disclosure - STOCK-BASED COMPENSATION PLANS (Details 1) Sheet http://www.zynexmed.com/role/StockbasedCompensationPlansDetails1 STOCK-BASED COMPENSATION PLANS (Details 1) Details http://www.zynexmed.com/role/StockbasedCompensationPlansTables 31 false false R32.htm 132 - Disclosure - STOCK-BASED COMPENSATION PLANS (Details Textual) Sheet http://www.zynexmed.com/role/StockbasedCompensationPlansDetailsTextual STOCK-BASED COMPENSATION PLANS (Details Textual) Details http://www.zynexmed.com/role/StockbasedCompensationPlansTables 32 false false R33.htm 133 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://www.zynexmed.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://www.zynexmed.com/role/StockholdersEquityTables 33 false false R34.htm 134 - Disclosure - STOCKHOLDERS' EQUITY (Details Textual) Sheet http://www.zynexmed.com/role/StockholdersEquityDetailsTextual STOCKHOLDERS' EQUITY (Details Textual) Details http://www.zynexmed.com/role/StockholdersEquityTables 34 false false R35.htm 135 - Disclosure - INCOME TAXES (Details Textual) Sheet http://www.zynexmed.com/role/IncomeTaxesDetailsTextual INCOME TAXES (Details Textual) Details http://www.zynexmed.com/role/IncomeTaxes 35 false false R36.htm 136 - Disclosure - PRIVATE PLACEMENT MEMORANDUM (Details) Sheet http://www.zynexmed.com/role/PrivatePlacementMemorandumDetails PRIVATE PLACEMENT MEMORANDUM (Details) Details http://www.zynexmed.com/role/PrivatePlacementMemorandumTables 36 false false R37.htm 137 - Disclosure - PRIVATE PLACEMENT MEMORANDUM (Details Textual) Sheet http://www.zynexmed.com/role/PrivatePlacementMemorandumDetailsTextual PRIVATE PLACEMENT MEMORANDUM (Details Textual) Details http://www.zynexmed.com/role/PrivatePlacementMemorandumTables 37 false false R38.htm 138 - Disclosure - DEFERRED INSURANCE REIMBURSEMENT (Details Textual) Sheet http://www.zynexmed.com/role/DeferredInsuranceReimbursementDetailsTextual DEFERRED INSURANCE REIMBURSEMENT (Details Textual) Details http://www.zynexmed.com/role/DeferredInsuranceReimbursement 38 false false R39.htm 139 - Disclosure - CAPITAL LEASES AND OTHER OBLIGATIONS (Details) Sheet http://www.zynexmed.com/role/CapitalLeasesAndOtherObligationsDetails CAPITAL LEASES AND OTHER OBLIGATIONS (Details) Details http://www.zynexmed.com/role/CapitalLeasesAndOtherObligationsTables 39 false false R40.htm 140 - Disclosure - CAPITAL LEASES AND OTHER OBLIGATIONS (Details Textual) Sheet http://www.zynexmed.com/role/CapitalLeasesAndOtherObligationsDetailsTextual CAPITAL LEASES AND OTHER OBLIGATIONS (Details Textual) Details http://www.zynexmed.com/role/CapitalLeasesAndOtherObligationsTables 40 false false R41.htm 141 - Disclosure - CONCENTRATIONS (Details Textual) Sheet http://www.zynexmed.com/role/ConcentrationsDetailsTextual CONCENTRATIONS (Details Textual) Details http://www.zynexmed.com/role/Concentrations 41 false false R42.htm 142 - Disclosure - RELATED PARTY TRANSACTIONS (Details Textual) Sheet http://www.zynexmed.com/role/RelatedPartyTransactionsDetailsTextual RELATED PARTY TRANSACTIONS (Details Textual) Details http://www.zynexmed.com/role/RelatedPartyTransactions 42 false false All Reports Book All Reports zyxi-20180331.xml zyxi-20180331.xsd zyxi-20180331_cal.xml zyxi-20180331_def.xml zyxi-20180331_lab.xml zyxi-20180331_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 60 0001144204-18-026144-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-18-026144-xbrl.zip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�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�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end

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company